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This thesis examined the efficacy of a primary care intervention in reducing progression to 
Type 2 Diabetes (T2D) in patients identified as ‘at risk’, defined as having a Glycated 
Haemoglobin (HbA1c) of between 42 and 47 mmol/mol. T2D is a metabolic disorder, which is 
characterised by high blood glucose, and associated with numerous health complications which 
are placing an unsustainable financial burden on the NHS.  
Study 1, a service evaluation of a GP-led intervention targeting life-style modification, 
indicated that a 30-minute one-to-one consultation reduced progression to T2D. Five hundred 
and ninety two pre-diabetic participants received the consultation, 12 months later 17 had 
progressed to T2D, 217 had reverted to normal blood glucose control while 358 remained in 
the pre-diabetes range. At 24 months post consultation, data were available on 292 participants, 
19 of whom had developed T2D, 119 had reverted to normal glucose control while 154 
remained pre-diabetic. While the result of the service evaluation showed great promise, the 
process identified several challenges which needed to be addressed before an appropriately 
powered randomised control trial (RCT) could be effectively conducted.  
Dietary and physical activity behaviours strongly influence the risk of T2D. Given self-report 
questionnaires relating to these lifestyle behaviours are prone to bias and reporting 
inaccuracies, work was undertaken to develop more effective ways of monitoring these 
behaviours. Research has shown metabolites present in urine can reflect dietary intake, as such 
Study 2 was undertaken to establish a robust and acceptable protocol for urine collection to 
monitor dietary behaviour. As physical activity has been shown to influence the urine 
metabolome at some exercise intensities, Study 3 was undertaken to assess the effects of 
moderate intensity exercise on the urine metabolome. Glycated Haemoglobin is increasingly 
quantified by point of care analysers, as such an analyser was to be used to track HbA1c changes 
during the final study in the thesis, comparisons with high powered liquid chromatography 
across a range of HbA1c values was conducted during Study 4.  
This thesis culminates in Study 5 which examined the feasibility of conducting a RCT to 
evaluate the effectiveness of a one-to-one consultation delivered through primary care 
compared to standard care. The RCT revealed the GP-led one-to-one lifestyle consultation to 
have no additional benefit on measures related to T2D compared to control, with HbA1c 
concentrations decreasing after six months in both treatments. The urine sampling procedure 
was effectively implemented in the RCT and successfully quantified 79 metabolites linked to 
foods and drinks, many of high health importance. Dietary behaviour was unaffected by 
treatment allocation. Level of physical activity, monitored in part by an electronic activity 
tracker, was also unaffected by treatment allocation. However, it was demonstrated that the use 
of such technologies was acceptable and feasible in monitoring healthy behaviours in 







Literature Review: Type 2 Diabetes and Pre-diabetes   
 
1.1. Introduction 
The UK National Health Service (NHS) identifies the current top five diseases responsible for 
premature death in individuals under the age of 75 years as cardiovascular disease, stroke, 
cancer, lung and liver disease. Future projections however suggest diabetes will enter the top 
five leading causes of death by 2030 (Tabak, Herder, Rathmann, Brunner and Kivimäki, 2012). 
Type II diabetes (T2D) is often a precursor to cardiovascular disease and stroke, as well as 
other health complications. It is estimated that approximately four million people in the UK 
are currently suffering with diabetes, 90% of whom have T2D, with Wales having the highest 
prevalence of the disease among the four UK nations, 7.4% (Diabetes UK). With a new 
diagnosis of T2D every two minutes, the financial burden placed on the NHS by the condition 
is becoming unsustainable. Of concern is a statistic reported by the NHS in 2014 stating one in 
three UK adults were classified as having pre-diabetes, a condition associated with increased 
risk of developing T2D. Crucially however, development of T2D, and associated diseases, can 
be prevented with lifestyle modification, including increasing physical activity and improving 
dietary habits (UK Department of Health, 2014).  
 
1.2. Type 2 Diabetes 
T2D is defined as a metabolic disorder of multiple aetiology, characterised by chronic 
hyperglycaemia with disturbances in carbohydrate, fat and protein metabolism (Alberti and 
Zimmet, 1998). During development of the condition the homeostasis of fasting and 
postprandial glucose concentration becomes abnormal, resulting in a chronic hyperglycaemic 
2 
 
state. T2D is associated with numerous complications including cardiovascular disease, stroke, 
hypertension, nephropathy, retinopathy and neuropathy (Grundy et al., 1999; Shlienger, 2013). 
The causes of T2D are multifaceted and are a result of both genetic and environmental factors 
(Das and Elbein, 2006) that cause decreased insulin secretion, because of impaired beta cell 
function, decreased insulin sensitivity, and increased insulin resistance.  
 
Insulin, alongside glucagon, is a major hormone responsible for the maintenance of glucose 
homeostasis. Insulin is secreted by the beta cells of the pancreas in response to increased levels 
of circulating glucose following a meal. As well as regulating blood glucose, insulin also 
influences lipid metabolism by increasing lipid synthesis in fat cells and decreasing the release 
of fatty acids from adipose tissue. Insulin regulates glucose homeostasis at numerous locations, 
reducing hepatic glucose production and increasing the rate of glucose uptake into skeletal 
muscle and adipose tissue (Sesti, 2006). Because of impaired insulin action, glucose transport 
into the liver, muscle and fat cells is compromised (Olokoba, Obateru and Olokoba, 2012) 
resulting in the progressive increase in plasma glucose levels which characterises T2D (Scheen, 
2003; Cerf, 2013).  
 
It is well established that poor dietary behaviours and physical inactivity increase the risk of 
T2D. Obesity, and more crucially, body fat distribution is implicated in the development of 
T2D (Montague and O’Rahilly, 2000). Obese individuals storing most of their fat in visceral 
adipose depots, in general, suffer greater adverse metabolic consequences compared to those 
who store similar amounts of fat in subcutaneous sites (Scheen, 2003). Increased visceral 
depots are associated with increases in the release of non-esterified fatty acids, causing 
reductions in insulin sensitivity. Work by Fujimoto, Abbate, Kahn, Hokanson and Brunzell 
(1994) found visceral fat to be strongly correlated with insulin resistance compared to centrally-
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located subcutaneous fat. Visceral fat is associated with beta cell dysfunction and is clearly 
present in individuals with T2D (Kahn, 2003; Malin, Finnegan, Fealy, Filion, Rocco and 
Kirwan, 2014). Beta cells are responsible for the secretion of insulin and their adequate 
function is a critical requirement for the fluctuating demand for insulin availability (Cerf, 
2013). Butler et al. (2003) found a 60% decrease in beta cell mass in individuals with T2D. 
The decline in beta cell function and mass is a result of several factors which contribute to 
eventual beta cell exhaustion and subsequently, beta cell demise (Cerf, 2013; Cernia and 
Dobreanu, 2013).  
 
Long term exposure to adversely high blood glucose (glucotoxicity) has damaging effects on 
insulin synthesis, secretion and beta cell survival. Numerous mechanisms which impair beta 
cell function because of chronic hyperglycaemia have been theorised. Prentki and Nolan (2006) 
suggest the increased insulin secretary request imposed on beta cells inflicts a high demand on 
endoplasmic reticulum, resulting in cellular stress. In chronic cases of endoplasmic reticulum 
stress, beta cell death may occur (Eizirik, Cardozo and Cnop, 2008). The prolonged exposure 
to free fatty acids (FFA) is also proposed to have negative consequences for beta cell function. 
FFA presence may result in accumulation of toxic fatty acid metabolites within the islet cells 
of the pancreas, otherwise referred to as lipotoxicity (Cernia and Dobreanu, 2013). Poitout and 
Robertson (2008) suggest long term exposure to increased fatty acid concentrations results in 
decreased insulin gene expression. Furthermore, when stressed by hyperglycaemia, pancreatic 
islets produce an inflammatory response resulting in the increased production of cytokines. 
Interleukin 1 beta (IL-1), interferon gamma (IFN-), tumour necrosis factor alpha (TNF-α), 
leptin and resistin are all cytokines that have been demonstrated to adversely affect 
pancreatic beta cell function (Wang, Guan and Yang, 2010). In contrast, the concentration of 
the cytokine adiponectin, a modulator of insulin action, is decreased in the presence of obesity 
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(Scheen, 2003). Low grade inflammation through obesity and high volume of adipose tissue is 
a primary source of cytokine presence in obese individuals in which inflammatory cytokines 
activate several kinases that interfere with insulin signalling (Tanti, Ceppo, Jager and Berthou, 
2012). Obesity desensitizes glucose receiving organs to the actions of insulin, therefore 
increasing insulin resistance and exacerbating the impairment in beta cell function. Once beta 
cell dysfunction is present, insulin secretion becomes impaired, resulting in persistently 
elevated blood glucose concentrations (Cerf, 2013). 
 
Insulin resistance is defined as a state of reduced responsiveness to normal circulating 
concentrations of insulin and has a major influence in the development of T2D (Savage, 
Peterson and Shulman, 2005). Primarily, insulin resistance in skeletal muscle manifests itself 
because of reductions in insulin stimulated glycogen synthesis. This is due to decreased glucose 
transport with multiple defects in insulin signalling responsible for impaired glucose 
metabolism (Sesti, 2006). Insulin’s primary targets are skeletal muscle, adipose tissue and the 
liver. Glucose uptake in skeletal muscle under insulin-stimulated conditions accounts for 75% 
of glucose disposal in a postprandial state compared to adipose tissue, where less glucose is 
metabolised (Sesti, 2006). Upon entering the cell, glucose is phosphorylated by hexokinase 
where it is either stored as glycogen or oxidised to produce adenosine triphosphate (ATP). 
However, in insulin resistant subjects this process can be interrupted. Abnormalities present in 
FFA metabolism produce damaging accumulations of lipids within both the muscle and liver, 
subsequently impairing functionality (Sesti, 2006). Work by Randle, Garland, Hales and 
Newsholme (1963) and later studies by Roden et al. (1996) and Dresner et al. (1999) have all 
demonstrated the presence of elevated FFA concentrations to result in decreased intracellular 
glucose concentrations because of inhibited glucose transport. The process of glucose transport 
is initiated by insulin stimulating the translocation of GLUT4, the glucose transporter.  
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The process of GLUT4 translocation requires the release of GLUT4 from an intracellular space, 
transport to the plasma membrane before fusion with the plasma membrane (Sesti, 2006); this 
in turn permits the movement of glucose from the blood into the cell via diffusion (Huang and 
Czech, 2007).  Work by Zierath, He, Gumà, Wahlström, Klip and Wahlberg-Henriksson (1996) 
found insulin-stimulated glucose transport in skeletal muscle in patients with T2D is down-
regulated in the presence of hyperglycaemia. An elevation in serum insulin concentration from 
54 to 588 pmol/L resulted in a 1.6-fold increase in GLUT4 in skeletal muscle plasma 
membranes collected from healthy control subjects. However, no significant increase was 
found in plasma membranes examined in T2D muscles, despite similar increases in serum 
insulin concentration. This finding was later confirmed by Garvey, Maianu, Zhu, Brechtel-
Hook, Wallace and Barron (1998) who examined GLUT4 translocation following insulin 
stimulation in insulin-sensitive and insulin-resistant nondiabetic groups, as well as T2D 
subjects. Their work demonstrated insulin stimulation to result in alterations in the subcellular 
localization of GLUT4 vesicles within the muscle in insulin-resistant subjects with and without 
T2D. Specifically, the defect was associated with abnormal accumulations of GLUT4 within 
dense membrane compartments from which insulin is unable to recruit GLUT4 to the cell 
surface, therefore demonstrating insulin resistance in both T2D subjects and non-diabetic 
insulin resistant subjects (Garvey et al., 1998). One explanation for insulin resistance in the 
skeletal muscle is a defect in the insulin-signalling pathway that controls the translocation of 
GLUT4 or in the molecular processes that are involved in the recruitment of GLUT4 containing 
vesicles to the plasma membrane, their docking, and their fusion with the membrane (Sesti, 





1.3. Pre-diabetes  
Pre-diabetes is a metabolic condition defined as blood glucose higher than considered normal 
but below the value resulting in a clinical diagnosis of T2D. Pre-diabetes, alternatively referred 
to as non-diabetic hyperglycaemia or impaired glucose tolerance (IGT) is a rapidly growing 
health issue which can develop into diagnosed T2D if left untreated (Falade, 2012). Mean blood 
glucose concentrations are rapidly increasing in both developing and developed countries 
where mean fasting plasma glucose (FPG) has risen by 0.1 mmol/mol since 1980 when 
measured in 2.7 million adults (Tabak et al., 2012). Evidence from the health survey for 
England (HSE) demonstrated pre-diabetes prevalence in 2003 was 11.6% which had increased 
to 35.3% by 2011. The International Diabetes Federation estimated that by 2030, 472 million 
people worldwide will have pre-diabetes (Tabak et al., 2012). Such increases are projected for 
future years in the absence of concerted interventions (Mainous III, Tanner, Baker, Zayas and 
Harle, 2014).  
 
Impaired fasting glucose (IFG) and IGT are both conditions which encompass pre-diabetes and 
may develop in isolation or in conjunction with one another. In the UK, IFG is diagnosed when 
fasting blood glucose concentration is higher than normal values (between 6.1 mmol/mol and 
7 mmol/mol) but does not increase abnormally after consumption of a 75 g glucose challenge 
(below 7.8 mmol/mol). IGT is diagnosed when blood glucose concentration is higher than the 
normal range 2 hours after a glucose tolerance test but not high enough to diagnose T2D 
(between 7.8 mmol/mol and 11.1 mmol/mol; Talking Diabetes, 2012). Pre-diabetes and T2D 
are simply points on a scale relating to blood glucose concentration with the risk factors for 
both conditions being; obesity (a body mass index (BMI) > 30 kg/m2), large waist 
circumference (> 31.5 inches in females and > 37 inches in men), sedentary lifestyle, high 
blood pressure (> 140 mmHg systolic, > 90 mmHg diastolic), family history of T2D, age and 
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ethnicity (Falade, 2012). The identification and diagnosis of pre-diabetes is of critical 
importance as an estimated 5-10% of people with pre-diabetes will manifest T2D within 12 
months while a similar percentage will revert to normal blood glucose levels (Tabak et al., 
2012). This percentage estimate is subject to social demographics (low and middle income 
regions; World Health Organisation, 2016), ethnicity (Bhopal et al, 2014) and differing T2D 
definitions. In unfavourable conditions, the percentage of those who develop manifest T2D 
will be higher. However, early detection of increased T2D risk can result in complete reversal 
of the condition if appropriate and timely lifestyle changes are made.   
 
Pre-diabetes and T2D can be diagnosed by recording the level of glycated haemoglobin 
(HbA1c) present in the blood. HbA1c develops when haemoglobin, the oxygen carrying protein 
within red blood cells, binds with glucose in the blood, and becomes ‘glycated’. Measuring 
HbA1c provides a more stable indicator of blood glucose concentration over time compared to 
other methods, such as a fasting blood glucose test or a glucose tolerance test (Falade, 2012). 
The measurement of HbA1c requires a single non-fasted blood sample and gives a measure of 
average blood glucose concentration over the preceding 8-12-week period and is considered 
the gold standard measure in otherwise healthy individuals (Landgraf, 2006). However, while 
the measurement of HbA1c is commonly used to monitor bloody glucose control and diagnose 
T2D, certain health complications and conditions can affect its reliability. Campbell, Pepper 
and Shipman (2019) suggest conditions which affects erythrocyte turnover will alter the age 
distribution of erythrocytes and subsequently affect HbA1c levels. For example, any condition 
which shortens the life-span of the red blood cell will cause the associated HbA1c value to be 
lower than expected for the average blood glucose level (Hardin, Grilley, Baron and Hale, 
1999) while in contrast, where the lifespan of the red blood cell is increased, the associated 
HbA1c is likely to be artificially higher (Radin, 2014). Specifically; anaemia, pregnancy and 
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liver, thyroid and kidney disease have all been implicated in causing alterations in HbA1c 
concentration. Therefore, such conditions must be considered by clinicians and researchers 
prior to monitoring T2D risk and diagnosing T2D using HbA1c. Despite the limitations 
associated with HbA1c measurement, it remains a widely used method for blood glucose 
monitoring in countries around the world. 
 
While HbA1c can be used to identify those at high risk of progressing to diabetes, there is 
uncertainty regarding the specific range of HbA1c that should be used to quantify pre-diabetes. 
For example, the American Diabetes Association (ADA) recommends a range between 39–46 
mmol/mol, while the International Expert Committee recommended 42–46 mmol/mol (Bell et 
al., 2020). However, alongside the health authorities of Australia and Canada, the UK, led by 
a collaborative group comprised of Public Health England & Wales, Diabetes UK and the NHS, 
state an HbA1c level of 42–47 mmol/mol is indicative of ‘high risk’ for T2D (NHS Diabetes 
Prevention Programme: Revised Guidance, 2017). A glucose tolerance test measures blood 
glucose following an overnight fast greater than eight hours and another, two hours after 75 g 
glucose challenge. In the UK, the blood glucose concentration after a glucose challenge for 
pre-diabetes is 7.8-11.1 mmol/mol. A glucose tolerance test will usually be completed only to 
confirm a diagnosis of pre-diabetes/T2D or if results from other tests are inconclusive (Falade, 
2012).  
 
A significant amount of evidence suggests T2D can be prevented and pre-diabetes reversed 
with lifestyle intervention. Diabetes UK suggests that “all people diagnosed with pre-diabetes 
or otherwise at risk of developing T2D should be offered lifestyle interventions that account 
for their risk of developing T2D”. Targets including increased physical activity, weight loss 
and improved dietary habits should be the primary aims for at risk individuals (Franz et al., 
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2003; Falade, 2012; Jensen et al., 2013). 
 
1.4. Combating T2D  
The beneficial effects on T2D of increasing physical activity, improving dietary behaviours 
and weight loss are all well documented. Physical activity has long been encouraged in 
maintaining physical health. Numerous early studies have demonstrated that individuals who 
are regularly active have a greater sensitivity to insulin than sedentary individuals (Lohman, 
Liebold, Heilmann, Senger and Pohl, 1978; King, Dalsky, Staten, Clutter, Van Houten and 
Holloszy, 1987; Hardin et al., 1995) with recent summary articles supporting these findings 
(Sigal, Kenny, Wasseman, Castaneda-Sceppa and White, 2006; Colberg et al., 2010; Jelleyman 
et al., 2015). Work by Mikines, Sonne, Farrell, Tronier and Galbo (1988) found insulin 
stimulated glucose uptake increased during, and remained elevated for 16 hours following, 
exercise.  Duncan, Perri, Theriaque, Hutson, Eckel and Stacpoole (2003) reported on the effect 
of a walking programme on overweight individuals. Insulin sensitivity improved significantly 
following six months of training, which involved three-seven sessions a week of 30 minutes 
duration, despite no changes in BMI or waist circumference. Similarly, insulin sensitivity was 
improved in a group of 19 overweight and obese females following a 12-week aerobic exercise 
programme independent of changes in body weight and body fat percentage (Nassis et al., 
2005). Houmard, Tanner, Slentz, Duscha, McCartney and Kraus (2004) examined the effect of 
different exercise intensities and durations on insulin sensitivity in 154 sedentary, overweight 
and obese subjects over a six-month period. Groups were categorised by training intensity and 
duration and included; a low-volume/moderate-intensity group, a low-volume/high-intensity 
group and a high-volume/high-intensity group. Training volume (miles per week) was achieved 
by exercising 115 minutes per week (low-volume/high-intensity group) or 170 minutes per 
week (low-volume/moderate intensity group and high-volume/high-intensity groups). All 
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exercising groups achieved a significant improvement in insulin sensitivity compared to 
control although prescribed exercise of 170 minutes per week achieved greater improvements 
in insulin sensitivity compared to 115 minutes per week, regardless of intensity.  
 
While the above studies reported improved glucose control because of physical exercise 
independent of weight loss, other studies have demonstrated the importance of reducing body 
mass in improving metabolic health. Wing, Blair, Bononi, Marcus, Watanabe and Bergman 
(1994) randomised 93 obese T2D patients into two different calorie restricted groups (1,674 or 
4,185 kJ/day; 400 or 1,000 kcal/day) to induce weight loss whilst examining changes in insulin 
sensitivity. With both groups’ achieving weight losses, patients with greater calorie restriction 
demonstrated lower fasting blood glucose values and greater insulin sensitivity, suggesting that 
the degree of calorie restriction and resultant weight loss influences fasting blood glucose and 
insulin sensitivity. The effect of weight loss on insulin sensitivity in obese individuals was also 
examined by Goodpaster, Kelley, Wing, Meier and Thaete (1999). Thirty-two sedentary 
individuals completed a four-month weight loss programme with repeated measures of insulin 
sensitivity. The programme resulted in significant decreases in weight, BMI, total fat mass and 
percentage body fat. The decreases in anthropometric data correlated with significant 
improvements in insulin sensitivity as well as decreases in serum leptin, triglycerides and 
cholesterol. Significant weight loss resulting from nine weeks of calorie restriction contributed 
to a 30% improvement in insulin stimulated muscle glucose uptake in insulin resistant subjects 
(Peterson, Dufour, Morino, Yoo, Cline and Shulman, 2012). Other work by Camps, Verhoef 
and Westerterp (2016) found insulin sensitivity improved significantly eight, 20 and 52 weeks 
from baseline following eight weeks of energy restriction and 44 weeks of weight maintenance. 
Insulin sensitivity was greater when weight loss was accompanied by physical activity as 
measured by a physical activity monitor.  The results indicate that maintaining or increasing 
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physical activity during weight loss is more beneficial for glucose metabolism compared to 
weight loss alone and provides further support for encouraging combined weight loss and 
increased physical activity during lifestyle intervention programmes.  
 
Abundant evidence supports the benefits of increased physical activity and weight loss in 
improving metabolic health in both T2D and pre-diabetes. Such behaviours are of vital 
importance in the prevention of T2D with studies demonstrating lifestyle intervention 
programmes to slow or prevent the progression of T2D and do so more effectively than 
pharmacological intervention, such a metformin (Diabetes Prevention Programme Research 
Group, 2002). Numerous studies have demonstrated the significant benefits of exercise and 
improved dietary behaviours in the prevention and control of T2D across different cohorts and 
in a variety of settings, such as experimental and health care settings. 
 
1.5. Experimental Studies  
Controlled experimental studies examining T2D prevention have provided abundant evidence 
for the use of lifestyle intervention in combating the disease. This evidence has since been 
translated and applied to clinical ‘real world’ practice by a variety of methods which have 
proved both viable and successful in many cases. In this section, studies are discussed if they 
included an intervention and control group with randomised participant allocation. If RCT 
studies were conducted within or alongside primary care, they are discussed in a separate 
section below.   
 
Evidence from the Diabetes Prevention Programme (US-DPP) Research Group (2002) 
involved a coordinated 27 centre randomised clinical trial to determine the effects of lifestyle 
intervention and pharmacological therapy on the incidence of T2D in individuals with IGT. 
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Subjects were randomised into one of three groups: standard lifestyle advice with metformin, 
standard lifestyle advice with placebo and the intensive lifestyle intervention. The primary aims 
of the intensive intervention arm, including 1079 subjects, was to achieve an initial 7% weight 
loss/weight maintenance and complete at least 150 minutes of physical activity each week. The 
weight loss and physical activity goals were selected as feasible targets which would prevent 
the onset of T2D. Dietary modification initially focussed on reducing fat intake rather than 
overall calorie intake. After several weeks, the concept and importance of calorie balance was 
introduced to subjects. Subjects met regularly with a personal lifestyle coach whose primary 
role was to deliver lifestyle education, including information on nutrition, physical activity and 
lifestyle change behaviours, provide motivation and collect subject data. Additionally, subjects 
were instructed to self-monitor fat and calorie intake daily throughout the first 24 weeks of 
intervention and record their levels of physical activity. Subjects were followed on average for 
2.8 years. Fifty percent of subjects in the intensive intervention group achieved the targeted 7% 
reduction in weight and 74% had reached 150 minutes per week of physical activity at 24 
weeks. Dietary changes assessed at one year by a food frequency questionnaire demonstrated 
a decreased daily mean energy intake of 249 kcal in the placebo group, 296 kcal in the 
metformin group and 450 kcal in the intensive lifestyle group. This was accompanied by a 
0.8% reduction in fat intake in the placebo and metformin group and a 6.6% reduction in the 
intensive lifestyle group. Incidence of T2D were 11.0, 7.8, and 4.8 cases per 100 person-years 
in the placebo, metformin, and lifestyle respectively. Compared to placebo, the lifestyle 
intervention reduced the incidence by 58% and metformin by 31%. The results demonstrate 
lifestyle intervention can prevent or delay the onset of T2D in high risk individuals. The effects 
of the intervention were similar for males and females, all racial and ethnic groups and did not 




Similar success was achieved by the Study on Lifestyle intervention and Impaired glucose 
tolerance Maastricht (SLIM) study which examined the effects of a three-year lifestyle 
intervention programme in individuals with IGT based in the Netherlands (Roumen, 
Corpeleijn, Feskens, Mensink, Saris and Blaak, 2008). One-hundred and forty-seven subjects 
were randomised into either the lifestyle intervention group or the control group. The lifestyle 
intervention was comprised of a physical activity programme and regular dietitian delivered 
dietary advice. Subjects were encouraged to increase moderate intensity physical activity to at 
least 30 minutes a day, five days per week. Advice was provided regarding how best to increase 
levels of physical activity and subjects were given the opportunity to participate in a free 
exercise programme designed specifically for the intervention which focussed on both aerobic 
and resistance exercise. Dietary advice was based upon national recommendations and 
delivered regularly to subjects following a three-day food record assessment of subjects’ diet. 
Target reductions in body weight were set at 5-7%. Control subjects received oral and written 
information regarding the benefits of a healthy lifestyle but received no personalised 
information or access to exercise classes. Several measurements were recorded at baseline and 
every year for three years which included; insulin resistance, body weight, body fat, waist 
circumference, maximal aerobic capacity, ECG, blood pressure and three-day food records. 
After one year, mean body weight decreased significantly more in the intervention group (2.7 
kg) compared to the control group (0.62 kg) and remained significantly different after three 
years. Additionally, increases in body fat percentage were significantly smaller in intervention 
group subjects compared to control. Aerobic capacity improved significantly in the 
intervention group and was associated with a significant increase physical activity. Conversely, 
aerobic capacity and physical activity levels declined in the control group. From the dietary 
measures recorded, fat intake decreased significantly more in the intervention group compared 
to the control group while fibre intake increased more in the intervention group compared to 
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control. After one year, plasma glucose levels and insulin resistance decreased in the 
intervention group while increases in plasma glucose and insulin resistance were observed in 
control subjects. After three years of follow up the difference between groups in plasma glucose 
concentration remained as high as 0.8 mmol/mol which was associated with a T2D incidence 
of 38% in control subjects and 18% in the intervention group, demonstrating 58% less 
progression towards T2D if treated by lifestyle intervention.   
 
Data from the Diabetes Education and Prevention with Lifestyle Intervention (DEPLOY) were 
reported by Ackermann, Finch, Brizendine, Zhou and Marrero (2008). This community-based 
randomised programme enlisted facilities owned by the YMCA to use as sites where the 
programme identified and educated adults on the risks of developing T2D and promoted the 
benefits of weight loss and physical activity. From two facilities, one site was used for 
individuals who received standard advice on healthy eating and physical activity (control) 
while the other was allocated for the intervention. From the 131 eligible participants, 92 
enrolled in the programme. Participants were recruited using a one-page letter which outlined 
pre-diabetes and the associated risks of developing T2D. Individuals suffering with one or more 
of the risk factors discussed in the letter were invited to attend a screening event at one of the 
YMCA facilities. During screening, BMI was assessed and the ADA diabetes risk assessment 
was completed. A capillary blood glucose sample was collected in people with a BMI greater 
than 24 kg/m2 and an ADA risk score greater than 10. Individuals with a capillary blood glucose 
value between 110-199 mg/dL were eligible to take part in the programme. Measures were 
collected at baseline (screening event), after 4-6 months and after 12-14 months. Individuals in 
both groups received information about T2D and advised to begin moderate physical activity 
and restrict calorie intake to achieve modest weight loss of between 5-10%. Dietary intake was 
measured using self-report (no information available on self-report method). Individuals in the 
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diabetes prevention programme group were offered access to the prevention programme; those 
who participated in this were placed into a group of between 8-12 people who met at a mutually 
agreed time. Group based activities focussed on goal setting and self-monitoring and took place 
over 16-20 weeks with a 5-7% weight loss goal targeted. In the intervention group, there was 
a 6% decrease in body weight, which equated to 5.7 kg loss. The control group was 
significantly different and recorded a 2% decrease in body weight, equating to a 1.8 kg. Similar 
results were found at the 12-14 month follow up sessions. The findings of the programme 
demonstrate that supervised interventions result in significantly positive changes in body 
weight, lowering the risk of developing T2D in those at increased risk of the disease. It was 
suggested that increased knowledge of pre-diabetes risk may assist in motivating some 
individuals to begin lifestyle modification 
 
In other work, a UK based randomised control trial, part of the European Diabetes Prevention 
Study, was conducted by Penn, White, Oldroyd, Walker, Alberti and Mathers (2009) and 
targeted T2D prevention in individuals with IGT (n = 102). The intensive behavioural 
intervention arm promoted increased physical activity and improved dietary habits whereas 
control provided minimal intervention. Baseline measures for both groups included an oral 
glucose tolerance test (OGTT), anthropometric (weight, waist circumference, % body fat) and 
blood measures, diet (photographic food atlas) and physical activity (integer scoring system 
based on MET scores) diaries and a lifestyle questionnaire (RAND 36). Participants 
randomised to the intensive behavioural intervention (n = 51) received regular dietary advice 
from a dietician and further supportive dietary material. Dietary targets included; > 50% total 
energy intake from carbohydrate, reduced total (< 30%) and saturated fat intake, increase fibre 
intake and reduce weight to achieve a BMI < 25 kg/m2. Intervention for physical activity aimed 
to increase participants’ physical activity level to at least 30 minutes moderate intensity each 
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day and received information and financial discounts for access to physical activity 
opportunities. Participants were seen by the intervention team five times in the first four months 
and then every three months thereafter for five years. Control participants received standard 
leafleted information on healthy eating and physical activity guidelines. Analysis after two 
years revealed incidence of diabetes was 55% less in the intervention group compared to 
control with weight significantly decreased in intervention at one year (-2.3 kg compared to 
0.01 kg) with small but sustained changes in BMI, dietary behaviours and physical activity 
associated with reduced T2D risk.  
 
In support, similar results were attained from a German cohort which demonstrated a diabetes 
prevention self-management programme (PREDIAS) resulted in significantly improved 
lifestyle factors associated with T2D (Kulzer, Hermanns, Gorges, Schwarz and Haak, 2009). 
A randomised control trial focussing on weight reduction as well as behavioural, metabolic and 
psychological factors was conducted in 182 participants with data collected at baseline and 12 
months including OGTT, weight, waist circumference, blood pressure, lipids and HbA1c. 
Measures for physical activity (German Federal Health survey) and nutrition (Three Factor 
Eating questionnaire) were also collected. Intervention participants received twelve 90-minute 
lessons covering topics including nutrition and physical activity. Control group participants 
received only written information detailing the topics. Significant improvements in body 
weight, BMI and waist circumference were observed in the intervention group compared to 
controls. While physical activity and dietary behaviours improved in both groups, changes 
were greater in intervention participants. However, despite improvements in factors associated 
with T2D risk, HbA1c and OGTT values remained similar at 12 months between treatments.  
 
Healthy-Living Partnerships to Prevent Diabetes (HELP PD) by Katula et al. (2011), aimed to 
17 
 
find innovative, cost effective systems to deliver lifestyle interventions targeting patients at 
risk of T2D within the local community. This study used community health workers (CHW) to 
implement lifestyle interventions designed to prevent diabetes. Data were collected at baseline 
and then every six months and up to 24 months of follow up. Recruitment was accomplished 
primarily through mass mailings to targeted post codes. Interested individuals contacted a study 
telephone number and were provided basic information about participation including steps in 
the screening and randomization process and the time commitment and expectations associated 
with participation before completing a telephone screening questionnaire. Fasting blood 
glucose, insulin and anthropometry were assessed at baseline and at the six- and 12-month 
visits. Community health workers were responsible for conducting the intervention group 
sessions, managing participants and collecting data on participant body weight during group 
sessions. The lifestyle weight loss intervention targeted decreased calorie intake and increased 
calorie expenditure through moderate physical activity. The primary objective was to produce 
a total weight loss of 5-7% during the first 6 months of treatment. During the second six 
months, participants were encouraged to continue to meet or maintain their weight loss goal 
providing BMI did not fall below 20 kg/m2. Participants met weekly for CHW led group 
sessions during the first six months. Fourteen different groups of 8-12 participants were 
conducted at various community sites. Participants also received three personalised 
consultations with a registered dietician during months one, three and six. During months 7-
12, participants received two scheduled contacts with the CHW each month, one group session 
and one telephone contact. Interventions were supported by a DVD series developed by a 
research team to cover nutrition and physical activity basics, energy balance, healthy eating, 
goal setting and problem solving. The enhanced usual care consisted of two individual sessions 
with a nutritionist during the first three months involving healthy eating and physical activity 
education to support weight loss.  
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Results were gathered from 301 participants with an average BMI of 32.8 kg/m2. Lifestyle 
weight loss participants lost a net of 6% of their body weight and 5 cm in waist circumference, 
similar results were observed for BMI. Fasting glucose decreased by 4.3 mg/dL in the lifestyle 
weight loss intervention versus a decrease of 0.4 mg/dL in the usual care participants. This 
intervention demonstrated that the HELP PD project was successful in reducing blood glucose, 
insulin, body weight, waist circumference and BMI over 12 months in overweight and obese 
individuals with pre-diabetes. While healthy eating advice was provided to participants in this 
study, no specific analysis of dietary change was undertaken. 
 
In another study, the ‘Pre-diabetes Risk Education and Physical Activity Recommendation and 
Encouragement’ (PREPARE) programme, based in the UK, aimed to improve glucose 
regulation in 98 overweight or obese individuals with IGT. The PREPARE programme was 
designed to assess the effectiveness of a group based structured education programme targeting 
individuals with pre-diabetes, promoting the benefits of physical activity, specifically walking 
(Yates, Davies, Sehmi, Gorely and Khunti, 2011). Subjects were randomised into one of three 
groups. Group one (control) subjects received an advice leaflet containing information relating 
to T2D. Group two subjects (education) received a structured three-hour education programme 
which was delivered by trained educators and provided information regarding the benefits of 
at least 150 minutes of physical activity each week in regulating glucose, action planning and 
goal setting. Group three subjects (education with pedometer) received the same three-hour 
education programme but were also provided with a pedometer and steps per day targets to 
assist with goal setting. Subjects in group two and three both received one-to-one counselling 
at three and six months. An OGTT was carried out at three, six and 12 months as well as 
measurements for body weight and waist circumference. Post two-hour glucose reduced 
significantly in group three subjects although no significant difference was observed in the 
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education only group. Six control participants, four education only participants and two 
education-with-pedometer participants were diagnosed with T2D after 24-months; this equated 
to a 19 and 61% reduction in the relative risk of developing diabetes in the education and 
education-with pedometer groups, respectively. These data provide support for the 
implementation of lifestyle interventions targeting high risk individuals while also 
demonstrating the potential use of wearable technology in combating T2D development. The 
feasibility of using such technology will be explored in a later chapter of this thesis.  
 
In contrast to the beneficial findings of other studies, a 16-week randomised control trial found 
no benefit of additional T2D preventative support compared to modest standard care (Nilsen, 
Bakke and Gallefoss, 2011). This work examined the effects of individual counselling 
compared to individual counselling with additional group education on lifestyle behaviours 
related to T2D in at risk participants (n = 182). These included; 5% weight reduction, 5 cm 
waist circumference reduction, improvement in exercise capacity and improved dietary 
behaviours. Participants receiving individual counselling met a physician at baseline, six, 12 
and 18 months whereas the additional group based educational programme participants 
attended six workshops covering diabetes avoidance, nutrition, physical activity, behaviour 
change, lifestyle planning and an element of physical training. At each visit, fasting blood, 
blood pressure, waist circumference and weight were recorded and an OGTT, dietary 
questionnaire (Smart Diet Score Questionnaire) and physical fitness assessment completed. 
Follow up at 18 months revealed significant improvements in anthropometric measures, 
aerobic capacity and dietary behaviour although diastolic BP increased. Significantly however, 
values for HbA1c remained similar after 18 months. Additional group intervention had no 
further benefit on the results, suggesting modest contact time with health professionals may 
provide enough stimuli to improve measures related to T2D risk. 
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Another community-based lifestyle intervention was administered at a community centre to 
low-income individuals at risk of T2D in the USA (Ockene et al., 2012). Three-hundred and 
twelve individuals were randomised to receive either lifestyle intervention or usual care. 
Lifestyle intervention participants received three individual and 13 group sessions focussing 
on T2D prevention, positive attitudes towards physical activity and dietary change, self-
monitoring and goal setting. Individual sessions were completed in participant’s homes and 
group sessions at a community site. Sessions were delivered by trained members of the 
community with experience of nutrition education, although none were dieticians. Following 
one year, intervention participants lost significantly more weight which was accompanied by a 
significant decrease in HbA1c and insulin resistance. Additionally, intervention participants 
demonstrated significantly greater reductions in percentage fat intake. Weight change was 
associated with session attendance with individuals attending more than seven sessions losing 
on average 4.75 lb compared to those attending less than seven sessions losing 0.13 lb.  
Changes in HbA1c were not associated with changes in dietary behaviour with the authors 
suggesting dietary analysis through a recall questionnaire was insufficiently sensitive to allow 
for meaningful analysis. Improved analysis techniques may be able to demonstrate, for 
example, associations between improved dietary behaviours with reductions in HbA1c. Such 
inaccuracies in dietary monitoring methods will be discussed and examined in latter chapters 
of this thesis.  
 
Individuals of south Asian origin have a well-established susceptibility to T2D, greater than 
other ethnic backgrounds, and therefore the Prevention of Diabetes and Obesity in South 
Asians (PODOSA) study tested the effectiveness of a three-year intervention targeting weight 
loss and increasing physical activity in this UK cohort (Bhopal et al., 2014). One-hundred and 
seventy-one participants were randomised to receive either the intervention, consisting of 15 
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visits from a dietician over three years, or control where participants received four dietician 
visits over the same period. All visits were co-ordinated by an academic research facility but 
took place in participant’s homes. Dietician visits in the intervention group focussed on T2D 
prevention, weight loss, increasing physical activity and improving dietary behaviours. 
Additionally, intervention participants received pedometers to monitor physical activity. 
Control group subjects received standardised written and verbal advice on T2D prevention, 
healthy eating, physical activity and how to access weight control and physical activity 
services. All participants were visited by a dietician after one, two and three years for 
monitoring. After one year, intervention participants lost more weight compared to control and 
this was sustained over three years. Control participants lost weight in year one but had gained 
weight by year three. Changes in body weight over three years were related to changes in BMI, 
waist and hip circumference. OGTT values decreased in both groups after three years although 
decreases were not significant. Progression to T2D however was lower in intervention 
participants while blood pressure remained similar across treatment groups. Financial analysis 
in the intervention group revealed a significant cost per person of £1126 to achieve modest 
changes in weight and other variables related to T2D development.  
 
1.6. Health Care Settings  
Compared to experimental settings, where resources are plentiful and often well-funded, T2D 
prevention in health care or ‘real world’ settings pose several challenges. Lifestyle intervention 
programmes often require considerable resources including; staff expertise, specialised 
equipment, appropriate facilities and time availability which are often unavailable or restricted 
in front line health care practice. Further to this, resource and time intensive intervention in 
clinical settings may decrease access for socioeconomically deprived and geographically 
isolated groups. Increasing financial burdens imposed on health services, caused in part by an 
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increasing and ageing population and reduced healthcare budgets, mean less time intensive and 
low-cost interventions are required to help tackle the increasing T2D prevalence. Therefore, 
several research studies have examined the effectiveness and viability of health care led 
prevention schemes on T2D incidence in at risk cohorts.  
 
Absetz et al. (2007) reports on the effectiveness of the Good Ageing in Lahti Region (GOAL) 
Lifestyle Intervention Trial conducted in health care centres in Finland. Three-hundred and 
fifty-two subjects at increased risk of T2D were contacted based on pre-identified risk factors 
including obesity, high blood pressure and impaired blood glucose values. To measure the 
success of GOAL, five key lifestyle changes were implemented including; < 30% of total 
energy intake from fat, < 10% of total energy intake from saturated fat, at least 15 g of fibre 
per 1000 kcal, at least four hours a week of moderate physical activity and > 5% reduction of 
body weight. It was hypothesised that the adoption of at least four of these lifestyle changes 
would be enough to prevent the onset of T2D and demonstrate that successful adoption of these 
objectives would indicate the intervention as a success for that individual. To support lifestyle 
change, individuals received six counselling sessions, five of which were conducted during an 
eight-week period and the final session taking place after eight months. During each 
counselling session, individuals were provided information on T2D prevention which was 
supported by group discussions, methods for effective goal setting and self-behavioural 
monitoring. Additionally, individuals received access to a dietician during one of the sessions 
and introduced to sports facilities by a sports officer. All lifestyle measures were collected by 
a practice nurse following recruitment and then after 12 months of the intervention. Dietary 
intake was measured using a three-day food diary. Compared to baseline measures, significant 
differences were found in the attainment of the lifestyle measures stipulated by the intervention 
after one year. The highest success rates were identified in individuals who already met the 
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lifestyle objectives during baseline (20% of total group). This is identified as a limitation, with 
the study suggesting the reason for this is due to recruitment occurring among healthcare 
patients who may already have had access to lifestyle counselling and therefore already having 
made positive changes to their lifestyle behaviours. The intervention decreased T2D risk 
factors which included marked reductions in diastolic blood pressure, weight and BMI (males) 
and waist circumferences (males and females) but did record a statistically significant increase 
in FPG in females and a non-significant increase in males. Despite increases in FPG, the values 
remained within a range considered to be normal.  
 
However, improved glucose values were demonstrated in a T2D prevention programme 
conducted in Australian primary health care using 237 participants at moderate and high risk 
of T2D, identified by FPG and/or an OGTT (Laatikainen et al., 2007). Participants received 
six 90-minute group sessions run by trained nurses covering topics including T2D education, 
diet, physical activity and goal setting techniques. Targets included reductions in body weight, 
total and saturated fat consumption, increase fibre consumption and to exercise more regularly. 
Measures including; height, weight, waist and hip circumference, blood pressure, fasting 
glucose and lipid profile were collected at baseline, three months and one year. From the 79 
patients with impaired glucose values at baseline, 42 reverted back to normoglycemia at 12 
months while five developed T2D. After three months, significant improvements in weight, 
waist circumference, total and LDL cholesterol were recorded and were sustained at 12-month 
follow up. Fasting glucose, HDL cholesterol, triglycerides and diastolic blood pressure were 
significantly improved after 12 months. Furthermore, questionnaire responses regarding bodily 
pain, physical functioning and mental health showed significant improvements after 12 
months. This study demonstrates the applicability of such a method to ‘real world’ clinical 
settings and suggests future implementation could be generalizable to wider primary health 
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care locations.  
 
A similar study by Payne et al. (2008) assessed the effectiveness of a low resource lifestyle 
modification programme targeting socioeconomically deprived and geographically isolated 
groups at risk of T2D in Australian primary care based on T2D risk factors. This work 
examined the effects of resistance training in the home compared to a gymnasium accompanied 
by appropriate clinical support. The 12-month intervention included goals to reduce weight by 
> 5%, achieve 150 minutes of weighted resistance exercise each week and an additional five 
sessions of moderate intensity exercise. Dietary goals included < 30% of total energy intake 
from fat and < 10% from saturated fat. Six 90-minute educational sessions covering topics 
including self-management, self-monitoring, goal setting, physical activity and dietary habits 
were completed by all participants before randomisation into 11 weeks of either home-based 
or gymnasium-based resistance exercise followed by a 33-week maintenance programme. 
Assessments on plasma glucose, blood pressure, blood lipids, BMI, waist circumference, 
physical activity level (Active Australia Survey) and dietary behaviours (Food Frequency 
Questionnaire) were made at baseline and after one year. 122 participants (4.9 % IFG and 32 
% IGT) were recruited of which 98 attended a one year follow up. Significant reductions were 
recorded in the proportion of participants with IFG or IGT while significant improvements 
were recorded in participants reaching dietary and body composition targets. Interestingly, 
home and gym-based resistance training resulted in similar changes across all the measured 
variables, except for systolic BP, which decreased significantly more in the gymnasium trained 
group. The effectiveness of a low resource cost effective T2D intervention led by primary care 
is demonstrated here and provides viable evidence that such an approach, where financial and 
resource restrictions exist, can help prevent T2D in deprived, isolated groups and may have 
potential to be applied to similar groups in other countries.  
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The Kaiser Permanente Colorado Organisation (KPCO) aimed to develop a weight loss 
programme effective in preventing the onset of T2D in primary health care settings with modest 
or limited resources. This study, by Almeida, Shetterly, Smith-Ray and Estabrooks (2010) had 
access to 14,379 individuals classified as having IFG. Individuals were eligible if fasting 
glucose was measured between 100 – 125 mg/dL. From the 12,468 individuals eligible based 
on the above guidelines, 1030 attended a single group meeting which gave advice and planning 
on healthy nutrition, physical activity and weight loss. Each intervention participant was 
matched with one or two control subjects who were not participating. Matching of control 
subjects to participating subjects was based on the month and year of the fasting glucose 
sample, sex, age (within five years) and BMI (within two units). Analysis after 12 months of 
the intervention revealed body weight had decreased significantly compared to matched 
controls. Individuals participating in the small group classes lost at least 5% of their body 
weight and were 1.5 times more likely to lose 5% of their body weight in comparison to control 
subjects. This study demonstrated a single session which provided advice on healthy eating 
and physical activity was beneficial in reducing weight in individuals considered to be pre-
diabetic and at risk of T2D. The work also showed the programme’s capability to be delivered 
within a primary health care setting of limited resources although does concede the intervention 
did not broadly reach all areas of the community at risk of diabetes and may suggest an element 
of self-selection. Despite this limitation, this work suggests a similar model could be applied 
to T2D prevention in the UK where financial and time resources are limited.  
 
In Finland, the National Program for the Prevention of T2D (FIN-D2D) was implemented in 
five hospital districts with the aim of identifying individuals at increased risk of T2D (Saaristo 
et al., 2010). Those identified were provided with lifestyle change support designed to reduce 
future risk of T2D development. High risk individuals were identified using the Finish Diabetes 
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Risk Score which was used opportunistically within health centres, pharmacies and health 
fayres. Individuals with risk scores > 15 were considered at increased risk of T2D and referred 
to FIN-D2D. Individuals were also considered eligible for referral if they had a history of IFG, 
IGT, cardiovascular disease or gestational diabetes. Measures including height, weight, waist 
circumference, blood pressure, and an OGTT and lipid profile were collected at baseline and 
follow up. The intervention visits comprised of individual counselling sessions as well as 
group-based meetings led by nurses. Sessions focused on body weight, meal frequency, fat 
intake, alcohol consumption, benefits of physical activity and smoking cessation. Group 
lectures regarding T2D and lifestyle behaviour change were also provided. The frequency and 
duration of visits varied between practices depending on local resources and circumstances. 
Baseline and one year follow up data from 2798 nondiabetic at risk individuals revealed a mean 
decrease in body weight of 1.3 kg in men and 1.1 kg in women with the reductions associated 
with a mean 1.3 cm decrease in waist circumference. Blood pressure decreased alongside total 
cholesterol, LDL cholesterol and triglyceride levels which decreased by 5-8% and 2-5% in men 
and women respectively. Seventeen and a half percent of individuals lost > 5% body weight, 
16.8% lost between 2.5 - 4.9% body weight and 46.1% maintained body weight. 19.6% of 
individuals gained > 2.5% body weight. The greatest decreases in blood pressure were observed 
in individuals who lost > 5% body weight. Incidence of T2D was 2% and 1.2% in men and 
women with normal baseline glucose tolerance, 13.5% and 7.4% in those with IFG and 16.1% 
and 11.3% in IGT respectively (Saaristo et al., 2010). Greater than 5% decreases in body 
weight were associated with a 69% reduction in T2D risk after one year and demonstrate 
moderate weight loss is effective in reducing the risk of T2D development.  
In 32 primary care centres in Japan existing resources were used to deliver lifestyle intervention 
to individuals at risk of T2D (Sakane et al., 2011). Three-hundred and four participants were 
randomised to detailed bi-annual T2D support, delivered by practice nurses covering topics 
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including general T2D information, T2D prevention, healthy eating and physical activity with 
additional regular contact delivered to support behaviour chance. Nutrition and physical 
activity were assessed by food frequency questionnaire and the compendium of physical 
activities, respectively. Control group participants received one group session on healthy 
lifestyle behaviours and T2D prevention at baseline although no additional support was given. 
Anthropometric and blood measures were collected regularly from both groups. Results after 
one year demonstrated significantly improved body weight, energy expenditure and insulin 
sensitivity in the intervention group compared to control. T2D incidence was lower in the 
intervention group compared to control but was not significant.  
 
As part of the Diabetes in Europe – Prevention using Lifestyle, Physical Activity and 
Nutritional intervention health care professionals in 18 primary health care facilities in Spain 
conducted T2D risk evaluation (Costa et al., 2012). Screening took place in the form of 
questionnaires which calculated individual diabetes risk scores and gathered further 
information such as age, sex, weight, height, waist circumference, use of medications, history 
of high blood glucose, physical activity, family history of diabetes and daily consumption of 
fruits and vegetables. On a second occasion an OGTT was performed to confirm eligibility, a 
blood glucose of > 7.8 mmol/mol and < 11.1 mmol/mol two hours post glucose load. Eligible 
participants also completed a basic questionnaire which was designed to offer baseline and 
future indications of dietary and physical exercise habits (FINDRISC). The study consisted of 
two separate interventions, the standard care intervention and the intensive intervention (group 
and individual). For all groups, targets were set for lifestyle intervention which included; 
consuming a maximum of 30% of daily energy from fat, a maximum of 10% of daily energy 
from saturated fat and a minimum of 3.6 g/1000 kj of fibre, completing a minimum of 30 
minutes of moderate intensity exercise a day, and achieving at least a 3% weight reduction. 
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Participants randomised into the standard care group received information on nutrition, 
cardiovascular health and T2D but received no additional support other than optional future 
visits to health care centres. Intensive group participants received a group based six-hour 
educational programme and additional training materials, and were provided with in-depth 
information on T2D risk, diet, physical exercise and tobacco use. Participants in the intensive 
‘individual’ group received similar information which was provided on a one-to-one basis. 
Regular phone contact was made with participants to ensure motivation was maintained 
throughout the intensive intervention. 168 individuals were placed into the standard care group, 
171 into the ‘individual’ intensive group and 162 into the ‘group’ intensive group. It is notable 
that there was a large dropout rate during the intervention process. In total, 228 individuals 
ceased their participation, 102 in the standard care group and 126 in the intensive interventions 
(breakdown of withdrawals from individual and group intensive interventions not provided). 
Reasons for ceasing involvement ranged from time commitments, illness and death. The 12-
month follow up found a modest 24.7% of individuals in the intensive group and 18.8% of 
individuals in the standard care group reduced their weight by at least 3% with the study also 
demonstrating the risk of developing diabetes was reduced by 36.5% in the intensive 
intervention group when compared to the standard care group. Subsequently, the study 
recommended all individuals attending health care centres should be screened for T2D with 
those at risk being referred to academically tested intervention programmes.  
 
In another European study, a comparison between T2D lifestyle intervention and usual care in 
Dutch general practice was investigated by Vermunt et al. (2012). Nine-hundred and twenty-
five participants from 14 practices were randomised to receive either intervention or usual care. 
Intervention participants received eleven 20-minute consultations focussing on behaviour 
change, five group meetings addressing diet and physical activity and an additional one-hour 
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consultation with a dietician. Control group participants received only oral and written 
information about T2D at baseline. Both groups attended follow up appointment after six, 18 
and 30 months. Despite significantly higher contact time in the intervention group, there was 
no significant difference in effects between intervention and control with both groups 
demonstrating modest changes in body weight, blood glucose concentration, physical activity 
and dietary intake. The authors suggest one possible explanation may be due to control 
participants becoming motivated to change behaviour by the prospect of annual check-up visits. 
This suggests time intensive intervention in primary care may not be necessary and only limited 
visits to primary care centres with subsequent monitoring are needed to achieve modest 
changes in variables associated to T2D.  
 
Despite previous studies consistently demonstrating the success of primary care lifestyle 
interventions reducing incidence of T2D, evidence from the UK (translating diabetes 
prevention research into clinical practice) remained to be elucidated, therefore leading to the 
UK based intervention ‘Let’s Prevent Diabetes’ (Gray et al., 2012). This work targeted 
evidence regarding the long-term effectiveness of a structured, educational diabetes prevention 
programme targeting lifestyle and behaviour change, conducted within primary care settings. 
The intervention programme consisted of two phases. Firstly, a screening phase to identify 
patients at risk of T2D using an automated validated risk tool and secondly, the intervention 
phase. The automated risk score used data routinely stored on practice computer databases. The 
top 10% of scorers from surgeries were considered at highest risk and invited for further 
screening. Patients were classified as pre-diabetes if fasting blood glucose ranged between 6.1-
6.9 mmol/mol and between 7.8-11 mmol/mol two hours following an OGTT. Height, weight, 
waist circumference, blood pressure, seven-day step count, T2D family history, smoking status, 
alcohol consumption, occupation, sleeping habits were all recorded alongside level of social 
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deprivation. Fat and fibre intake were assessed using the DINE food frequency questionnaire.  
 
Eligible patients were randomised at GP practice level by an independent researcher into either 
the control arm or intensive arm intervention. Control patients received an information booklet 
detailing the risk factors associated with T2D and how changes to physical activity levels and 
lifestyle can be used to prevent or delay progression of T2D. Control arm patients attended 
follow up appointments at the same time points as the intensive arm patients. Patients in the 
intensive arm intervention received the same information booklet as the control arm patients 
as well as an invitation to ‘Let’s Prevent’, a six-hour structured education programme, nursing 
support phone calls every three months and a yearly three-hour updated structured education 
programme to review key messages and personal action plans. The goals from the programme 
were to achieve > 5% reduction in body weight, total fat intake < 30% of total energy intake, 
total saturated fat intake < 10% of total energy intake and increase fibre intake to > 15g for 
every 1000 calories consumed. For physical activity, patients were to increase their daily 
walking to 45 minutes per day or complete 4,500 steps. Patients received a pedometer to allow 
self-monitoring of physical activity to help promote goal setting and encouraged to increase 
their total by 500 steps per day, every two weeks. Throughout the three-year study, intervention 
arm patients were supported by three monthly phone calls from a nurse trained to support 
patients in behaviour change. Data were collected at six, 12, 24 and 36 months.   
 
A total of 880 patients were recruited into the study from 43 general practices with 447 patients 
and 433 patients randomised into the intervention and control arms respectively. Patients 
attending the initial educational session and at least one further session (retainers) were less 
likely to develop T2D in comparison to patients in the control arm.  Retainers were associated 
with improved glucose control and daily step count and reduced HbA1c, weight, waist 
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circumference and anxiety. The results from the ‘Let’s Prevent Diabetes’ study demonstrate 
that high risk patients who engage with and are retained in a T2D prevention programme are 
at less risk of developing T2D in comparison to patients who received standard care. The study 
highlights the importance of engaging with patients who are classified as non-engagers and 
non-retainers as these hard-to-reach groups exhibit high risk T2D characteristics. Furthermore, 
the likelihood of study participation based upon socio-economic status demonstrates the 
requirement to test such intervention programmes across a range of different cohorts where 
intervention success may vary.  
 
Given the relative success of Gray et al’s findings in combating T2D in the UK, NHS England, 
in partnership with Public Health England and Diabetes UK, implemented the NHS Diabetes 
Prevention Programme (NHS DPP), an intensive lifestyle management intervention aimed at 
individuals at high risk of T2D. Launched in June 2016, patients are screened at primary care 
level with those considered at risk, based upon elevated HbA1c (42-47 mmol/mol) and/or BMI 
> 25 kg/m2, offered 13 educational group sessions over a nine-month period. Each session lasts 
between one and two hours and focuses on education and exercise with the aims of improving 
dietary behaviours, increasing physical activity and targeting weight loss. The programme is 
designed primarily to decrease the current and future workload burden on the NHS by 
providing an end to end behaviour change intervention outside of immediate primary care to 
reduce the future prevalence of T2D through the delivery of an evidence-based intervention. 
The NHS DPP intends to have the programme available across the entirety of England by 2019 
with 100,000 places available each year for patients to access. As a recently implemented and 
ongoing programme, full analyses of the intervention have yet to be undertaken. However, 
early indications suggest the programme is exceeding targets for both referrals into and patient 
engagement in the programme, resulting in a mean weight loss of 3.7 kg after 1 year of 
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participation (NHS DPP, 2018) and a decrease in HbA1c of 1.26 mmol/mol (Valabhji et al., 
2019). Data detailing the characteristics of participants engaging with the DPP demonstrate it 
is successfully reaching groups who are most at risk of T2D. In year one of the programme for 
example, 25% of patients were from black and ethnic minority groups, and 45% were under 
the age of 65 years. Data also found that 44% of those taking up the programme are male; a 
significantly higher percentage than typically attend commercial weight loss programmes. 
Significantly though, this programme is only available to patients in England, with no such 
access available for the remaining countries within the UK, including Wales, where T2D 
incidence is highest.  
 
1.7. Summary 
Abundant evidence demonstrates the significant impact lifestyle interventions, which promote 
and facilitate increased physical activity and improving dietary behaviours, have on T2D 
development in at-risk groups. Improvements in measures related to T2D risk have been 
demonstrated across groups of different nationality, ethnicity and socio-economic background, 
suggesting strong applicability to all populations, although such assumptions must be examined 
in untested cohorts. A common theme however in many of the above studies and interventions 
is the volume of resources required for successful T2D prevention.  
 
For example, while numerous intervention programmes have shown health benefits, some are 
time intensive, resource heavy and financially expensive, with Bhopal et al. (2014) 
demonstrating significant costs of over £1000 per participant. In other cases, resource heavy 
programmes did not always result in additional benefit to at risk persons. A 16-week 
randomised control trial found no benefit of additional T2D prevention support (Nilsen, Bakke 
and Gallefoss, 2011) when the effects of short individual counselling sessions were compared 
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to individual counselling with additional group education on lifestyle behaviours relating to 
T2D. Additional group intervention had no further benefit on T2D related outcomes, 
suggesting modest contact time with health care professionals provided sufficient stimuli for 
patients to improve measures related to T2D risk, including anthropometric measures, aerobic 
capacity and dietary behaviours. In support of this conclusion, the work by Vermunt et al. 
(2012) found participants in the intervention group, who received eleven 20-minute 
consultations focussing on behaviour change, five group meetings addressing diet and physical 
activity and an additional one-hour consultation with a dietician, demonstrated no significant 
changes in body weight, blood glucose concentration, physical activity and dietary intake in 
comparison to control participants who received only written T2D advice. The authors suggest 
a possible explanation may be because control participants became motivated to change 
behaviour by the prospect of annual check-ups with a health care professional. This could 
suggest time intensive intervention in primary care may not be necessary and only limited visits 
to primary care locations with subsequent monitoring are needed to achieve changes in 
variables associated to T2D. Almeida, Shetterly, Smith-Ray and Estabrooks (2010) support 
this notion in their findings where it was demonstrated that a single session providing advice 
on healthy eating and physical activity was beneficial in reducing weight in individuals 
considered to be pre-diabetic and at risk of T2D. The work also showed the programme’s 
capability to be delivered within a primary health care setting of limited resources and suggests 
a similar design could be implemented in other health authorities and targeted towards pre-
diabetic groups where effective treatments are required which can be feasibly implemented 
within health board budgets. Furthermore, findings by Gray et al. (2012) suggest that 
participation in the ‘Lets Prevent Diabetes’ study was dependent upon socio-economic status 
and therefore demonstrates the requirement to test intervention programmes across a range of 
different cohorts and locations where intervention success may vary.  
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Based on the evidence of increasing T2D prevalence in the UK, intervention in some form is 
crucial in preventing T2D. However, the degree to which healthcare services should intervene 
and to what depth interventions should go to achieve a balance between effectiveness and 
resource cost, is debatable. As stated by Dunkley et al. (2014), who reviewed the effectiveness 
of lifestyle interventions in preventing T2D, more research is needed to establish the best 
strategies for maximizing both cost-effectiveness and longer-term maintenance of weight loss 
and diabetes prevention effects.  An intervention design, based on upon a single appointment 
with a healthcare professional where information on T2D risk and ways to combat T2D 
development is given, may provide enough benefit for pre-diabetes patients in some cohorts as 
well as limit the time, resource and financial pressures often experienced within healthcare 
settings in trying to combat non-communicable diseases, such as T2D. Given the alarming 
increase in incidence of T2D in the UK, the implementation of lifestyle interventions that are 
effective in preventing the development of T2D in those at increased risk is critical. This is 
especially crucial for both patients and UK healthcare providers in locations where no T2D 
prevention pathways are currently in place. While T2D prevention programmes have been 
implemented and evaluated successfully in countries across the world, there is a lack of lifestyle 
intervention programmes for people at risk of T2D living in Wales. Despite significant support 
being provided for T2D prevention in England, a similar model for the remaining areas of the 
UK has yet to be implemented, nor has significant funding been made available to address the 
issue. This is despite the prevalence of the disease being highest in Wales compared to the 
remaining areas of the UK (Diabetes UK, State of the Nation, 2015) and there being a 
considerably portion of the Welsh population at increased risk of T2D. Given the health 
complications associated with T2D as well as financial implications involved in treating the 
condition, it is of extreme importance that an effective pathway is implemented within NHS 
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Wales’ healthcare structure which has been thoroughly evaluated and proven to be effective in 
reducing population T2D risk.  
 
1.8. Thesis Aims and Objectives 
The overall aims and objectives of this thesis are: 
 
Aim: 
Evaluate the efficacy of an educational consultation delivered through primary care in reducing 
progression to T2D in a north Ceredigion pre-diabetic population.  
 
Objectives: 
 Complete service evaluation of the North Ceredigion GP cluster pre-diabetes 
intervention. 
 Develop and validate methods to quantify dietary changes over time. 
 Establish the feasibility of conducting a randomised control trial to establish the 










Chapter Two:  
 




The cost of the care and treatment associated with diabetes across the UK is currently estimated 
at £23.7 billion per year (includes both the direct and indirect costs; Diabetes UK, State of the 
Nation, 2015). By 2035 it is predicted that this will increase to £39.8 billion by which time it 
is estimated 4.9 million people will have T2D. In Wales the incidence of T2D is increasing at 
an alarming rate, in 2015 it was estimated that 182,600 people had T2D and by 2025 that 
number will increase to 300,000 (Diabetes UK, State of the Nation, 2015). The financial 
implications for NHS Wales are huge, with approximately 10% of the annual budget spent on 
treating the condition and its complications, a figure that equates to approximately £500 million 
spent treating a highly preventable disease (Diabetes UK, State of the Nation, 2015). Of great 
concern are the estimated 540,000 individuals in Wales currently at risk of developing T2D as 
approximately 10% of unaddressed cases will progress to T2D (Tabak et al., 2012). In the 
absence of effective treatments and interventions these estimations are projected to increase 
(Diabetes UK, State of the Nation, 2015).  Given the increasing rate of T2D cases in Wales and 
projected future cases, there is an urgent need for effective intervention programmes which can 
delay or prevent the onset of T2D. 
 
In England the NHS, in partnership with Public Health England and Diabetes UK, have 
implemented the NHS Diabetes Prevention Programme (NHS DPP), an intensive lifestyle 
management intervention aimed at individuals at high risk of T2D. Patients are offered at least 
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13 sessions, each lasting between one and two hours, which focus on education and exercise 
with the aims of improving dietary behaviours, increasing physical activity and targeting 
weight loss. The NHS DPP intends to have the intervention available across England by 2019 
with 100,000 places available each year for patients to access. In Wales however, no such 
programme is available. Given the success of other interventions in preventing T2D (DPP 
Research Group (2002), Almeida, Shetterly, Smith-Ray and Estabrooks (2010), Yates, Davies, 
Sehmi, Gorely and Khunti, (2011), Gray et al., (2012) and Piper, Marossy, Grffiths and 
Adegboye (2017)), there is an evidence-base for the implementation of a similar preventative 
model within Wales where the incidence of T2D is increasing year on year. 
 
The Hywel Dda University Health Board (HDUHB) covers approximately 25% of the 
landmass of Wales, containing the local authorities of Pembrokeshire, Carmarthenshire and 
Ceredigion. The HDUHB has an estimated patient population of 375,000, of which 5.9% 
(22,000) have diabetes (Diabetes Delivery Plan, 2013-2016). Patients in north Ceredigion are 
served by seven GP surgeries which make up the North Ceredigion GP cluster. Three of these 
surgeries are in Aberystwyth: Church, Padarn and Ystwyth with the remaining four located in 
Borth, Tregaron, Llanilar and the Tanyfron surgery located in Aberaeron. In 2015 the cluster 
initiated a GP-led pre-diabetes intervention targeting lifestyle modification, aimed at reducing 
the number of patients developing T2D by identifying, educating, monitoring and signposting 
patients to lifestyle support services. The intervention consisted of a 30-minute one-to-one 
patient consultation delivered through general practice with opportunity for exercise (NERS) 
and dietary (FoodWise) referral. Previous work has shown that a single educational session 
focussing on improved lifestyle behaviours can be successful in reducing incidence of T2D in 
healthcare (Almeida, Shetterly, Smith-Ray and Estabrooks, 2010). Additionally, significant 
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reductions in T2D risk following referral to lifestyle groups outside of primary care have been 
demonstrated (Piper, Marossy, Grffiths and Adegboye, 2017).  
 
Aim: 
• Evaluate the efficacy of a T2D prevention programme with a 30-minute educational 
consultation aimed at reducing the risk of patients developing T2D in the North Ceredigion 




• Compare HbA1c, body mass, BMI, waist circumference and blood pressure, measured during 
the initial 30-minute one-to-one consultation and subsequent follow up appointments at 12 and 







2.2.1. Participants and Ethical Approval 
The seven surgeries which make up the North Ceredigion cluster were serving a total of 47,107 
patients when the programme commenced (Table 2.1). Each surgery reviewed patient records 
and identified up to 4.5% of their patient list for invitation into the programme.  
Inclusion criteria: 
 Registered patient at a participating surgery 
 Between the ages of 18-75 years old  
 HbA1c between 42-47 mmol/mol  
 
GP professional judgement, using National Institute for Health and Care Excellence (NICE) 
guidance, was used for any patient where eligibility was unclear. 
Exclusion Criteria: 
 Existing comorbidities which would make exercise contraindicated 
 
 
Table 2.1. Summary of practice populations as of 1st April 2016 and the number of patients 
invited to engage in the programme, 4.5% of patient list 
 
Surgery Practice populations (1st April 2016) 4.5% of practice population 
Borth 2,664 120 
Church 11,150 501 
Llanilar 3,215 144 
Padarn 11,577 520 
Tanyfron 7,426 334 
Tregaron 3,553 160 
Ystwyth 7,516 338 
TOTAL 47,107 2,118 
 
 





The pre-diabetes intervention programme was developed by Aberystwyth University (IBERS) 
in conjunction with the seven participating surgeries. Specifically, the structure of the 30-
minute one-to-one consultation was developed by Aberystwyth University and Church 
Surgery. During the developmental phase, the consultation was designed and suitable 
information leaflets and questionnaires relating to pre-diabetes were identified (detailed 
below). Information regarding the structure and contents of the consultation was then 
disseminated to the remaining six surgeries to begin the initial stages of the intervention.  
 
The information included in the consultation and supporting documentation was based upon 
the latest NICE guidelines regarding physical activity and healthy eating behaviours. Eligible 
patients received an information pack via the postal service to their home address outlining 
their T2D risk and inviting them to attend an appointment at their registered surgery for a 30-
minute, one-to-one consultation with a health care professional (this could be a practice nurse 
or GP and varied from surgery to surgery). Patients were encouraged to book their consultation 
either by phone call or in person at the surgery.  
 
Within the information pack (see appendix; A, B, C, D) patients received; an invitation letter; 
a GP designed leaflet providing general information on pre-diabetes and the risks associated 
with T2D, a dietary intake questionnaire (Starting the Conversation) and the International 
Physical Activity Questionnaire - Short Form (IPAQ-SF). The IPAQ-SF is a seven-point 
validated questionnaire designed primarily for physical activity surveillance in adults and 
represents a feasible approach for conducting physical activity surveillance in large groups (van 
der Ploeg et al., 2010). The IPAQ-SF collects data on the amount of time respondents complete 
vigorous and moderate physical activity, the amount of time spent walking and sitting, with 
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responses for all questions based upon a typical week. The cumulative amount of time spent 
engaging in each activity is used to categorise respondents as either inactive, minimally active 
or HEPA (Health Enhancing Physical Activity) active. Work by Craig et al. (2003) 
demonstrated the IPAQ-SF to correlate reasonably well (P = 0.4) with accelerometer data in a 
UK cohort. The Starting the Conversation questionnaire is an eight-point validated screening 
method designed for clinical practices to quickly assess patient dietary habits. It identifies 
dietary patterns and was derived from a validated 54-item instrument (Paxton, Strycker, 
Toobert, Ammerman and Glasgow, 2011). The questionnaire scores respondents on a scale 
between zero and 16. A score of zero indicates a healthy, balanced diet whereas a score of 16 
indicates an unhealthy diet. Both questionnaires were completed by patients prior to the 
consultation. Responses from the Starting the Conversation and IPAQ-SF questionnaires were 
used to help identify goals for patients and provide appropriate conversational direction during 
the second half of the consultation (data from questionnaires were not forwarded by the 
surgeries for analysis).  
 
On arrival at the surgery, patients were met by a health care professional and the questionnaire 
responses were returned and scored. During the first phase of the consultation, baseline data 
were collected including; body mass (kg), height (cm; to calculate BMI), waist circumference 
(cm) and BP (mmHg). If a HbA1c had not been recorded during the preceding two months a 
blood sample was taken; analysis took place at Bronglais Hospital Pathology Laboratory, 
Aberystwyth.  All data collected were added to the patient’s medical record.  
 
During the second phase of the consultation patients were engaged in conversation, during 
which information regarding the benefits of physical activity and healthy eating in relation to 
T2D risk were discussed; all recommendations were based upon NICE guidelines. Physical 
42 
 
activity advice included the recommended completion of at least 150 minutes of moderate 
intensity activity each week, such as 30 minutes per day on five days of the week, or 
alternatively, 75 minutes of vigorous intensity activity spread across the week or combinations 
of moderate and vigorous intensity activity. Patients were also advised to undertake resistance 
exercise to improve muscle strength on at least two days a week as well as minimise the amount 
of time spent being sedentary for extended periods. Summarised advice regarding healthy 
dietary behaviours included eating at least five portions of a variety of fruit and vegetables 
every day, basing meals on wholegrain carbohydrates, choosing lower fat and lower sugar diary 
options, consuming beans, pulses, fish, eggs, lean meat and other proteins, choosing 
unsaturated oils and spreads, drinking six-eight cups/glasses of fluid a day and limiting the 
consumption of alcohol to no more than 14 units per week.  
 
Based on the professional judgement of the health professional, patients were signposted to 
local physical activity groups (walking clubs/parkrun UK/University exercise classes). 
Referrals were also made to the nutrition education initiative, Foodwise for Life, an eight-week 
evidence-based approach to weight management designed by public health dietitians in Wales 
and delivered by Public Health Network Cymru. Foodwise for Life focuses on adopting 
improved dietary habits, increasing levels of physical activity and employing behaviour change 
strategies to help facilitate weight loss. Each session consists of structured discussions, 
practical learning and group activities where participants enhance their understanding in 
relation to food portion sizes, food labelling, the benefits of regular physical activity and weight 
management planning. Patients requiring supervised exercise were referred to the National 
Exercise Referral Scheme (NERS). NERS is a structured 16-week supervised exercise 




1. An initial consultation collecting physiological data including resting heart rate, blood 
pressure, BMI and waist circumference, completion of lifestyle questionnaires, 
introduction to local leisure facilities and goal setting.  
2. Access to individualised and/or group exercise classes.  
3. Discounted rates for exercise activities.  
4. Four- and 16-week reviews with an exercise professional, evaluating targets set and 
goals achieved.  
5. Health check upon completion of 16 weeks and signposted to exit routes.  
6. Eight-month progress check conducted by a health professional and 12-month review 
including a repeated health check.  
 
Patients attended follow up appointments at their surgery after approximately 12 and 24 months 
with the same data collected as per the initial 30-minute consultation. In some cases, data 
relevant to the intervention were added to patient records during other GP appointments and 
therefore not collected during the initial consultation or follow up appointments. In such 
instances, data were only included in statistical analysis if they were collected within two 
months of the initial consultation or the follow up appointments. The primary outcome measure 
for evaluation of the intervention was HbA1c. Secondary outcomes were anthropometric 
measures and blood pressure.  
 
2.2.3. Data Extraction  
Data extraction for 12 months follow up took place in February 2017. Extraction for 24 months 
follow up took place between April and July 2018. Data were only included for analysis if 
returned during these extraction time points. Examination of 12-month data revealed 
inconsistencies in data extraction search terms, with some surgeries providing more data than 
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others. Therefore, pilot work prior to 24-month data extraction was conducted alongside 
Church surgery. This ensured a standardised data extraction method and meant the delivery of 
anonymised data from general practice to Aberystwyth University was tested prior to the 
remaining surgeries extracting and returning their 24-month data. Pilot data extraction by 
Church surgery took place in October 2017. To generate relevant patient data on the variables 
associated with the intervention database search terms were confirmed by Church surgery and 
distributed to the other practices to ensure all patient data were produced from identical search 
criteria before returned for analysis.  
 
2.2.4. Statistical Analysis  
All statistical analyses were performed using SPSS (version 17.0 for windows, SPSS Inc, 
Chicago, IL). Normally distributed data are presented as mean ± SD. For patients who attended 
a baseline and 12-month follow up appointment, normally distributed 12-month follow up data 
were analysed using paired t-tests. Non-normally distributed data are presented as median 
(range). Non-normally distributed 12-month follow up data were analysed using Wilcoxon 
signed rank test. For patients who attended a baseline, 12- and 24-month follow up 
appointment, normally distributed data were analysed using one-way repeated measures 
ANOVA. Significant differences were identified using post-hoc analysis with paired t-tests. 
Non-normally distributed data were analysed using Friedman’s test with significant differences 
in the data identified by post-hoc analysis with Wilcoxon signed rank test.  Correlation analysis 
was conducted to identify relationships in the data after the intervention by analysing change 
in body mass, BMI and waist circumference with change in HbA1c using Pearson’s (parametric 
data) and Spearman’s (non- parametric data) correlation test. Data from the seven surgeries 
were pooled and analysed as a total patient cohort. In addition, data from each of the seven 
surgeries were analysed independently. Statistical significance was accepted at P < 0.05. All 
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data are presented tabularly. Where statistically significant findings are observed, the data are 













































Figure 2.1 Eligible patients followed up after 1 and 2 years following a 30-minute one-to-one 
consultation with a health care professional in a primary care setting. *Data not provided by 









2.4. Baseline to 12-month follow up 
2.4.1. Subjects 
In February 2017 analysis of preliminary data took place, data on patients who had attended 
the initial 30-minute one-to-one consultation and a 12-month follow up appointment (n= 129) 
were analysed. The results from this analysis formed part of an interim report which was 
distributed to the participating surgeries, the HDUHB and presented at the Welsh Endocrine 
and Diabetes Society Spring conference, 2017 (Thatcher and Gregory, 2017). Between April 
and July 2018 data were extracted from the patient records for all surgeries, data for baseline 
and 12-month follow-up were available for 592 patients. 
 
2.4.2. Baseline to 12-Month HbA1c 
Analysis of HbA1c revealed significant decreases in six surgeries, due to limited data from 
Padarn surgery for HbA1c (n = 2) analysis was not conducted independently. HbA1c decreased 
in Borth surgery (P = 0.00), Church surgery (P = 0.00), Llanilar surgery (P = 0.00), Tanyfron 
surgery (P = 0.00), Tregaron surgery (P = 0.00) and Ystwyth surgery (P = 0.00). When the 
data were pooled across surgeries a significant decrease in HbA1c was observed (P = 0.00) 
(Table 2.2A and Figure 2.2). Of the 592 patients identified as pre-diabetic at baseline, 408 
patients’ HbA1c decreased, 96 increased and 88 remained the same. Of the 408 patients who 
had a reduction in HbA1c, 217 were below 42 mmol/mol, taking them below the threshold for 




Table 2.2A. HbA1c, Body Mass, BMI and Waist Circumference at baseline and 12 months following a 30-minute one-to-one consultation with a 
health care professional in a primary care setting. Data are represented as median (range). Statistical significance* is accepted at P < 0.05. (**An 
HbA1c of 112 mmol/mol provided by Ystwyth surgery at 12 months). 
 
 Borth Church Llanilar Padarn Tanyfron Tregaron Ystwyth Total 
HbA1c (mmol/mol) 
Number of Patients 93 106 99 2 54 115 123 592 
Baseline 43 (5) 43 (5) 44 (5)  44 (5) 43 (5) 44 (5) 44 (5) 
12 Months  43 (18) 42 (10) 42 (16)  42 (90) 42 (14) 43 (81) 42 (85)** 
Significance  0.00* 0.00* 0.00*  0.00* 0.00* 0.00* 0.00* 
Body Mass (kg) 
Number of Patients 65 103 92 8 55 94 94 511 
Baseline 79.6 (88.5) 78 (93) 80.8 (73) 99.8 (69.4) 82 (98.5) 86.1 (87) 83 (100) 82 (114.6) 
12 Months  79.2 (82.7)  75 (98) 81 (73) 100.6 (79.5) 83 (95)  85 (87) 81 (100) 81 (110) 
Significance  0.03* 0.00* 0.98 0.44 0.13 0.33 0.11 0.00* 
BMI (kg/m2) 
Number of Patients 62 103 92 8 55 93 93 506 
Baseline 28.1 (26.3) 28.3 (29) 28.9 (30.3) 38 (17.2)   28.6 (28.7) 30 (31.5) 29.5 (29) 29.0 (34.6) 
12 Months  28.5 (25.9) 27.6 (29.4) 29.1 (28.6) 38.2 (21.3)   28.3 (26.8) 30 (24.2) 29.2 (32.6) 28.8 (36.3) 
Significance  0.58 0.00* 0.96 0.31 0.30 0.40 0.89 0.00* 
Waist Circumference (cm) 
Number of Patients 23 99 69 7 55 53  306 
Baseline 104 (47) 99 (64) 100 (55)  124 (27) 104 (73) 101 (61)  100 (73) 
12 Months  104 (46) 97 (69) 97 (66) 124 (37) 104 (74)  102 (51)  100 (81) 






Table 2.2B. Systolic BP and Diastolic BP at baseline and 12 months following a 30-minute one-to-one consultation with a health care professional 
in a primary care setting. Data are represented as median (range). Statistical significance* is accepted at P < 0.05. 
 
 Borth Church Llanilar Padarn Tanyfron Tregaron Ystwyth Total 
Systolic BP (mmHg) 
Number of Patients 58 97 62 8 55 84 112 476 
Baseline 132 (108) 130 (60) 135 (56) 135 (45) 127 (52) 132 (90) 140 (93) 133 (110) 
12 Months  130 (73) 130 (50) 132 (87) 143 (48) 132 (61) 134 (83) 137 (87) 132 (97) 
Significance  0.72 0.41 0.98 0.39 0.90 0.15 0.36 0.81 
Diastolic BP (mmHg) 
Number of Patients 58 97 62 8 55 84 112 476 
Baseline 70 (48) 80 (53) 78 (43) 75 (51) 78 (34) 78 (50) 75 (46) 77 (70) 
12 Months  70 (64) 80 (52) 79 (49) 80 (49) 78 (44) 78 (52) 80 (52) 78 (74) 











Figure 2.2. Pooled HbA1c data from seven GP surgeries at baseline (M0) and 12 months (M12) 
following a 30-minute one-to-one consultation with a health care professional in a primary care 






















































Baseline (M0) 12 Months (M12)
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2.4.3. Baseline to 12-Month Body Mass & BMI 
Body mass and BMI decreased significantly at 12 months in Church surgery (P = 0.00) and 
Borth surgery (P = 0.03) with no significant difference found in the remaining five surgeries 
(P > 0.05). Pooled body mass and BMI data from the seven surgeries revealed a significant 




Figure 2.4A/2.4B. Pooled Body Mass (3A) and BMI (3B) data from seven GP surgeries at 
baseline (M0) and 12 months (M12) following a 30-minute one-to-one consultation with a 
health care professional in a primary care setting. *Significantly different (P < 0.05) from 











































2.4.4. Baseline to 12-Month Waist Circumference 
Data for waist circumference from Ystwyth surgery was not provided and therefore analysis 
was not possible. Waist circumference decreased significantly in Church and Llanilar surgeries 
(P = 0.00) although no significant changes were found in the remaining four surgeries (P > 
0.05). Analysis of pooled data for waist circumference revealed a significant difference (P = 
0.01) (Table 2.2A and Figure 2.5).  
 
 
Figure 2.5. Pooled Waist Circumference data from six GP surgeries at baseline (M0) and 12 
months (M12) following a 30-minute one-to-one consultation with a health care professional 
in a primary care setting. *Significantly different (P < 0.05) from baseline. Data are represented 














































2.4.5. Baseline to 12-Month Blood Pressure 
 
Systolic BP remained unchanged across all surgeries and when the data were combined (P > 
0.05). Diastolic BP increased significantly in Llanilar (P = 0.02) and Ystwyth (P = 0.01) 
surgeries although remained unchanged in the remaining five (P > 0.05). Pooled data for 




Figure 2.6. Pooled diastolic blood pressure data from six GP surgeries at baseline (M0) and 12 
months (M12) following a 30-minute one-to-one consultation with a health care professional 
in a primary care setting. *Significantly different (P < 0.05) from baseline. Data are represented 






























Table 2.3. Correlation Coefficients for change in HbA1c and changes in Body Mass, BMI and Waist Circumference between baseline and 12 
months following a 30-minute one-to-one consultation with a health care professional in a primary care setting. 1 Pearson’s Correlation Test; 2 
Spearman’s Correlation Test. Statistical significance* is accepted at P < 0.05. 
 
 Borth Church Llanilar Tanyfron Tregaron Ystwyth Total 
Change in Body Mass / Change in HbA1c 
Correlation Coefficient 0.31 1 0.18 2 0.03 2 0.57 1 0.31 2 0.39 2 0.26 2 
Significance  0.01* 0.06 0.72 0.00* 0.00* 0.00* 0.00* 
Change in BMI / Change in HbA1c 
Correlation Coefficient 0.18 2 0.21 2 0.04 2 0.54 1 0.30 2 0.36 2 0.26 2 
Significance  0.16 0.03* 0.64 0.00* 0.00* 0.00* 0.00* 
Change in Waist Circumference / Change in HbA1c 
Correlation Coefficient 0.09 2 0.19 2 0.05 2 0.29 1 0.00 2  0.13 2 





2.4.6. Baseline to 12-Month Correlation Analysis  
Significant correlations were found between body mass changes and HbA1c changes in Borth 
(r = 0.31, P = 0.01), Tanyfron (r = 0.57, P = 0.00), Tregaron (r = 0.31, P = 0.00) and Ystwyth 
surgeries (r = 0.39, P = 0.00) and when analysed as a total cohort (r = 0.26, P = 0.00) (Table 
2.3 and Figure 2.7). Significant correlations between changes in BMI and changes in HbA1c 
were found in Church (r = 0.21, P = 0.03), Tanyfron (r = 0.54, P = 0.00), Tregaron (r = 0.30, 
P = 0.00), Ystwyth (r = 0.36, P = 0.00) and when analysed as a total cohort (r = 0.26, P = 0.00) 
(Table 2.3 and Figure 2.8). Lastly, a significant correlation between change in waist 
circumference and change in HbA1c was found in Tanyfron surgery (r = 0.29, P = 0.02) and 
when the data were combined (r = 0.13, P = 0.02) (Table 2.3 and Figure 2.9).  
 
 
Figure 2.7. Correlation of pooled body mass change and HbA1c change between baseline and 
12 months following a 30-minute one-to-one consultation with a health care professional in a 




























Figure 2.8. Correlation of pooled BMI change and HbA1c change between baseline and 12 
months following a 30-minute one-to-one consultation with a health care professional in a 
primary care setting.  
 
 
Figure 2.9. Correlation of pooled waist circumference change and HbA1c change between 
baseline and 12 months following a 30-minute one-to-one consultation with a health care 






























































2.4.7. Baseline, 12- and 24-Month Follow Up  
Between April and July 2018 data were extracted from the patient records for all surgeries, data 
for baseline, 12- and 24-month follow-up were available for 292 patients, Padarn surgery did 
not provide 24-month data. 
 
2.4.8. Baseline, 12- and 24-Month HbA1c 
There were significant changes in HbA1c across the 24-month follow-up period in all surgeries 
except for Tanyfron. Significant differences in HbA1c were found in Borth surgery (P = 0.01), 
with post-hoc analysis revealing decreases between baseline and 12 months (P = 0.00) but no 
significant difference between baseline and 24 months (P = 0.21), HbA1c between 12 and 24 
months remained similar (P = 0.20). HbA1c decreased significantly in Church surgery (P = 
0.00), post-hoc tests revealed decreases between baseline and 12 months (P = 0.00) and 
baseline and 24 months (P = 0.00), values between 12 months and 24 months remained similar 
(P = 0.73). Analysis of Llanilar surgery patients revealed significant changes in HbA1c (P = 
0.00), post-hoc testing showed HbA1c decreased from baseline to 12 months (P = 0.00) and 
baseline to 24 months (P = 0.00), values did not change between 12 and 24 months (P = 0.17). 
Values from Tregaron surgery demonstrated an overall change in HbA1c (P = 0.00) decreasing 
between baseline and 12 months (P = 0.00) and baseline and 24 months (P = 0.00) with values 
remaining similar between 12 and 24 months (P = 0.94). HbA1c values in patients from Ystwyth 
surgery changed significantly (P = 0.03) also, a decrease between baseline and 24 months was 
found (P = 0.04) although differences between baseline and 12 months (P = 0.14) and 12 and 
24 months (P = 0.93) were not significant. When HbA1c was analysed as a total cohort, analysis 
indicated a significant change in the data (P = 0.00), pooled HbA1c differed significantly 
between baseline and 12 months (P = 0.00), and between baseline and 24 months (P = 0.00) 
but remained unchanged between 12 and 24 months (P = 0.13) (Table 2.4A and Figure 2.10). 
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At 24 months following the one-to-one consultation 119 of the 292 patients had reverted to 
normal HbA1c (41%), 154 remained categorised as pre-diabetic (53%) and 19 developed T2D 




Table 2.4A. HbA1c, Body Mass, BMI and Waist Circumference at baseline, 12 and 24 months following a 30-minute one-to-one consultation with 
a health care professional in a primary care setting. Parametric data are represented as mean ± standard deviation. Non-parametric data are 




 Borth Church Llanilar Tanyfron Tregaron Ystwyth Total 
HbA1c (mmol/mol) 
Number of Patients 21 75 80 20 56 40 292 
Baseline 44 (5) 44 (5) 44 (5) 44 (5) 42 (5) 45 (5) 44 (5) 
12 Months  43 (5) 42 (10) 42 (15) 43 (8) 42 (10) 43 (78) 42 (84)** 
24 Months 43 (27) 42 (17) 42 (12 44 (24) 42 (14) 44 (27) 42 (35) 
Significance 0.01* 0.00* 0.00* 0.20 0.00* 0.03* 0.00* 
Body Mass (kg) 
Number of Patients 12 67 67  39 31 216 
Baseline 81.6 ± 22.6 76 (65) 83 (73)  86 ± 15.5 79.1 (73.4) 81.7 (94.2) 
12 Months  80.2 ± 22.3 74 (63) 82 (73)  86.4 ± 14.1 78.6 (81.8) 81 (94.7) 
24 Months 79.8 ± 24.2 74 (64) 83.5 (75)  87.1 ± 14.3 77.5 (81.3) 81.9 (100.9) 
Significance 0.36 0.00* 0.50  0.28 0.00* 0.07 
BMI (kg/m2) 
Number of Patients 11 67 68  39 31 216 
Baseline 29.9 ± 5.8 28.4 (23.7) 28.5 (28.1)  29.5 ± 4.6 32.0 ± 5.5 29.3 (32) 
12 Months  29.7 ± 5.2 27.1 (23) 29 (26.1)  29.4 ± 4.2 31.3 ± 5.9 29.0 (27.9) 
24 Months 30.0 ± 6.6 27.6 (23.5) 28.8 (28.2)  29.6 ± 4.4 30.8 ± 5.6 28.9 (32.8) 
Significance 0.93 0.00* 0.51  0.23 0.00* 0.00* 
Waist Circumference (cm) 
Number of Patients  57 26 16 17  116 
Baseline  96.9 ± 10.4 102.5 ± 12.5 104.6 ± 20.6 102 (53)  99 (73) 
12 Months   95.7 ± 10.7 98.4 ± 13.2 106.6 ± 21.7 105 (47)  98 (74) 
24 Months  94.7 ± 10.9 98.8 ± 14.0 104.0 ± 20.0 102 (50)  97 (78) 




Table 2.4B. Systolic BP and Diastolic BP at baseline, 12 and 24 months following a 30-minute one-to-one consultation with a health care 
professional in a primary care setting. Parametric data are represented as mean ± standard deviation. Non-parametric data are represented as median 
(range). 
 
 Borth Church Llanilar Tanyfron Tregaron Ystwyth Total 
Systolic BP (mmHg) 
Number of Patients 11 66 44 20 36 34 211 
Baseline 136 ± 16 130 (50) 135 (86) 128 ± 15 132 (60) 141 ± 15 132 (76) 
12 Months  136 ± 9 130 (50) 132 (87) 132 ± 12 135 (57) 139 ± 14 133 (87) 
24 Months 135 ± 15 130 (89) 131 (38) 133 ± 13 136 (54) 137 ± 15 132 (89) 
Significance 0.91 0.24 0.51 0.39 0.34 0.55 0.80 
Diastolic BP (mmHg) 
Number of Patients 11 66 44 20 36 34 211 
Baseline 72 (16) 80 (53) 76 ± 9 79 ± 7 76 ± 8 77 ± 9 78 (54) 
12 Months  80 (44) 79 (52) 79 ± 9 78 ± 7 76 ± 8 80 ± 10 80 (57) 
24 Months 80 (31) 75 (40) 77 ± 7 76 ± 9 77 ± 9 79 ± 11 78 (52) 






Figure 2.10. Pooled HbA1c data from six GP surgeries at baseline (M0), 12 months (M12) and 
24 months (M24) following a 30-minute one-to-one consultation with a health care 





Figure 2.11. Patient numbers in each diabetes classification at baseline (M0), 12 months 






















































BASELINE (M0) 12 MONTHS (M12) 24 MONTHS (M24)
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2.4.9. Baseline, 12- and 24-Month Body Mass & BMI 
Data from Church surgery patients demonstrated a significant decrease in body mass (P = 
0.00), with post-hoc analysis indicating body mass decreased between baseline and 12 months 
and baseline and 24 months (P = 0.00) while values between 12 and 24 months were unchanged 
(P = 1.00). A significant decrease was present in Ystwyth surgery patients (P = 0.00) where 
values decreased between baseline and 12 months (P = 0.04) and baseline and 24 months (P = 
0.00) while remaining similar between 12 and 24 months (P = 0.15). No significant changes in 
body mass were found in Borth, Llanilar and Tregaron surgeries or when the data were pooled 
(P > 0.05) (Table 2.4A). Twenty-four-month body mass data were not provided by Tanyfron 
surgery.   
 
In Church surgery patients BMI changed significantly (P = 0.00) with a significant decrease 
between baseline and 12 months and baseline and 24 months (P = 0.00) and no difference 
between 12 and 24 months (P = 0.76). Data from Ystwyth surgery indicated a significant 
decrease in BMI between baseline and 24 months (P = 0.00). No significant changes in BMI 
were found in Borth, Llanilar or Tregaron surgeries (P > 0.05). Twenty-four-month BMI data 
were not provided by Tanyfron surgery. Pooled BMI data indicated a significant difference (P 
= 0.00) with a significant decrease in BMI between baseline and 12 months (P = 0.01) and 
baseline and 24 months (P = 0.00), no significant differences were found between 12 and 24 






Figure 2.12. Pooled BMI data from five GP surgeries at baseline (M0), 12 months (M12) and 
24 months (M24) following a 30-minute one-to-one consultation with a health care 




2.4.10. Baseline, 12- and 24-Month Waist Circumference  
Waist circumference differed significantly in patients from Church surgery (P = 0.00) with a 
significant decrease from baseline to 24 months (P = 0.00) although differences between 
baseline and 12 months and 12 and 24 months were insignificant (P > 0.05). Similarly, waist 
circumference decreased in Llanilar surgery patients (P = 0.03), with a significant decreased 
from baseline to 12 months (P = 0.02) and from baseline and 24 months (P = 0.03), values 
between 12 and 24 months were similar (P = 1.00). No significant changes in waist 
circumference were found in Tanyfron or Tregaron surgeries (P > 0.05). Borth and Ystwyth 
surgeries did not provide 24-month waist circumference data. Analysis on pooled data for waist 
circumference revealed a significant overall decrease between baseline and 24 months (P = 
0.00). Values decreased, albeit insignificantly, between baseline to 12 months (P = 0.11) and 





















Figure 2.13. Pooled Waist Circumference data from four GP surgeries at baseline (M0), 12 
months (M12) and 24 months (M24) following a 30-minute one-to-one consultation with a 




2.4.11. Baseline, 12- and 24-Month Blood Pressure  
Across 24 months, systolic and diastolic BP remained unchanged across all surgeries and when 















































2.4.12. Baseline and 24 Month Correlation Analysis  
 
Significant correlations between change in body mass and change in HbA1c were found in 
Borth (P = 0.00), Church (P = 0.01) and Ystwyth (P = 0.00) surgeries and when analysed as a 
total cohort (P = 0.00) (Table 2.5 and Figure 2.14). For change in BMI and change in HbA1c, 
significant correlations were found in Church surgery (P = 0.02) and in the total cohort (P = 
0.00) (Table 2.5 and Figure 2.15). Similarly, significant correlations were found in change in 
waist circumference and change in HbA1c in Church surgery (P = 0.03) and as a total cohort (P 






Figure 2.14. Correlation of combined body mass change and HbA1c change between baseline 
and 24 months following a 30-minute one-to-one consultation with a health care professional 
































Table 2.5. Correlation Coefficients for change in HbA1c and changes in Body Mass, BMI and Waist Circumference between baseline and 24 
months following a 30-minute one-to-one consultation with a health care professional in a primary care setting. Pearson’s Correlation Test 
represented by 1 and Spearman’s Correlation Test represented by 2. Statistical significance* is accepted at P < 0.05. 
 
 
 Borth Church Llanilar Tanyfron Tregaron Ystwyth Total 
Change in Body Mass / Change in HbA1c 
Correlation Coefficient 0.74 2 0.30 2 0.20 2  0.19 2 0.47 2 0.30 2 
Significance  0.00* 0.01* 0.09  0.24 0.00* 0.00* 
Change in BMI / Change in HbA1c 
Correlation Coefficient 0.48 2 0.28 2 0.20 2  0.10 2 0.25 2 0.23 2 
Significance  0.05 0.02* 0.09  0.54 0.18 0.00* 
Change in Waist Circumference / Change in HbA1c 
Correlation Coefficient  0.27 2 0.04 2 0.49 2 0.01 1  0.19 2 





Figure 2.15. Correlation of combined BMI change and HbA1c change between baseline and 
24 months following a 30-minute one-to-one consultation with a health care professional in a 





Figure 2.16. Correlation of combined waist circumference change and HbA1c change 
between baseline and 24 months following a 30-minute one-to-one consultation with a health 



























































The purpose of the one-to-one consultation was to reduce the onset of T2D in a group of at-
risk individuals through their engagement in a GP-led pre-diabetes intervention in seven 
surgeries in Ceredigion, Wales. Analysis of follow up data at 12 and 24 months in patients 
exposed to the intervention demonstrated a significant overall decrease in HbA1c, a key variable 
associated with increased risk of T2D. The findings compare favourably to other published 
work which has examined the effects of lifestyle intervention on T2D development in 
individuals at increased risk of the condition. Previous studies examining the role of lifestyle 
intervention in managing T2D incidence, for example the DPP Research Group (2002), 
Almeida, Shetterly, Smith-Ray and Estabrooks (2010), Yates, Davies, Sehmi, Gorely and 
Khunti, (2011), Gray et al. (2012) and Piper, Marossy, Grffiths and Adegboye (2017) have all 
successfully demonstrated significant health outcomes following lifestyle intervention. 
Previous reviews state lifestyle intervention to be at least as effective as drug treatment in 
combating progression to T2D (Gillies et al., 2007). Additionally, Sheng et al. (2019) found 
lifestyle modification, involving improved nutrition, increases in exercise level and weight loss 
contributed to health by reducing BMI, body weight, waist and hip circumference, systolic and 
diastolic pressure, fasting, and two-hour postprandial blood glucose, total cholesterol and 
increasing HDL. Given the significant impact of lifestyle intervention on a wide range on health 
outcomes related to T2D as well as other health complications associated to obesity, physical 
inactivity and poor dietary behaviour including cardiovascular disease, cancer, lung and liver 
disease, it is credible to argue that lifestyle intervention has a wider ranging impact on health 
compared to pharmacological intervention alone when targeting T2D. While numerous 
lifestyle intervention programmes have been conducted previously, this is the first study to 
evaluate the efficacy of a GP-led pre-diabetes intervention, which involves a 30-minute one-
to-one consultation targeting lifestyle modification, in primary care. 
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The primary outcome measure of this evaluation was HbA1c, which is an indication of the 
amount of glucose present in the blood over the previous eight to 12-week period and provides 
a more stable indication of blood glucose over time compared to other methods such as a fasting 
blood glucose test or an OGTT. An HbA1c between 42–47 mmol/mol is indicative of ‘high 
risk’ for T2D and therefore the intervention’s primary aim was to identify individuals within 
this range and reduce their HbA1c through lifestyle modification, which has previously been 
demonstrated to be effective. The data presented demonstrate significant decreases in HbA1c 
when analysed as individual surgeries as well as when the data were pooled. In many cases, 
participation in the intervention led to HbA1c decreasing to values below the range considered 
to increase the risk of T2D development. The data for HbA1c recorded post intervention reached 
values considered to be healthy by NHS Wales, Public Health Wales and Diabetes UK in 37% 
of cases after 12 months (217 of 592 participants) and 41% of cases after 24 months (119 of 
292 participants). Conversely, 3% (17 of 592 participants) and 6.5% (19 of 292 participants) 
had HbA1c values which fell in the diabetes range after 12 and 24 months, respectively. These 
numbers compare favourably with Tabak et al. (2012) who report that approximately 5-10% 
of unaddressed cases of pre-diabetes will progress to T2D within 12 months, while a similar 
percentage will revert to normal control. 
 
The primary risk factors associated with pre-diabetes and increased HbA1c are; obesity (BMI 
> 30 kg/m2), large waist circumference (> 94 cm males / > 80 cm females) and high blood 
pressure (> 140 / 90 mmHg; Falade, 2012). Therefore, these variables were recorded during 
the initial 30-minute one-to-one consultation and after 12 and 24 months to evaluate the 
intervention’s effect on each risk factor and identify if any changes were associated with 
decreases in HbA1c. Significant overall decreases in pooled data for body mass, BMI and waist 
circumference after 12 months and BMI and waist circumference after 24 months support other 
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work in the literature with similar findings, although the clinical significance of BMI changes 
in particular is debateable. Examples include significant decreases in body mass (Absetz et al., 
2007; Ackermann, Finch, Brizendine, Zhou and Marrero, 2008; Almeida, Shetterly, Smith-Ray 
and Estabrooks, 2010), BMI (Absetz et al., 2007) and waist circumference (Katula et al., 2011) 
12 to 24 months following intervention and baseline data collection. In five practices, and in 
pooled data, correlations were evident between changes in HbA1c and anthropometric measures 
after 12 months, demonstrating the potential effectiveness between reductions in body mass, 
BMI and waist circumference with decreases in HbA1c with a similar trend evident at 24 months 
in three surgeries and in the pooled data.  Excess body fat is strongly associated with impaired 
glycaemic control due to ineffective insulin signalling (Klein et al., 2004) while weight loss 
has been demonstrated to lessen insulin resistance and improve glycaemic control (Peterson, 
Dufour, Morino, Yoo, Cline and Shulman, 2012; Camps, Verhoef and Westerterp, 2016). 
Evidence in a review produced by Gummesson, Nyman, Knutsson and Karpeors (2017) shows 
a relationship between weight loss and HbA1c reduction, finding HbA1c values decreased by 0.1 
percentage points for every 0.1 kg lost when studies focussing on weight loss and HbA1c were 
examined. Similar findings suggest weight loss and decreased waist circumference are 
associated with improved HbA1c values in obese patients who underwent an intensive weight 
management programme (Rothberg et al., 2017).  
 
Decreases in HbA1c were positively correlated with decreases in body mass, BMI and waist 
circumference in individual surgeries and pooled data. In other cases, however, decreases in 
HbA1c occurred independently of changes in anthropometric measures. A possible explanation 
for this finding may be attributed to increased levels of physical activity undertaken by the 
patient. The benefits of physical activity in improving health outcomes were discussed as part 
of the 30-minute one-to-one consultation. Patients were encouraged to increase their level of 
71 
 
weekly physical activity to 150 minutes of moderate intensity exercise, 75 minutes of vigorous 
intensity exercise or a combination of both intensities plus additional resistance exercise. In 
many cases, patients were also referred to classes which specialised in supervised exercise 
provision, such as NERS. Previous work has demonstrated significant improvements in insulin 
sensitivity following exercise, independent of significant changes in body mass (Duncan, Perri, 
Theriaque, Hutson, Eckel and Stacpoole, 2003; Nassis et al., 2005). The effects of increased 
exercise induced GLUT4 translocation through increased skeletal muscle contraction support 
this notion (Lund, Holman, Schmitz and Pedersen, 1995). The acute effects of exercise on 
glucose metabolism are also well documented. Duncan, Perri, Theriaque, Hutson, Eckel and 
Stacpoole (2003) found insulin sensitivity improved significantly following six months of 
walking training in previously sedentary individuals with the improvement in insulin 
sensitivity occurring in the absence of weight loss. Ross (2003) supports this finding, 
suggesting modest exercise is associated with significant improvements in glucose and lipid 
metabolism and should be performed on a regular basis. Further evidence found 12 weeks of 
aerobic training improved insulin sensitivity in overweight and obese subjects without changes 
in body mass or percentage body fat (Nassis et al., 2006).  
 
While the present intervention aimed to significantly reduce anthropometric values across all 
surgeries, this data may demonstrate the importance of increasing levels of physical activity in 
patients with pre-diabetes, even in the absence of weight loss. The data may also suggest that 
patients engaged more in physical activity compared to improving dietary habits given HbA1c 
values improved despite lack of body weight decreases in some surgeries. While patients were 
asked to provide an indication as to their physical activity and dietary habits during the initial 
consultation visit, this information was not followed up at 12 and 24 months by surgeries, nor 
were the initial questionnaire responses provided for analysis. To gain a thorough 
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understanding as to the specific reasons why HbA1c values improved, further work within this 
cohort must collect data on change in physical activity and dietary behaviours. Accurate 
methods for recording physical activity can be achieved using electronic activity trackers while 
modern methods for dietary recording, including analysis of biological samples (e.g. urine 
and/or plasma), have been developed (Favé et al., 2011, Beckmann et al., 2013 and Lloyd et 
al., 2013). Assessment of both behaviours can also utilise self-report questionnaire although 
issues of reliability of such practices may be a limiting factor (Wrieden et al., 2003). While the 
‘Starting the Conversation’ questionnaire for diet and IPAQ-SF for physical activity were 
easily administered to patients and provided some insight into patient behaviour, the 
information provided is both limited in depth and prone to respondent bias (Lee, McDowell, 
Leung, Lam and Stewart, 2011). Accurate recording of dietary and physical activity behaviours 
using enhanced methodologies will contribute knowledge as to the primary reasons for 
improved glycaemic control following lifestyle intervention initiatives and may help to inform 
future directions for primary care lifestyle modification programmes in pre-diabetes.  
 
This work demonstrates a feasible and potentially effective method for lifestyle modification 
in pre-diabetes resulting in decreased HbA1c values; however, there are some limitations within 
the present study which require discussion and further development prior to future research 
being undertaken. Primarily, whilst efforts were made to standardise the 30-minute one-to-one 
consultation as much as possible to ensure all patients received the same level of intervention 
and care, it is likely individual GP surgeries, and specifically the health professionals delivering 
the consultations, adopted different approaches when consulting with patients. While it is 
acknowledged that consultations will vary from one another depending on the patient, some 
surgeries demonstrated greater changes in HbA1c and anthropometry in comparison to others 
with the differences in values possibly represented by altered approaches to the consultation 
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by the health professional. For example, patients from Church surgery demonstrated significant 
decreases in values for HbA1c, weight, BMI and waist circumference whereas patients from 
Llanilar surgery only recorded reductions in HbA1c and waist circumference. These results may 
infer conflicting focusses during the consultation and possible uses of motivational language 
and techniques by a particularly inspiring health professional. This may suggest a more robust 
structure for the consultation is required to achieve similar results across the entire patient 
cohort. Borelli (2011) states treatment fidelity is key to making conclusive statements about 
treatment effects. The health practitioners delivering the consultation must be of equal ability 
to ensure a consistent delivery of the T2D intervention across all participating surgeries. Should 
the responsibility of consultation delivery be shared between general practitioners and nurse 
practitioners, both should have specific and appropriate training in delivering T2D lifestyle 
interventions. Standardised protocols for pre-diabetes discussion should be developed to help 
counter this limitation in the future as well as co-ordinated training days for all health 
professionals involved in consultation delivery.  
 
Inconsistencies in data collection and delivery were also an issue. Despite protocols being 
developed and agreed between the cluster GP surgeries and the research team prior to the 
initiation of the intervention, some surgeries failed to collect all the data requested by the 
research team and in the case of one surgery, did not deliver the results as requested and were 
therefore not included in large sections of data analysis. Furthermore, lack of data regarding 
attendance to the National Exercise Referral Scheme and Foodwise for Life programme makes 
it difficult to understand the potential benefits of lifestyle referral in pre-diabetes within this 
cohort. While the research team repeatedly sought this information from the cluster, it was not 
possible to receive for reasons outside of the researcher’s control. Improved systems are 
required which communicate patient attendance between lifestyle referral programmes and 
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primary care which can be placed on patients’ medical records in the same way other data are 
(e.g. HbA1c results, body mass, BMI etc.). Whilst one surgery provided information on referral 
of patients to lifestyle programmes, confirmed attendance figures were not provided and 
therefore statistical analysis of such data were not possible.  
 
In addition, while a number of significant results were demonstrated in the current work, it is 
important to consider the clinical relevance of these findings also. Following analysis of year 
one follow up data, a number of significant results were observed including HbA1c and body 
mass in Borth surgery. Despite these data providing a P value lower than 0.05, it is clear they 
are clinically insignificant findings. For HbA1c in Borth surgery, values remained similar 
between baseline and one year (43 mmol/mol) while body mass only decreased by 0.4 kg. 
Similarly, combined totals for BMI between baseline and one year only decreased by 0.2 kg/m2. 
In addition, after year two follow up, Tregaron surgery observed a significant result for HbA1c 
when in fact values remained at 42 mmol/mol throughout the intervention. Clinical significance 
should reflect the extent of change, whether the change makes a real difference to patient lives 
and how long the effects last (Ranganathan, Pramesh and Buyse, 2015). When considering this 
statement, it is clear the results discussed here do not meet the definition of clinically significant 
and should be treated with caution in the wider evaluation of the intervention.   
 
Lastly, a key factor in the future implementation of this intervention is its cost effectiveness. 
Currently, no formal financial assessment has been undertaken to determine the cost of the 
intervention per patient, with only estimated costs available. Should further work demonstrate 
this intervention to be a success, it is crucial a financial assessment is conducted to support the 
intervention’s implementation at a national level. Demonstrating cost effectiveness will show 
the wider implications of lifestyle intervention on health outcomes and associated costs 
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compared to pharmacological-only approaches, such as metformin. For example, Herman et 
al. (2009) found a lifestyle intervention targeting T2D prevention was cost-effective in all age 
groups while a metformin intervention did not represent good use of resources for persons older 
than 65 years of age. A similar cost effectiveness finding for the current programme would be 
advantageous in promoting the use of the current intervention in future primary care settings. 
The results of this work demonstrate promise in reducing T2D prevalence in at risk groups, 
however, given the design of the study as a cohort observation, it is difficult to identify the 
primary reasons for reduction in HbA1c and associated risk factors. Potential drivers of 
behaviour change may have included; the initial letter confirming T2D risk and accompanying 
information and/or the information received during the one to one consultation. Future work 
must include a randomised control trial to assess the effectiveness of the consultation in 
comparison to current practice in pre-diabetes care in Wales (written information only). Greater 
understanding of physical activity and dietary practices in at risk groups also needs to be 
explored to assess the effects of the consultation and/or standard care on these lifestyle 
behaviours. Therefore, the latter chapters of this thesis will explore methods of dietary 
monitoring using urine sampling as a robust method for quantifying consumption of foods of 
importance to health using biomarker identification. The feasibility of implementing a 
randomised control trial will then be developed and delivered within primary care to compare 
the effectiveness of the consultation to current standard practice and assess if a large-scale trial 
can be conducted successfully across the HDUHB. Physical activity recording (using activity 
trackers) and dietary monitoring by urine and plasma sampling will be utilised within the 
randomised control trial to assess the consultation’s effect on physical activity and nutritional 
behaviours.  
 
In conclusion, this chapter has demonstrated the potential effectiveness of a 30-minute one-to-
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one consultation with a healthcare professional in lowering HbA1c values in patients at 
increased risk of developing T2D. Future work needs to establish the precise mechanisms 



























Literature Review: Dietary Monitoring Methods  
 
3.1. Dietary Monitoring Methods  
The findings from Chapter two suggest engagement in a GP-led lifestyle modification 
intervention can result in a reduction in HbA1c and improvement in other outcomes related to 
risk of developing T2D. However, one limitation identified during the evaluation of the 
intervention was the lack of accurate monitoring of healthy behaviours, specifically diet. While 
information on participants’ dietary intake was sought at the start of the intervention by the 
healthcare professional delivering the consultation, this information was not followed up at 12 
or 24 months. Additionally, the questionnaire used (Starting the Conversation) was both short 
and broad in its line of questioning and therefore unable to examine dietary behaviour in 
persons at risk of T2D in detail. While questionnaires such as ‘Starting the Conversation’ are 
easily and quickly administered and simply analysed, they lack the depth and detail required to 
provide accurate and specific information on dietary behaviour and are prone to reporting bias. 
It is important to obtain reliable information on dietary intake as there is a robust evidence base 
which links diet with the risk of developing a number of chronic medical conditions, including 
T2D (Bingham, 2002). Good dietary behaviours, including intake of antioxidant vitamins, fat 
and plant polysaccharides, vegetables and fruit, are linked with a decreased incidence of 
chronic conditions (Bingham, 2002). To understand the risk of disease development in free 
living individuals accurate measures of habitual dietary intake are necessary, something that is 





The use of dietary monitoring to assess habitual diet or dietary change following intervention 
is beneficial for both the participant and the researcher. Dietary monitoring, of which there are 
several well-established methods, was originally derived from disease surveillance and is 
designed to build a greater understanding of nutrition which can lead to improvements in 
nutritional behaviours in different populations (Mason and Mitchell, 1983). Information from 
dietary monitoring can help improve the understanding of problems associated with 
malnutrition in developing countries, to assist in the long-term planning of health and 
development and, most pertinently here, to provide information on programme management 
and evaluation (Mason and Mitchell, 1983). National policies, public health and nutrition 
programmes and timely warning and prevention programmes can all benefit from robust 
dietary monitoring (Mason and Mitchell, 1983). Recording dietary behaviours following 
lifestyle intervention provides an opportunity to assess dietary adherence and if necessary, 
provide ongoing support to patients who require further nutritional guidance to prevent future 
disease development. Established methods of dietary monitoring include; weighed food 
records, estimated food records, 24-hour recall, multiple pass recall and food frequency 
questionnaires (Wrieden et al., 2003). However, while each method has beneficial features, 
these forms of dietary monitoring contain limitations which result in data inaccuracies and 
misreporting, which ultimately leads to misinterpretation.  
 
3.2. Limitations of Established Dietary Recording Methods 
 
3.2.1. Weighed and Estimated Food Records  
A weighed food record requires an individual to record every food and drink item prior to 
consumption (Wrieden et al., 2003). Individuals provide a detailed description of the food item, 
and its weight, in a specifically designed booklet. Leftover food is also recorded so an accurate 
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calculation can be made on the amount of food consumed in a diet (Wrieden et al., 2003). This 
method is described as the “gold standard” when compared to other forms of dietary monitoring 
(Hamer, Mchnaughton, Bates and Mishra, 2010; Johnson, 2002; Wrieden et al., 2003) although 
as reported by Trabulsi and Schoeller (2001), not free from limitation. It has been 
acknowledged previously that weighed food diaries are subject to measurement error, both 
random and systematic (Trabulsi and Schoeller, 2001). While random error such as writing 
mistakes can occur, Trabulsi and Schoeller (2001) focus their attention mainly on systematic 
errors, primarily the under reporting of food intake which can lead to misleading conclusions 
relating to diet and disease.  
 
Under reporting of food intake is the failure of respondents to record all the food items they 
consume during the recording period or incorrectly weighing the food consumed and is defined 
as a discrepancy between reported energy intake and measured energy expenditure without any 
change in body mass (Poslusna, Ruprich, de Vries, Jakubikova, van’t Veer, 2009; energy 
expenditure is often determined using the doubly labelled water method1). In addition, previous 
work has also reported that weighed dietary recording can influence an individual’s habitual 
food choices, resulting in altered food consumption and in some cases, a loss in body weight 
(Goris, Westerterp-Plantenga and Westerterp, 2000; Prentice et al., 1986). Furthermore, 
Gersovitz, Madden and Smiciklas-Wright (1978) suggest that as the number of dietary 
monitoring days increase, recording inaccuracies also increase. The study reports a decrease in 
validity on the fifth, sixth and seventh day of recording, demonstrating a high respondent 
burden, a weakness reported in previous work (Wrieden, et al., 2003). Reporting inaccuracies 
                                                          
1 Individuals are provided with a weighed oral dose of 2H2
18O and then required to provide 
urine samples at specific points over a time course. Carbon dioxide output is recorded as the 
difference in the water pool, measured by 2H2, and the bicarbonate plus water pool, measured 
by 18O, and energy expenditure estimated. The recorded energy expenditure should be equal to 
energy intake when changes in mass have been considered (Bingham, 2002). 
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have also been identified in several other studies including percentage underestimations of 13 
and 32%, in women and men, respectively (Goran and Poehlman, 1992), 27% (Reilly et al., 
1993), 20% (Tomoyasu, Toth and Poehlman, 2000) and 11% (Tomoyasu, Toth and Poehlman, 
2000). Other work has found obese subjects to underestimate dietary intake (Prentice et al., 
1986; Litchman et al., 1992; Buhl, Gallagher, Hoy, Matthews and Heymsfield, 1995; and 
Black, Bingham, Johansson and Coward, 1997). Subject motivation is another potential reason 
for under reporting, with the weighed food record perceived as tedious and time consuming 
(Hill and Davies, 2002). Lack of motivation is an important factor to consider when analysing 
weighed food diaries and should be considered with other methods of dietary recording also. 
Participant experience in the method can also influence the accuracy of data recording. 
Champagne et al. (2002) reported a lack of experience in the use of weighed dietary recording 
resulted in reduced recording accuracy when compared to data from dieticians trained in dietary 
recording. Given that this method is designed to be used by the general population, most of 
whom are inexperienced in dietary monitoring, it is perhaps unsurprising that under reporting 
is so prevalent in many studies.   
 
The estimated food record is similar in design to a weighed food record, however, the 
quantification of food and drink consumed by an individual is estimated using common 
household food measures and photographs, as opposed to being weighed (Wrieden et al., 
2003). While the estimated food record is a widely used form of dietary monitoring and carries 
a lower respondent burden in comparison to weighed food diaries (Wrieden et al., 2003) it 
again has limitations. Poslusna et al. (2009) reviewed 11 studies which employed estimated 
food records, they found the number of participants who under reported to range from 11.9 to 
44% while the percentage of over reporters ranged from 3.5 to 7%. Individual studies have 
shown significant underestimations of food intake when using estimated food diaries. For 
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example, Samaras, Kelly and Campbell (1999) demonstrated an overall under reporting of 
energy intake by 32% of participants, with 18% of individuals of a healthy weight, 39% of 
overweight individuals and 44% of obese individuals classed as under reporters. Similarly, 
Lafay et al. (2000) found under reporting of food compared to energy expenditure (16% in this 
study) was not the result of a systematic underestimation of meal size containing all food items 
but rather associated with food items which are considered bad for an individual’s health. A 
similar finding was reported by O’Loughlin et al. (2013) who used an estimated food diary 
when studying the efficacy of a wearable camera in increasing the accuracy of dietary analysis. 
Participants were provided with a wearable camera and asked to complete a one day estimated 
food diary. The results demonstrated that out of the 34 participants in the study, only one 
participant returned a food diary which closely matched the images obtained from the wearable 
camera. The study highlighted a significant under reporting of food intake compared to energy 
expenditure, ranging from 10-18%, when using the estimated food diary alongside the camera. 
A lack of ability to accurately report portion size, despite clear written and verbal instruction, 
was the primary reason why significant under reporting was prevalent in the study’s sample.  
 
Given the significant burden both weighed and estimated food diaries impose, where 
respondents are required to record all daily food and beverage consumption, they are both 
inappropriate and ineffective methods for monitoring habitual diet in numerous groups and in 
longitudinal studies where mis-reporting has shown to increase over time. While still limited, 
other methods which provide a less burdensome indication of long-term dietary behaviour, 
where intake is recalled as opposed to immediately recorded, can give more informative data 





3.2.2. Twenty-four Hour and Multiple Pass Recall  
Twenty-four-hour recall requires an individual to list, to a trained interviewer, all the food and 
drink they have consumed in the past 24 hours (Wrieden et al., 2003) and is another regularly 
utilised method (Castell, Serra-Majem and Ribas Barba, 2015). Twenty-four-hour recall relies 
on an accurate memory (a limitation in the elderly and subjects 12 years of age and under; 
Castell et al., 2015) and the ability to accurately report food intake (Wrieden et al., 2003). To 
assist the respondent, the interviewer may use photographic prompts to help with portion size 
estimation. The information provided to the interviewer should describe the type of food 
consumed and that food’s characteristics, such as whether the food is fresh, frozen, pre-
prepared, canned or preserved (Castell et al., 2015). While this method of dietary recording 
carries a lower respondent burden (compared with weighed and estimated diet records) and is 
suitable for large scale surveys (Wrieden et al., 2003; Raina, 2013), it does not provide an 
accurate representation of an individual’s long-term dietary exposure (Raina, 2013). Therefore, 
it is difficult to develop associations between chronic disease development (T2D for example) 
and habitual food intake based upon the results of a 24-hour recall (Raina, 2013).  
 
Previous work demonstrates that one 24-hour recall is inadequate in representing habitual 
dietary intake. Seventy-nine female participants completed seven 24-hour recalls over a period 
of two weeks whilst also measuring energy expenditure using the doubly labelled water method 
(Yungsheng et al., 2009). The aim of this study was to establish how many 24-hour recalls 
were required to provide an accurate indication of individual dietary habits. Analysis revealed 
mean energy expenditure of the participants was 2115 kcal per day. The first 24-hour recall 
revealed a mean intake of 1501 kcal per day. The second and third recalls were significantly 
higher (2246 and 2315 kcal per day, respectively). Averaging the first and second recall 
provided a better estimate of energy intake compared to the first recall alone. Averaging of the 
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three recalls provided an even greater energy intake approximation (Yungsheng et al., 2009) 
although any further recalls did not improve energy intake estimation. The results led to the 
conclusion that a single 24-hour recall is an inadequate measure of energy intake and 
demonstrated that three recalls were necessary to provide an accurate indication of habitual 
dietary exposure (Yungsheng et al., 2009). This is supported in another study which suggests 
a minimum of five recalls may be necessary to establish an individual’s habitual intake (Castell 
et al., 2015). The collection of numerous 24-hour recalls can cause increased complication in 
field work, requiring a greater time commitment from both the participant and interviewer to 
collect the dietary data (Castell et al., 2015).  
 
A validation of the 24-hour dietary recall method reported a large over estimation of protein 
intake in a group of 244 participants when compared to protein intake measured by a 24-hour 
urine sample (Kahn et al., 1995). Twenty-four-hour urine samples had previously demonstrated 
to be a useful indicator of protein consumption three to four days following intake (Kahn, 
1987). Participants returned their 24-hour urine specimen on the same day as a 24-hour recall 
being recorded. The urine was collected on a day within the week prior to the recall interview 
taking place. Protein intake was reported to be higher via 24-hour recall when compared to 24-
hour urine, specifically, lightweight men tended to exaggerate protein intake compared to other 
groups. This led the authors to suggest that misinformation on dietary intake provided by 
participants may lead to incorrect conclusions regarding diet-disease relationships (Kahn et al., 
1995). Similarly, work by Novotny et al. (2003) measured a range of participant characteristics 
to identify possible reasons for under reporting of diet when using 24-hour food records. 
Ninety-eight healthy adult volunteers provided two 24-hour recalls to a registered dietician, the 
second recall three to ten days after the first. Energy expenditure was measured using either 
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the doubly labelled water method (44 participants) or the intake balance method2 (54 
participants). All participants completed questionnaires measuring social desirability, memory 
(to identify if memory was associated with misreporting) and lifestyle behaviours. For all 
participants, the answers provided in the two 24-hour dietary recalls were averaged and 
compared against energy expenditure. As a group, energy expenditure differed significantly 
from reported energy intake by 294 kcal per day. The difference between energy intake and 
expenditure was significantly different for women but not for men (Novotny et al., 2003). 
Eighty-five percent of women under reported their intake while 15% over reported compared 
to 61% of men who under reported intake while 39% over reported. For both sexes, under 
reporting of intake was associated to increased body fat. Under reporting was also associated 
with various factors related to body image, which included a weight loss attempt in the previous 
12 months, weight gain over the previous ten years and difference in reported weight from a 
participant’s ‘ideal’ weight (Novotny et al., 2003). The memory test for men and the social 
desirability score for women, as well as increased body fat, provided indications of 
misreporting of energy intake. The need for social desirability which led women to misreport 
their energy intake significantly more so than men has been reported in previously mentioned 
studies regarding other forms of dietary recording (Hill and Davies, 2002).  
 
Comparison of the 24-hour recall method and a food frequency questionnaire was made by 
Schatzkin et al. (2003) demonstrating a food frequency questionnaire to under report energy 
intake by 30-40% compared to a 24-hour recall which underestimated by 10-20%. While the 
24-hour recall method in this study under reported energy intake to a lesser extent compared to 
a food frequency questionnaire, the results provided by a 24-hour recall were still inaccurate 
                                                          
2 The intake balance method required participants to consume a pre-prepared diet which 
provided an energy content equal to average energy expenditure, estimated by a registered 
dietician and altered weekly based upon the participants weight (Novotny et al., 2003) 
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when compared to energy expenditure. Four-hundred and eighty-four healthy volunteers 
completed two food frequency questionnaires and two 24-hour recalls, separated by 
approximately three months.  Participants received a dose of doubly labelled water during visit 
one and returned two weeks later for the doubly labelled water assessment (Schatzkin et al., 
2003). Despite the results demonstrating the 24-hour recall method to be more reliable than a 
food frequency questionnaire, the study did suggest that a single 24-hour recall is ineffective 
in measuring energy intake and multiple recalls are required, supported by Yungsheng et al. 
(2009). While increasing the number of 24-hour recalls may increase the accuracy of estimated 
energy intake, the monetary expense of conducting this method of dietary recording in a large 
cohort, due to high administrative costs, would not provide an effective solution to dietary 
monitoring (Schatzkin et al., 2003).       
 
Multiple pass recall shares similarities with the 24-hour recall method in that individuals are 
required to recall their dietary intake from the past 24-hour period. ‘Multiple pass’ relates to 
the steps involved in the interview process (Wrieden et al., 2003) and was designed to minimise 
under reporting (Reilly, Montgomery, Jackson, MacRitchie and Armstrong, 2001). The first 
pass records all the foods that have been consumed, the second records information on the 
meals and snacks that have been consumed as well as the time and place of consumption. The 
third pass then prompts for foods and snacks which the individual may have forgotten to recall 
previously. This information is then followed up by a final stage which records any further 
food items as well as recording portion sizes (Wrieden et al., 2003).  
 
Energy intake measured by multiple pass recall was compared to energy expenditure by Reilly 
et al. (2001). This study used 41 children between the ages of three and four to assess a multiple 
pass recall. Recall interviews were completed over the telephone following an interview with 
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the primary carer of the child. The multiple pass recalls were completed over three days within 
the seven days of energy expenditure measurement via the doubly labelled water method, 
encompassing two weekdays and a weekend day. The selection of days for the recalls was 
suggested to provide an adequate summation of energy intake in children (Reilly et al., 2001). 
Extending the recall further than three days was considered, but it was concluded that additional 
days would add a considerable burden to the primary carers (Reilly et al., 2001) and arguably 
not applicable in realistic practice. Despite no significant difference between energy intake and 
expenditure when comparing sexes, intake was significantly different to expenditure by 600 kj 
(143 kcal) per day when the group was analysed. Despite advantages such as a relatively 
modest average total interview time of 32 minutes over three days and a well-tolerated recall 
process, the multiple pass recall resulted in significant over estimation of energy intake 
compared to energy expenditure. While the authors suggest that an increase dietary assessment 
phase may have increased precision, they argued that increasing this phase would be at the 
expense of participant compliance (Reilly et al., 2001).  
 
Under controlled conditions, in a study conducted in a group of 42 men, Conway, Ingwersen 
and Moshfegh (2004) examined the accuracy of a multiple pass recall when compared to actual 
energy intake measured over one day. In the first week of the two-week study, BMI and body 
fat percentage were collected. During one day within the second week, participants consumed 
three meals at a human research facility. Participants were free to select from a wide assortment 
of pre-weighed food, independent of other participants and were instructed to only consume 
foods provided by the investigators during the day. The food selection made by participants 
was observed inconspicuously by a dietician. Any food left over was weighed and recorded 
with adjustments then made for energy intake. Participants were free to take home weighed 
snacks to consume in the evening but were requested to return any uneaten items the following 
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day. A multiple pass dietary recall was completed the day after the controlled food consumption 
protocol and compared to actual energy intake as observed by the study’s investigators. There 
was no significant over or under reporting of carbohydrate, protein or fat demonstrating in this 
study that a multiple pass recall is an effective method for assessing energy intake. However, 
the research was conducted under controlled conditions, and therefore it is difficult to use the 
results to conclude that multiple pass recall is reliable method when used in a ‘real world’ 
environment, as demonstrated by other work.  
 
In support of this statement, disease related malnutrition in over 85’s (a group in which 18% 
are at medium or high risk of malnutrition but often excluded from many studies because of 
age; Davies et al., 2014), was examined by Mendonca et al. (2016) using multiple pass recall. 
Seven-hundred and ninety-three participants, including both males and females, completed two 
multiple pass recalls with a trained nurse on non-consecutive days. Following the exclusion of 
missing data, 192 of the remaining 731 participants, 26.3% of the entire group, were identified 
as mis-reporters. Specifically, 158 participants (21.6%) were classed as under reporters 
whereas 34 participants (4.7%) were considered over reporters. Due to the age of the 
participants involved, it is possible that under and over reporting of energy intake may be due 
to reduced memory capacity, a limitation mentioned above (Castell et al., 2015) and should be 
considered a weakness in the multiple pass method when using an elderly sample.   
 
If dietary information is recorded accurately, recall methods can provide useful information on 
quantifying acute dietary intake. However, as stated by Raina (2013), recalls cannot provide 
an accurate representation of an individual’s long-term dietary pattern which is required to 
provide information on habitual diet and chronic disease associations and intervention 
effectiveness. Conducting multiple recalls to gather greater information on dietary behaviour 
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causes increased complication in field work and requires a greater time commitment from both 
the participant and interviewer (Castell et al., 2015), meaning such a method is unrealistic in 
studies aiming to capture habitual diet data.   
 
3.2.3. Food Frequency Questionnaire (FFQ)  
The FFQ comprises a list of foods and several options relating to the frequency of consumption 
such as times a day, week or month. The aim of collecting food intake information over various 
time frames is to gain a greater understanding of habitual diet (Wrieden et al., 2003). The FFQ 
can be self-administered or completed via interview, making it a relatively simple and cost-
effective method for monitoring diet (Shim, Oh and Kim, 2014). Like other methods however, 
the FFQ can be subject to both under and overestimation of food intake.  
 
Schaefer et al. (2000) demonstrated the FFQ to underestimate the intake of fat and protein 
whilst overestimating carbohydrate consumption. Results derived from the FFQ were 
significantly different compared to actual intakes for saturated fat, monounsaturated fat and 
protein in individuals fed a high-fat diet and for polyunsaturated fat, saturated fat, fibre, and 
cholesterol in the lower-fat diet participants and like the findings by Schatzkin et al. (2003; 
discussed above). Similarly, Kowalkowska, et al. (2013) demonstrated protein intake to be 
overestimated by 34.7 g and fat intake by 48.6 g per day when measured using the FFQ. In 
another study, mean nutrient intake was found to be significantly overestimated with FFQ by 
both sexes, but more so by women (Paalanen et al., 2006). Women overestimated intake of 17 
out of 21 nutrients including polyunsaturated fatty acids, long chain n - 3 fatty acids, 
carotenoids and vitamin E while vitamin C was overestimated in both sexes. Men significantly 
overestimated all foods with the FFQ except for wheat, butter, margarine, cheese, poultry, 
sausages and coffee when compared to a standard three-day food record (Paalanen et al., 2006). 
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The FFQ is however a widely used instrument for dietary monitoring and its use is supported 
by Sun (2017) who suggests FFQs should be considered as the best approach to measuring 
habitual diet in large populations given their cost, representativeness, and the extent of 
participant involvement compared to other methods. The validity of the FFQ is supported by 
the ability of dietary intakes to predict long-term disease risk with FFQ assessments of trans 
fat intake alongside plasma biomarkers, demonstrating trans-fat intake to be detrimental to 
cardiovascular health (Sun, 2017). Other recent work by Guasch-Ferré, Bhupathiraju, and Hu 
(2018) state the FFQ to be easily administered with a low respondent burden which provide 
multiple-week records on dietary intake. While the studies above have demonstrated 
limitations in using the FFQ, its application to large populations makes it a useful tool for 
measuring dietary intake in epidemiological studies. Liu et al. (2013) found statistically 
significant correlations between FFQ and 24-hour recalls (except for male protein intake) 
although correlations did vary depending on the nutrient measured (r = 0.13 to 0.61). Limits of 
agreement (Bland Altman plots) however demonstrated no serious systematic bias between the 
two dietary instruments over the range of mean intakes.  
 
Other work by Khalesi, Doshi, Buys and Sun (2017) found the FFQ to correlate reasonably 
well with three-day food diaries (r = 0.39 to 0.69) with Bland Altman plots demonstrating 
acceptable agreement when dietary intake was recorded in a population of Australian adults. 
In support, further work by Whitton et al. (2017) found the FFQ to correlate reasonably when 
assessed against 24-hour recall, fasting plasma and urine biomarkers. The correlation between 
FFQ and 24-hour recall responses was 0.40 while significant associations were also observed 
between the FFQ and several biomarkers within plasma and urine including; isoflavones and 
soy protein intake (r = 0.46), carotenoids and fruit and vegetable intake (r = 0.34), plasma 
eicosapentaenoic acid and docosahexaenoic acid and fish/seafood intake (r = 0.36), and plasma 
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odd chain saturated fatty acids (SFA) and dairy fat intake (r = 0.25). 
 
The unique challenges posed in the complex assessment of the human diet means the 
development of different dietary assessment tools in epidemiological studies has been a focus 
of research for a significant period. While each method discussed has both strengths as well as 
limitations, the FFQ is considered here to be the most appropriate way to measure habitual diet 
in large populations. Compared to other methods, the FFQ is relatively inexpensive, provides 
a broad representation of dietary behaviour over time, and does not require intense participant 
involvement. Despite the FFQ being considered a usable methodology for long-term dietary 
assessment, validation by other methods should be utilised to confirm FFQ data, which can be 
prone to systematic error. However, on the basis that participants are provided with appropriate 
instruction and guidance, the FFQ can feasibly be used for the purpose of ranking individuals’ 
dietary exposures in epidemiological studies if later validated.  
 
3.2.4. Summary of Established Dietary Recording Methods 
A review of established methods for dietary monitoring demonstrate a range of limitations 
which effect their reliability, making it difficult to accurately understand habitual diet. High 
respondent burden, influences on food consumption (Goris, Westerterp-Plantenga and 
Westerterp, 2000; Prentice et al., 1986), lack of previous user experience (Champagne et al., 
2002) and decreases in recording accuracy over time (Gersovitz, Madden and Smiciklas-
Wright, 1978) all negatively impact the weighed food record while over and underestimation 
of food intake (Poslusna et al., 2009; Schaefer et al., 2000) and reliance on memory (Castell et 
al., 2015; Wrieden et al., 2003) are limitations of other methods such as the estimated food 
diary, 24-hour recall, multiple pass recall and the FFQ. Additionally, perceptions of body image 
and social desirability also appear to negatively influence the above methods (Hill and Davies, 
91 
 
2002). Furthermore, such methods are inappropriate for use with certain groups such as the 
elderly (Searle et al., 2002) or obese individuals (Weber et al., 2001) who often underestimate 
energy intake. These issues are especially pertinent when trying to establish dietary behaviours 
in clinical groups where dietary behaviour change may be crucial in preventing future chronic 
disease development. While acknowledging that some dietary recording methods are more 
feasible than others in monitoring dietary status, it is challenging to quantify individuals’ 
dietary behaviour precisely and accurately using questionnaires alone, especially when 
collecting data in large-scale epidemiological studies. Therefore, the opportunity to validate 
responses to dietary questioning should be explored as a matter of importance.  
 
3.3. Dietary Monitoring Using Urinary Biomarkers         
Due to the limitations associated with conventional dietary monitoring tools, measurement of 
urinary biomarkers using metabolite profile techniques, offers both an alternative approach for 
measuring dietary exposure as well as the opportunity to validate existing dietary recording 
methods (Favé et al., 2011). Urine contains a high number of individual metabolites which act 
as biomarkers reflective of dietary exposure. The development of dietary biomarkers can more 
accurately classify an individual’s dietary intake in comparison to questionnaires and as a 
result, improve the understanding between diet and disease (Gorman, Gibbons and Brennan, 
2013; Perez 2017) as well as confirm adherence to dietary recommendations (Heinzmann et 
al., 2010). 
 
Metabolomics is the study of small molecules present in biofluids with one key aim being to 
enhance knowledge of metabolic pathways relevant to human nutrition (Gibney, Walsh, 
Brennan, Roche, German and Van Ommen, 2005). As advancing chemical technologies, mass 
spectrometry (MS) and nuclear magnetic resonance (NMR) provide opportunity for 
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widespread analysis of metabolites, nutrients and other compounds which are present in urine 
and other biofluids (Gibney, Walsh, Brennan, Roche, German and Van Ommen, 2005). 
Targeted analytical approaches focus on specific subsets of predefined metabolites and follow 
a hypothesis-lead approach of metabolites of known identity while untargeted metabolomics 
detect thousands of unknown metabolites that may provide novel information on biological 
pathways with clinical relevance and can be conducted within cohort studies to validate other 
forms of dietary monitoring (Guasch-Ferré, Bhupathiraj and Hu, 2018). 
 
Foods contain thousands of non-nutritive secondary metabolites which once digested and 
metabolised, result in the presence of metabolites in bodily fluids, including  urine and blood 
(Favé, Beckman, Draper and Mathers, 2009) with more than 6800 fully annotated metabolites 
listed on the Human Metabolome Database relevant to diet, as well as other metabolic 
intermediates (Guasch-Ferré, Bhupathiraj and Hu, 2018). Metabolite profiling of serum and 
plasma can be used for dietary analysis as demonstrated in studies including: El-Sohemy et al. 
(2002); Pollard et al., (2003); Floegel et al. (2013); Schmidt et al. (2015); Esko et al. (2017). 
Urine concentration is modulated primarily by a person’s fluid intake and micturition pattern, 
which creates additional challenges, compared to homeostatic controlled plasma. Large 
metabolite concentration ranges can be caused by a number of other factors too, including age, 
gender, genetic background, diurnal variation, health status and physical activity level (Bouatra 
et al., 2013). This can be problematic given the concentration of urine influences the 
concentration of urinary biomarkers (Ralib et al., 2012), therefore, to account for differences 
in urine concentration between individuals, all samples must normalized in an additional step 
prior analysis to ensure all measurements are made within the same dynamic range to avoid 
misleading results. Furthermore, urine biomarkers undergo biotransformation often resulting 
in multiple derivatives of single compound; which adds to the challenge of using urine 
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biomarkers for measuring dietary intake. However, urine as a bio specimen is less invasive 
than blood collection, less expensive to obtain, and affords greater collection volumes, thus 
making it a highly useful biological resource for large clinical and population studies. 
Additionally, Favé et al. (2009) demonstrated urine composition remained consistent in a time 
window of two to four hours after meal consumption, consequently affording a flexible time 
window for postprandial urine sampling.  
 
Previous work has demonstrated urine to be as useful as plasma in identifying metabolites 
representative of habitual diet (Playdon et al., 2016). Numerous studies have been conducted 
to both identify and validate dietary biomarkers using urinary metabolomic approaches. While 
it is unlikely that biomarker assessment will replace traditional dietary recording methods 
entirely, the use of metabolomics in identifying novel and robust biomarkers of dietary 
exposure and intake can both enhance and validate such methods (Gorman, Gibbons and 
Brennan, 2013).   
 
Generally, the adoption of urinary metabolomics to classify dietary biomarkers has been 
achieved either by acute dietary intervention to identify specific food biomarkers, analysis of 
dietary patterns and metabolic profiles to identify biomarkers, or identifying biomarkers from 
cohort studies (Gorman, Gibbons and Brennan, 2013). Several studies have been conducted 
which have successfully identified biomarkers of foods with links to health importance 
including meat, fish, vegetables, fruits, wholegrain, tea, coffee and sugar as well as biomarkers 
of unhealthy behaviours, such as smoking and alcohol consumption.  
 
3.3.1. Biomarkers for Fruit and Vegetables 
Fruit and vegetable intake is a highly important component of a healthy diet. Conversely, 
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decreased fruit and vegetable intake is associated with poor health and increased risk of 
developing non-communicable diseases (Slavin and Lloyd, 2012). Therefore, the identification 
of biomarkers for fruit and vegetable consumption is an important step in developing enhanced 
dietary monitoring using urine metabolomics. Mennen et al. (2006) studied correlations 
between the intake of polyphenol-rich foods and beverages and the urinary concentrations of 
13 polyphenols and metabolites from a population of free-living individuals. Participants (n = 
53) completed a two-day dietary record within which 24-hour urine was collected throughout 
the second day and a spot urine sample collected on the morning of the third day. Correlations 
were discovered between apple consumption and coumaric acid, isorhamnetin, kaempferol and 
pholertin; red fruit consumption with kaempferol; orange consumption and hesperetin; citrus 
fruit and fruit juice consumption with hesperetin, caffeic acid and naringenin and total fruit and 
fruit juice intake with naringenin, gallic and 4-O-methylgallic acid, isorhamnetin, kaempferol, 
hesperetin, naringenin and pholertin. Fruit juice consumption also resulted in increased 
concentrations of quercetin in an earlier study by Young et al. (1999). Furthermore, positive 
correlations were identified between vegetable intake and enterolactone concentrations. This 
work demonstrates several correlations between the intake of polyphenol-rich foods and 
beverages and the excretion of polyphenols in urines of free-living individuals and suggests 
phenolic compounds in spot urine samples may be biomarkers indicative of polyphenol 
consumption. In support, ferulic acid and its derivatives are also suggested as general markers 
of polyphenol rich foods by Hodgson et al. (2004).  
 
Urinary biomarkers of citrus fruit consumption were investigated by Heinzmann et al. (2010), 
eight participants consumed standardised meals for three days as well as an additional mixed 
fruit meal on day two with urine samples collected four times each day. Analysis revealed 
significant metabolic changes between pre and post fruit meals with an observed increase in 
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the excretion of proline betaine, tartaric acid and hippuric acid, of which proline betaine 
demonstrated the strongest correlation. Consequently, citrus fruit and citrus fruit juice samples 
were analysed for concentrations of proline betaine. All citrus samples contained proline 
betaine but varied depending on the fruit (orange > lime > satsuma > grapefruit > lemon; 
Heinzmann et al., 2010). These findings were then applied to a large cohort of participants (n 
= 499) who completed two multiple pass dietary recalls and provided a 24-urine sample across 
the same period with the procedure repeated after three weeks. Analysis revealed significantly 
greater concentrations of proline betaine in participants who reported citrus fruit consumption 
compared to those that recorded no citrus fruit intake. Subsequently, the findings of this work 
led to the conclusion that proline betaine can be regarded as a specific and sensitive biomarker 
of citrus fruit consumption.  
 
Additionally, the role of proline betaine as a biomarker for citrus fruit consumption was also 
investigated by Lloyd, Beckmann, Favé, Mathers and Draper (2011) across two studies. Study 
one; subjects (n = 12) attended a clinical research facility (CRF) on two occasions, separated 
by several months. Subjects collected all urine after the consumption of a standardised evening 
meal up until and including the first morning void sample, collected prior to attending the 
clinical research facility. Following an overnight fast, urine was collected before subjects 
received a standardised breakfast including 200 ml of orange juice (Lloyd et al., 2011). Further 
urine samples were collected two, four and six hours after breakfast consumption. Study 2; 
eleven subjects attended the CRF for six identical test days, separated by a minimum of one 
week, over the duration of 14 months. A non-targeted metabolomics approach using flow 
infusion electrospray ionisation mass spectrometry (FIE-MS) successfully discovered and 
structurally identified biochemical markers of citrus exposure in urine in the study one subjects. 
This finding was confirmed in the study two subjects across 14 months, demonstrating the 
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presence of proline betaine to be a strong indicator of both acute and habitual consumption of 
citrus containing foods.  
 
The discovery of a broader range of metabolites present in urine that act as biomarkers in foods 
of high health importance was investigated by Lloyd et al. (2011). Twenty-four subjects 
consumed a standardised evening meal before attending the test day following a minimum 12-
hour overnight fast with fasting urine samples collected on arrival. Subjects visited the CRF 
six times over a period of eight months and were provided with either a standardised breakfast 
including cornflakes with milk or with a breakfast in which the cornflakes and milk were 
replaced with one of four test foods. The test foods consisted of; a cruciferous vegetable (200 
g of steamed broccoli), a berry fruit (200 g raspberries), oily fish (20 g salmon) or a whole 
grain wheat cereal with 125 ml of ultra-high temperature treated semi-skimmed milk (Lloyd et 
al., 2011). Urine samples were collected one and a half, three, and four and a half hours after 
breakfast consumption. Consumption of each of the four breakfasts was randomised and 
interspersed with consumption of two standardised breakfasts over the six visits. Analysis 
found consumption of broccoli and raspberries resulted in increases in ascorbate, which is 
abundant in both fruit and vegetables, evidenced by Stella et al. (2006).  
 
The consumption of cruciferous vegetables is inversely correlated to many human diseases 
including cancer (breast, lung, and bladder), diabetes, and cardiovascular and neurological 
disease and therefore work examining potential biomarkers of cruciferous vegetable was 
undertaken by Edmands et al. (2011), using 20 healthy male participants. Separated into three 
stages of 14 days, the study included: a period of restricted cruciferous vegetable consumption 
(stage one); a phase of high cruciferous vegetable intake where participants consumed 250 g 
per day of both broccoli and brussel sprouts (stage two) followed by a wash-out period with 
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restricted cruciferous vegetable consumption (stage three). Each participant provided all 
cumulative urine over 48 hours on completion of each stage. Urine samples analysed after each 
phase demonstrated significant discrimination between stages of cruciferous vegetable 
consumption with the concentration of S-methyl-l-cysteine sulfoxide significantly elevated 
following high cruciferous vegetable intake.  
 
In a later study, Lloyd, Beckmann, Haldar, Seal, Brandt and Draper (2013) developed a data 
driven strategy to identify urinary biomarkers indicative of habitual exposure to different food 
items described in a typical FFQ without a long-term food intervention. A standardised evening 
meal was provided to subjects (n = 68) on the evening prior to each visit to the CRF. Twenty-
four-hour urine samples were collected the day before each CRF visit at weeks four, eight and 
twelve. Subjects provided a fasting spot urine sample at the CRF before biometric 
measurements were recorded. The assessment of habitual exposure to different food groups 
was assessed using a validated FFQ and was available for subjects to estimate their diet on four 
occasions over a 12-week period. The FFQ used in this study was a simplified 58 food item 
version of the original 139 component version. Average consumption of each food category 
was assessed, and each subject given a consumption score. The strategy for biomarker 
discovery depended on the ability to define differential dietary exposure classes for each dietary 
component (containing > eight individuals; Lloyd et al., 2013). Subjects were categorized in 
terms of their intake for the 58 dietary components on a scale comprised of: <one time/week, 
one time/week, two-four times/week, five-six times/week, one time/day and >one time/day. In 
total, 38 dietary components were considered suitable for biomarker classification based on 
substantial differential exposure (Lloyd et al., 2013). The study found good separation of 
metabolite profiles between subjects reporting low and high citrus fruit consumption which 
confirms the finding in an earlier study by Lloyd et al. (2011) examining proline betaine as a 
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biomarker of citrus exposure. Discrimination between exposure levels improved linearly when 
low consumers of citrus were compared to subjects reporting increasingly higher intakes. This 
finding was similar for all foods examined, with consumption frequency and food 
distinctiveness proving influential in whether differential dietary exposures could be detected 
(Lloyd et al., 2013).  Biomarkers for single distinctive foods were also examined in each of the 
consumption frequency classes. Consumption of tomatoes was associated with the presence of 
hippuric acid, hydroxyhippuric acid, caffeic acid sulfate and hydroxyphenyl-valerolactone 
sulfate derivative, the presence of which are generally associated with colonic fermentation of 
dietary polyphenols (Lloyd et al., 2013). Other work examining biomarkers of plant-based 
polyphenol rich foods by Vetrani et al. (2014) found dihydroxybenzoic acid to be another 
metabolite indicative of polyphenol exposure when measured in urine profiles of participants 
consuming diets with different levels of polyphenol content. Similar studies examining the 
identification of biomarkers for plant-based foods include rhamnitol as a biomarker of apple 
consumption (Tomnita et al., (2015) and dopamine sulfate as a biomarker for banana intake 
(Wang et al., 2018).   
 
Quantification of dietary biomarkers in foods of high health importance in the UK collected 
from urines of free-living individuals (n = 6) was investigated by Lloyd et al. (2016). 
Metabolite levels in urine collected before sleep or upon waking revealed a group of 
biomarkers which correlated with reported dietary intake. Fruit and vegetable intake correlated 
with hippuric acid, citrus fruit intake with proline betaine, cruciferous vegetable intake with D, 
L-Sulforaphane-N-acetyl-L-cystine and grapes with tartrate. Tartaric acid was later identified 
as a dose-responsive urinary biomarker of grape intake and subsequently quantified in 
volunteers following several four-day dietary interventions including 0 g, 50 g, 100 g, and 150 
g per day of grapes in standardized diets (Garcia-Perez et al., 2016). Resveratrol is also stated 
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to be abundant in grapes and excreted following intake (Meng, Maliakal, Lu, Lee and Yang, 
2004). Furthermore, work concerning metabolite profiles following ingestion of foods and 
diets of high health importance has investigated the urinary metabolome of individuals exposed 
to range of diets based upon WHO dietary guidelines (Garcia-Perez et al., 2017). The analysis 
of dietary patterns as opposed to specific foods provided an opportunity to examine 
relationships between different diets and potential development of non-communicable 
diseases. Nineteen participants attended a research facility for a period of 72 hours on four 
occasions, consuming four different diets in a randomised crossover design. Visits were 
separated by at least five days. Each dietary intervention was developed in accordance with 
WHO guidelines for healthy nutrition. High energy density is associated with non-
communicable diseases and therefore the diets had a range of densities. Diet-one most closely 
matched WHO guidelines and was least energy dense whereas diet-four was least matched and 
most energy dense. During each inpatient visit, urine was collected across three periods (0900-
1300, 1300-1800 and 1800-0900) and pooled to create a 24-hour sample. Analysis of samples 
revealed clear separation in metabolic profiles of 24-hour urines between diets one and four 
with the presence of 19 metabolites significantly higher in diet-one compared to diet-four, 
reflecting higher intake of fruits including; rhamnitol, 4-hydroxyhippurate, hippurate, tartrate, 
and glycolate and vegetables; N-acetyl-S--propenyl-cysteine sulfoxide, N-acetyl-S-methyl-
cysteine sulfoxide, and S-methylcysteine sulfoxide. Nine metabolites were significantly higher 
after consumption of diet-four in comparison to diet-one (Garcia-Perez et al., 2017).  
 
3.3.2. Biomarkers for Meat and Fish  
Given the reported association between meat consumption, chronic disease and mortality 
(Larsson and Orsini, 2013) numerous studies have examined biomarkers reflective of meat 
intake, while biomarkers of fish, associated with a healthy diet (Hosomi, Yoshida and 
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Fukunaga, 2012), have also been examined. Myint et al. (2000) examined the correlation 
between reported meat consumption by FFQ and urinary methylhistidine excretion. The study 
found moderately strong correlations between reported meat intake and excretion of 
methylhistamine in urine alongside strong discrimination between vegetarian and omnivore 
diets while a review by Dragsted (2010) suggests potential biomarkers of dietary meat intake 
include creatine, creatinine, carnitine, carnosine, anserine and 3-methylhistidine.  
 
Cross, Major and Sinha (2011) examined creatinine, taurine, 1-methylhistidine, and 3-
methylhistidine as potential biomarkers for red meat consumption. In a randomised crossover 
feeding design, 24-hour urine samples were collected from 17 individuals who consumed four 
different controlled diets including; vegetarian, low red meat (60 g per day), medium red meat 
(120 g per day) and high red meat (420 g per day). When compared to the vegetarian and low 
red meat diets, all four metabolites were significantly higher in the medium and high red meat 
diets. Concentrations for 1-methylhistidine and 3-methylhistidine were significantly different 
for every diet type, increasing in urine concentration as the amount of meat consumed in the 
diet increased, therefore suggesting both may be good biomarkers for red meat consumption.  
 
The study by Lloyd et al. (2011) which examined foods of high health importance (discussed 
above) found dietary exposure to smoked salmon associated with 1-melthylhistidine and 
anserine, which are known to be highly abundant in the skeletal muscle of salmon and other 
oily fish and is supported by previous work (Abe, 1983; Abe, Okuma, Sekine, Maeda and 
Yoshiue, 1993). Urinary concentration of trimethylamine N-oxide (TMAO), a metabolite of 
trimethylamine and a degradation product formed from carnitine, also increased following 
smoked salmon consumption, concentrations of which are associated with fish consumption 
and supported by Stella et al. (2006). Similarly, methylhistidine was identified as a biomarker 
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of oily fish consumption in the later work by Lloyd et al. (2013) while 1- and 3- methyl-
histidine (chicken and oily fish) and dimethylamine and TMAO (fish) were identified as meat 
and fish biomarkers in the work by Garcia-Perez et al. (2017).  
 
Markers of general protein as opposed to specific food items have also been proposed with 
Patel et al. (2012) suggesting higher urinary concentrations of p-Cresol sulfate may be 
indicative of protein intake when compared to vegetarian diets, where concentrations were 
markedly lower. Similarly, work by Poesen et al. (2015) found indoxyl sulfate, a metabolite of 
dietary tryptophan, was significantly increased in urinary concentration in subjects consuming 
high protein compared to low protein diets. Dietary intake of protein sources was further 
examined by Cheung et al. (2017) in which four groups of ten subjects consumed increasing 
quantities of either chicken, red meat, processed meat or fish over a three-week period. 
Identical breakfasts, lunches and evening meals were served at 0800, 1200, and 1900, 
respectively, on each of the three consecutive days in the same week. Meat or fish was served 
at midday and evening meals for each group. Subjects consumed their habitual diet during the 
four remaining days of each week. All meals provided similar intakes of energy and fibre, but 
the amounts of proteins, fats, and carbohydrates varied each week. For example, week one: 
13% protein, 30% fat, 57% carbohydrate, week two: 20% protein, 35% fat, 45% carbohydrate; 
and week three: 30% protein, 40% fat, 30% carbohydrate. The amount of meat or fish 
consumed therefore increased with the percentage of protein in the diet during each week. 
Twenty-four-hour urine samples were collected from the second void of day two until the first 
void of day three (Cheung et al., 2017). Metabolites including 3-methylhistidine, anserine, 
carnosine, 3-acylcarnitines and trimethylamine-N-oxide associated with meat or fish intake. 
Specifically, 3-methylhistidine and anserine was associated with chicken intake with anserine 
presence specific to chicken consumption. Trimethylamine-N-oxide correlated with fish intake 
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while carnosine and 3-acylcarnitines was associated more generally with meat intake and meat 
and fish intake respectively.  
 
3.3.3. Biomarkers of Wholegrain and Soy  
Evidence suggests that wholegrain consumption plays an important role in chronic disease 
prevention by facilitating antioxidant defence systems and moderating the risk factors of 
cancer, cardiovascular diseases, and other chronic diseases (Zhu, Wang, Sha and Sang, 2016). 
Biomarkers reflective of long-term wholegrain rye and wheat intake include 
dihydroxyphenylpropionic acid (Soderholm, Koskela, Lundin, Tikkanen and Aldercreutz, 
2009) and benzoxazolinone (Koistinen et al., 2018). In soy studies, a randomized controlled 
study was used to compare a high and low-soy diets in 76 healthy adults over ten weeks with 
results demonstrating concentrations of isoflavones and their gut microflora metabolites in 
urine were significantly higher in the participants with high soy intake compared to those who 
consumed low amounts of soy (Wiseman et al., 2004). Daidzein has been suggested as a 
biomarker of soy intake, with work by Ahn-Jarvis, Clinton, Riedl, Vodovotz and Schwartz, 
(2012) demonstrating increased excretion of daidzein following soy consumption. Morimoto, 
Beckford, Franke and Maskarinec (2014) support this, suggesting urinary isoflavonoid 
excretion, of which daidzein forms part of its class, is an excellent biomarker for discriminating 
soy consumption following a randomised control trial involving low and high soy diets.   
 
3.3.4. Biomarkers for Caffeine, Coffee and Tea 
Consumption of coffee and tea has been associated with reduced mortality (Van den Brandt, 
2018) with previous research substantiating such associations (Khan and Mukhtar, 2013; 
Grosso et al., 2014; Petta and Marchesini, 2017) while intake of caffeine is associated with 
both positive and negative health outcomes (Ruxton, 2009). Research by Crews, Oliver and 
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Wilson (2001) demonstrated that 24-h urine after caffeine intake allowed for quantification of 
caffeine as a metabolite representative of caffeine consumption. Rechner, Spencer, Kuhnle, 
Hahn and Rice-Evans (2001) suggest chlorogenic acid presence in urine is mainly attributed to 
coffee intake (amongst other dietary items) while Hodgson et al. (2004) suggests that ferulic 
acid and its derivatives may also provide usefulness as a biomarker for coffee consumption, as 
well as polyphenol rich foods. Vanillic acid is also proposed as a possible coffee biomarker by 
Rechner et al. (2001) and trigonelline by Slow et al. (2004). In the work by Mennen et al. 
(2006), correlations were identified between coffee consumption and caffeic acid. 
Additionally, research by Sang, Lee, Yang, Buckley and Yang (2008) found consumption of 
tea resulted in the presence of metabolites associated with tea polyphenols in human urine and 
included; epigallocatechin, glucuronide, methylated epigallocatechin glucuronide, methylated 
epigallocatechin sulfate, epicatechin glucruronide, epicatechin sulfate and methylated 
epicatechin sulfate.  
 
3.3.5. Biomarkers of Cocoa, Sweeteners and Sugar 
Excessive intake of rapidly absorbed sugars and other sweetened items is a major health 
concern given sugar’s association with health complications, including pre-diabetes, T2D and 
cardiovascular disease. Work by Wilson et al. (1999) examined acesulfame-k as a biomarker 
of sweetener intake. Analysis of 48-hour food diaries and 24-hour urines found good agreement 
between reported intake of artificial sweeteners and acesulfame-k presence in 24-hour urine.    
More recently, Beckmann et al. (2016) examined the metabolic effects of acute sucrose 
exposure with the aim of identifying metabolites which correlate with sucrose intake in a 
randomised control design. Standard meals low in carbohydrate content and no extrinsic sugars 
were provided to subjects (n = 90) on the evening prior to the test day, at lunch and on the 
evening of the test day.  Subjects collected all their urine following consumption of the evening 
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meal up until the first morning void prior to arrival at the test facility. Aside from the test drink, 
subjects avoided sucrose intake throughout the study protocol. Subjects fasted for 12 hours 
before arriving at the test facility where a spot urine and blood sample were collected. The test 
drink, containing 0, 50 or 100 g sucrose in water, was provided before a further urine sample 
and blood sample was collected after three hours. Subjects consumed a standard lunch, similar 
in content to the breakfast, before urine samples were collected after six and nine hours. A 
standard evening meal was consumed before urine was collected for the rest of the evening, 
overnight and first morning void. Subjects fasted for 12 hours following the evening meal 
before returning to the test facility to provide a final, post 24-hour urine sample and blood 
sample (Beckmann, et al., 2016). This work demonstrated ingestion of sucrose to influence 
over 120 metabolites present in urine and plasma which discriminated between sucrose 
treatments. Metabolites directly correlated to sucrose intake included sucrose and fructose.  
 
In the Garcia-Perez et al. (2017) study clear discrimination was observed in urinary glucose 
between diet one (diet most closely matching WHO guidelines) and diet four (diet least 
matching WHO guidelines) demonstrating increased sugar intake was detectable in urine 
samples across varying diets. Furthermore, recent work by Michielsen, Almanza-Aguilera, 
Brouwer-Brolsma, Urpi-Sarda and Afman (2018) propose methylxanthines as candidate 
biomarkers for cocoa consumption following a systematic review of the literature regarding 
cocoa and liquorice intake studies.  
 
3.3.6. Biomarkers for Smoking and Alcohol  
The negative health consequences of smoking and alcohol consumption are extremely well 
established in the literature with both contributing to the development of non-communicable 
chronic disease, and subsequently, the significant economic health burden imposed on health 
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services (Scarborough et al., 2011). Therefore, the establishment of biomarkers which can 
monitor smoking status and alcohol consumption can prove beneficial in tracking unhealthy 
behaviours. In a study using 1580 smokers and 3126 non-smokers, analysis found 
concentrations of both nicotine and cotinine varied considerably in urine depending on 
smoking status (Heinrich et al., 2005). Significantly, intake of food containing nicotine was 
not identified as source of nicotine and cotinine presence in urine with tobacco smoking the 
only source for the urinary presence of these biomarkers. In support of this work, the use of 
cotinine as a biomarker for cigarette smoking was confirmed by Petersen, Leite, Chatkin and 
Thiesen (2010) while 2-cyanoethylmercapturic acid is advocated as a biomarker of cigarette 
smoking by Scherer et al. (2010) and 3-hydroxypropylmercapturic acid by Gregg, Minet and 
McEwan (2013). Research examining alcohol exposure, by Mackus et al. (2017), used 36 
healthy social drinkers as participants. Comparison of urine samples between an alcohol 
consumption and alcohol-free day demonstrated concentrations of ethyl glucuronide to be 
significantly elevated following alcohol intake and correlated significantly with urinary 
ethanol, which is abundant in alcohol, as well as individual headache scores, a symptom 
traditionally associated with alcoholic induced illness. While ethyl glucuronide concentration 
did not correlate with the number of alcoholic drinks consumed, the authors concluded their 
findings to demonstrate ethyl glucuronide as a potential biomarker of alcohol consumption.  
 
3.3.7. Dietary Patterns 
Assessment of dietary patterns as opposed to identification of biomarkers associated to specific 
foods is another line of research undertaken in urinary metabolomics. As already discussed, 
work by Lloyd et al. (2013) developed a data driven strategy to identify urinary biomarkers 
indicative of habitual exposure to different food groups, finding significant differences in 
markers for citrus consumption between high and low intake patterns. Additionally, the study 
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by Garcia-Perez et al. (2017) successfully identified metabolic differences in urine profiles 
between contrasting diets of high and low quality, based on WHO guidelines, as well as 
identifying biomarkers of specific foods. This work is supported by other literature which has 
focussed on habitual dietary patterns and metabolomic profiles.  
 
O’Sullivan, Gibney, and Brennan (2011) conducted a study involving 160 volunteers finding 
dietary intakes could be separated into three distinct clusters. Cluster one was represented by a 
high energy contribution from whole-meal bread, milk, fish, confectionary, and desserts and a 
lower contribution from energy drinks. Cluster two was characterised by a high energy 
contribution from foods including savoury snacks, low-fat milk, yogurts, fruit, poultry, and 
sauces and a lower contribution from energy drinks. Cluster three contributions included white 
bread, sugars and preserves, butter and spreads, red meat, red-meat dishes, meat products, and 
alcohol and a lower contribution from vegetables compared with the cluster one and two. 
Significantly, analysis of participant urine allowed the identification of metabolites associated 
with different dietary patterns. Several of the metabolites identified were associated with the 
consumption of specific food groups, demonstrating habitual diet to be represented in 
metabolic data.  
 
Other work by Vazquez-Fresno et al. (2015) examined the urinary profiles of 98 participants 
consuming either a Mediterranean diet, Mediterranean diet with olive oil, a Mediterranean diet 
with nuts or a controlled low-fat diet. Urine analysis revealed significant separation in urine 
profiles between the Mediterranean diets and the low-fat diet. Analysis revealed that the most 
prominent hallmarks concerning the Mediterranean diet groups were related to the metabolism 
of carbohydrate, creatine, creatinine, amino acids, lipids and microbial cometabolites 
(Vazquez-Fresno et al., 2015). Conversely, hippurate, trimethylamine-N-oxide, histidine, 
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methylhistidine, carnosine, anserine and xanthosine were prominent in urines of low-fat diet 
consumers, demonstrating the ability of urinary metabolomics to classify individuals based 
upon the dietary intake pattern. Further to these findings, work by Gibbons et al. (2017) found 
urinary metabolomic data could be used to classify individuals into either “healthy” (e.g. intake 
of breakfast cereals, low fat and skimmed milks, potatoes, fruit and fish, fish dishes) or 
“unhealthy” diets (e.g. intake of chips/processed potatoes, meat products, savoury snacks and 
high-energy drinks) in nutrition data from 567 participants. Table 3.1 presents a summary of 
the major food groups and the urinary metabolites associated with consumption in the diet. 
 
3.4. Summary 
Notwithstanding the limitations associated with traditional forms of dietary monitoring, it is 
likely questionnaire-based methods will continue to be utilised in both primary care and within 
academic research for the foreseeable future. This is because for many foods and nutrients, 
specific biomarkers are not yet available. Additionally, for foods which do have established 
biomarkers, they are unable to quantify the amount of food and drink consumed by an 
individual. However, through the successful identification of biomarkers of foods of high 
health importance encompassing fruit, vegetables, meat, fish, wholegrain, tea, coffee, sugar, 
successful discrimination of metabolic profiles derived from different diets as well as 
biomarkers for smoking and alcohol consumption, it is now possible to both improve and 
validate traditional dietary monitoring methods with urinary metabolomics to develop an 
improved understanding of diet and nutrition status. Urine can be easily and non-invasively 
collected, is less expensive to obtain than other biofluids and can be collected in large volumes, 
therefore making it a highly useful biological resource for large clinical and population studies 




Evidence of questionnaire validation using urinary biomarkers has been demonstrated in 
several studies including Lloyd et al. (2013) and more recently by Fraser et al. (2016) who 
found good correlation between several urinary biomarkers and reported food intake by 
repeated 24-hour recalls and FFQ. However, a limitation of many of the studies discussed is 
the requirement for participants to either provide inconvenient 24-hour urine samples at home 
or attended regular and lengthy visits to research facilities to provide urine samples for 
metabolomic assessment. Such limitations suggest the development of simplified protocols to 
monitor habitual diet in free-living environments using metabolomic technologies is a prudent 
next phase of research. The potential of such advances will allow for greater confidence in 
results derived from questionnaire based dietary monitoring as responses from such can be 
validated. This is especially useful in groups known to misreport dietary intake and those at 
increased risk of non-communicable disease where habitual dietary monitoring can be used to 
assess the efficacy of lifestyle interventions with regards to dietary advice. The challenge 
therefore is to determine how best, robust and reliable urinary data can be collected from free 
living individuals in the community, without causing inconvenience and disruption to everyday 










Table 3.1. Summary table of urinary metabolites linked to dietary exposure  
Dietary Component  Biomarker   
Fruits and Vegetables 
General fruit and fruit juice 
intake  
naringenin, gallic and 4-O-methylgallic acid, isorhamnetin, kaempferol, 
hesperetin, naringenin, pholertin, rhamnitol, 4-hydroxyhippurate, hippurate, 
tartrate, glycolate, quercetin, ferulic acid 
General vegetable intake  hippuric acid, N-acetyl-S--propenyl-cysteine sulfoxide, N-acetyl-S-methyl-
cysteine sulfoxide, S-methylcysteine sulfoxide, ferulic acid  
Apple coumaric acid, isorhamnetin, kaempferol, pholertin, rhamnitol 
Red fruit Kaempferol 
Citrus fruit and fruit juice hesperetin, caffeic acid, naringenin, proline betaine 
Cruciferous vegetables S-methyl-l-cysteine sulfoxide, D, L-Sulforaphane-N-acetyl-L-cystine 
Tomatoes hippuric acid, hydroxyhippuric acid, caffeic acid sulfate and hydroxyphenyl-
valerolactone sulfate 
Potato Calystegine 
Banana dopamine sulfate 
Grapes  tartaric acid, resveratrol  
Legumes  pyrogallol  
 
 
Protein, Meat and Fish 
General meat intake  methylhistamine, creatine, creatinine, carnitine, carnosine, anserine, taurine 
General fish intake  trimethylamine N-oxide 
General protein intake  p-Cresol sulfate, indoxyl sulfate, tryptophan 
Red meat 1-methylhistidine, 3-methylhistidine 
Oily Fish 1-melthylhistidine, anserine 
Chicken  anserine  
 
Wholegrain and Soy 





Caffeine, Coffee and Tea 
Caffeine Caffeine 
Coffee chlorogenic acid, ferulic acid, caffeic acid, vanillic acid  
Tea epicatechin (and derivatives) 
 
Sugar and Cocoa 
Sweetener  acesulfame-k 
General sugar intake  sucrose, fructose, glucose  
Cocoa methylxanthines  
 
Smoking and Alcohol  
Smoking nicotine, cotinine, 2- cyanoethylmercapturic acid, 3-hydroxypropylmercapturic 
acid  
 







Chapter Four:  
 
General Methods  
 
4.1. Studies  
This thesis is comprised of five studies including; Study one: The efficacy of a GP-led pre-
diabetes intervention targeting lifestyle modification; Study two: A protocol for accurate 
monitoring of habitual diet in a free living environment using multiple spot urine samples; 
Study three: The effects of acute moderate exercise on the urinary metabolome; Study four: 
Comparison of the Alere Afinion AS100 point of care analyser and HPLC in the determination 
of HbA1c; Study five: The feasibility of conducting a randomised control trial to evaluate the 
effectiveness of a focussed 15-minute one-to-one consultation to improve blood glucose 
control in pre-diabetes. In instances where methods are used in more than one study, they are 
detailed in this chapter. Where methods are used only once, they are detailed in respective 
research chapters. Given study one’s design as a service evaluation which informed later work 
within this thesis, methods are described previously in chapter two and not included here.    
 
4.2. Ethical Approval 
Necessary approval for all studies was granted prior to any subject recruitment or testing 
procedures taking place. Ethical approval for studies two, three and four was granted by 
Aberystwyth University Research Ethics Committee using an online application system. Study 
five required NHS ethical approval by a Wales Research Ethics Committee (REC Seven). A 
full application was submitted through the Integrated Research Application System (IRAS), an 
online application that creates application forms for relevant parties, including the National 
Health Service (NHS) REC and Hywel Dda University Health Board Research. The application 
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was reviewed in full by an ethics committee comprised of both health professionals and lay 
members. The review was attended in person by both the chief investigator and academic 
supervisor. The application received immediate favourable opinion without protocol revision 
and was subsequently registered with www.ClinicalTrials.gov. 
 
4.3. Participants and Recruitment  
Participants were given written and verbal information on the purpose and protocol of studies 
before giving their consent to proceed. All participants who took part in studies were informed 
their participation was voluntary and they were free to withdraw at any point without giving 
prior notice or reason for withdrawal which would not affect their future participation in 
research or their right to healthcare. Participants wishing to confirm their interest or to receive 
further information did so by telephone, email or visiting the University research facility in 
person. Recruitment for studies two, three and four was by social media, University email 
bulletins, fliers and word of mouth. Recruitment for study five was achieved by letter of 
invitation via surgery patient records. 
 
4.4. Anthropometry Measures  
For descriptive and analytical purposes, height (Holtain Ltd, Crymych, UK) and body mass 
(wearing loose fitting clothing; Seca 899, Hamburg, Germany) were recorded by the same 
investigator.   
 
4.5. Blood Collection 
Participants were seated in a phlebotomy chair and the process of blood sampling was 
explained in full. Following sample site selection, the skin at the sampling site was cleaned 
with an alcohol swab and allowed to dry. For venous blood, samples were obtained by 
113 
 
venepuncture from an antecubital vein using a 21-gauge needle and drawn into a six ml 
heparinised vacutainer with minimal stasis (BD Vacutainer Systems, Plymouth, UK). For 
capillary blood, a sample was collected from the middle or index finger using a lancet (Accu-
Chek Safe-T-Pro Plus Lancet, Roche Diabetes Care Limited, UK). All blood samples were 
collected by the investigator. 
 
4.6. HbA1c Analysis  
For analysis of venous blood, separate 1.5 μl samples of whole blood were transferred from a 
heparinised vacutainer into separate HbA1c and lipid test cartridges and analysed respectively 
by an automated point of care (POC) blood analyser (Alere Afinion AS100, Abbot, Cheshire, 
UK).  For capillary blood, 1.5 µl of whole blood was collected directly into the HbA1c test 
cartridge from the puncture site. Control samples containing different target HbA1c 
concentrations were assayed by the POC analyser according to the manufacturer’s instructions 
on the morning of each participant’s visit to ensure the detection range was operating between 
20-140 mmol/mol. Test samples involved taking 1.5 µl of whole blood, collected either directly 
from the capillary puncture site or from the EDTA/LH vacutainer before loading in to the POC 
analyser. The blood sample was automatically diluted and mixed with a solution resulting in 
the release of haemoglobin from the erythrocytes. The sample solution was then transferred to 
a blue boronic acid conjugate, which binds to the cis-diols of glycated haemoglobin. The 
reaction mixture was soaked through a filter membrane with all precipitated haemoglobin, 
glycated and non-glycated, remaining on the membrane, the excess conjugate was removed 
using a washing reagent. The POC analyser then evaluated the precipitate on the membrane. 
By measuring the reflectance, the blue (glycated haemoglobin) and the red (total haemoglobin) 
colour intensities were quantified with the ratio between them proportional to the percentage 
of HbA1c in the sample. Following sample loading, the POC analyser produced an HbA1c 
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percentage within three minutes, displayed on the digital screen. An identical process was 
followed for lipid samples.  
 
4.7. Urine Collection Procedures 
In study two, the urine collection kit consisted of; 14 cm non-sterile urine collection straws 
(Vacutest Kima, Rome, Italy), four ml additive free evacuated vacutainer tubes (Vacutest 
Kima, Rome, Italy) and 125 ml transparent polypropylene collection containers (Praxisdienst, 
Longuich, Germany) (Figure 5.1). Collection straws and vacutainer tubes were contained in a 
650 ml plastic container (Poundland, Wednesbury, UK). The same equipment was used in 
study three. In study five, participants received three urine collection kits for each collection 
phase. The kits consisted of; three 14 cm non-sterile urine collection straws, six 4 ml additive 
free evacuated vacutainer tubes, housed within absorbent pouches and sealed plastic bags, and 
a 125 ml collection container. Collection straws, vacutainer tubes and collection container were 
contained within addressed cardboard boxes suitable for human biofluid postage (Figure 4.1). 
All urine storage equipment and instructions were fully compliant with the UN3373 standard 
for Category B biological substances. In all studies where urine was collected, participants 
received instructions to fill a collection container with a mid-stream urine sample to minimise 
the possibility of bacterial contamination from urethral contaminants (Gilbert, 2006). The tip 
of the transfer straw was submerged into the urine and a vacutainer tube was inserted into the 
transfer straw to draw the urine into the vacutainer. Any remaining urine in the container was 
deposited within the lavatory. The collection container was rinsed with tap water and reused 
for further samples. Collection straws were returned and disposed of safely in laboratory-based 
sharps bins. Following their return to the investigator, samples were frozen at -80°C to await 














Figure 4.1. The urine collection kit used by participants in the randomised control trial (chapter 
8) including; addressed cardboard postage box, collection straws, vacutainers and collection 
container.   
 
4.8. Urine sample preparation, extraction and adjustment  
To account for differences in fluid intake between participants, all urine samples were 
normalized by refractive index before analysis. This ensured all measurements were made 
within the same dynamic range. Refractive index normalization takes the complete 
composition of the sample into account when normalising, not just the concentration of a single 
analyte. Samples were defrosted overnight in a 4 °C refrigerator. Once thawed, samples were 
centrifuged (14000 RPM for five min at 4 °C), placed on ice and aliquots of thawed urine (1000 
μl) were transferred into two ml labelled Eppendorf tubes. The remaining sample volume was 
returned for freezing at −20°C. A hand-held Refractometer (Bellingham Stanley™ Brix 54 
Model) was calibrated with de-ionised water (dH2O) and dried with tissue according to the 
manufacturer’s instruction. 200 μl of urine was transferred onto the refractometer dish and a 
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value recorded when the refractometer returned three identical values consecutively. The 
refractometer was rinsed with dH2O between samples and dried prior to the next recording. 
Specific gravity correction factors were calculated per participant as the fold change of 
individual sample specific gravity to the specific gravity of the sample in the whole sample set 
that recorded the minimum value (Wilson et al., 2019). Based on refractometer values, aliquots 
of the required amounts of urine from centrifuged two ml Eppendorf tubes and dH2O were 
transferred into new two ml Eppendorf tubes on ice to make up 500 μl for extraction. 500 µl of 
pre-chilled (−20°C) H2O: MeOH (3:7) was added to each adjusted sample and vortexed. 
Samples were returned for freezing at -80°C to await analysis. 24 hours prior to analysis, 
samples were moved to a 4°C refrigerator and thawed fully.    
 
4.9. Flow infusion electrospray ionisation-high resolution mass spectrometry 
(FIE‑HRMS), multivariate modelling, classification and feature selection 
This phase of analysis was completed by colleagues within the Institute of Biological, 
Environmental and Rural Sciences (IBERS; Aberystwyth University) who have specialised 
expertise in FIE‑HRMS, multivariate modelling, classification and feature selection (see 
acknowledgements). Methods used within this phase of analysis have also been utilised in other 
work within the IBERS laboratory (Lloyd et al., 2019).  
 
High resolution flow infusion fingerprinting was acquired on either an Exactive Orbitrap 
(Thermo Finnigan, San Jose, CA) or a Q-Exactive + (Thermo Finnigan, San Jose, CA) mass 
spectrometer. The Exactive Orbitrap mass spectrometer (Thermo Finnigan, San Jose, CA), was 
coupled to an Accela (Thermo Finnigan, San Jose, CA) ultra-performance liquid 
chromatography system front end. Twenty μl of sample was injected into the electrospray 
ionisation (ESI) source via a flow solvent (mobile phase) of pre mixed HPLC grade MeOH and 
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ultra–pure H2O (7:3) with a total acquisition time of three minutes. Flow rate was maintained 
at 200 μlmin-1 for zero to one and half minutes and then 600 μlmin-1 for one and half to three 
minutes. Positive and negative ionisation modes were acquired simultaneously using fast 
polarity switching. For each ionisation mode, one scan event was used to acquire all mass 
spectra (positive; 55.00 – 1000.00 m/z, negative; 63.00 – 1000.00 m/z), with a scan rate of 1.0 
Hz. The resolution was 100,000 with an automatic gain control target of 5 x 105 and a maximum 
injection time of 250 ms. The Q- Exactive Plus Orbitrap mass spectrometer (Thermo Finnigan, 
San Jose, CA), coupled with a Unimate 3000 liquid chromatography tower (Dionex, Thermo 
Scientific) front end. Twenty μl of sample was injected into the ESI source via a flow solvent 
(mobile phase) of pre-mixed HPLC grade MeOH and ultra–pure H2O (7:3) with a total 
acquisition time of three minutes. Flow rate was maintained at 200 μl minutes-1 for zero to one 
and half minutes and then 600 μlmin-1 for one and a half to three minutes. Positive and negative 
ionisation modes were acquired simultaneously using fast polarity switching. For each 
ionisation mode, one scan event was used to acquire all mass spectra (positive; 80.00 – 1200.00 
m/z, negative; 80.00 – 1200.00 m/z) with a scan rate of 1.0 Hz. The resolution was 280,000 
with an automatic gain control target of 5 x 105 and a maximum injection time of 250 ms. 
 
Dimensionality reduction of the mass spectra was performed by taking each m/z value from 
scans about the apex of the infusion profile and binning the m/z and intensity values for direct 
comparison of urine fingerprints, before signal annotation. For feature selection, supervised 
random forest (RF) classification was conducted using the random forest package using R 
software (R Core Team, 2013). RF classification margins were used to evaluate the 
performance of classification models (Enot et al., 2008) which is defined as the proportion of 
votes for the correct class minus the maximum proportion of votes for the other classes—the 
larger the margin, the more confidence in the classification (Fave et al., 2011). Models were 
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acceptable if RF margins were >0.3. Other classification performance identifiers included: 
Accuracy, defined as the proportion of correctly classified data points among all data points 
where accuracy values ranged from zero to one (one equates to perfect classification); the area 
under the Receiver Operating Characteristic (ROC) curve (AUC) which aggregates 
performance across the entire range of trade-offs between true positive rate and false positive 
rate and ranges from 0.5 (indicating random performance) to 1.0 (denoting perfect 
classification; Fave et al., 2011). For metabolite signal annotation, accurate m/z values were 
extracted to allow identification of metabolites at one–five ppm and queried using MZedDB, 
an accurate mass annotation database used to annotate signals by means of neutral loss and/or 
adduct formation rules (Draper et al., 2009; Lloyd et al., 2019).  
 
Figure 4.2. Example of a spectrum fingerprint output following FIE‑HRMS   
 
4.10. Quantification of known dietary biomarkers  
Quantification of known biomarkers was performed on a TSQ Quantum Ultra triple quadrupole 
(QQQ) mass spectrometer (Thermo Scientific), equipped with a heated electro-spray ionization 
source and coupled to an Accela UHPLC system (Thermo Scientific; Lloyd et al., 2019). For 
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Hydrophilic Interaction Liquid Chromatography analysis, chromatographic separation was 
performed on a ZIC-pHILIC column. The mobile phase consisted of 10 mm ammonium acetate 
in water: acetonitrile (95:5) and 10 mm ammonium acetate in water: acetonitrile (5:95). HPLC 
was carried out in low pressure mode with zero and 650 bar as minimum and maximum 
pressures, respectively. For reverse phase (RP) analysis, chromatographic separation was 
performed on Hypersil Gold (1.9 μm, 200×2.1 mm2) (Thermo Scientific). The mobile phase 
consisted of 0.1% formic acid in H2O and 0.1% formic acid in MeOH. For RP analysis the flow 
rate was maintained at 400 μlmin−1. The high-performance liquid chromatography was carried 
out in high pressure operating mode with zero and 1000 bar as minimum and maximum 
pressures, respectively. For both chromatographic analyses, column oven and autosampler tray 
were maintained at 60 and 14°C, respectively. To ensure consistent sample delivery, 20 μl were 
injected using a 20 μl loop and partial loop injection mode. After each injection, syringe and 
injector were cleaned using a 10% HPLC grade MeOH solution in ultra-pure water (1 ml flush 
volume) to avoid sample carryover. Spectra were collected at a scan speed of 0.010 and 0.003 
seconds for HILIC and RP analysis, respectively. A scan width of 0.010 u and peak width of 
0.7 FWHM were used for both HILIC and RP analyses. Mass spectra were acquired in multiple 
reaction monitoring mode, in positive and negative ionization mode simultaneously using 
optimized values of shimmer offset, collision energy, and tube lens for each MRM transition. 
Absolute concentrations were calculated using a nine-point calibration curve (0.006561 to 100 
μgml−1 for each biomarker). Xcalibur (V3.0.63, Thermo Fisher Scientific) was used for peak 







Table 4.1. Known biomarkers of dietary intake measured in research chapters 
Biomarker Dietary Component  
2-Cyanoethylmercapturic acid Tar (Smoking) 
 
2,3-Dihydroxyphenylpropionic acid Wholegrain 
 
3-Hydroxyhippuric acid Fruit & Vegetables 
 




3,4-Dihydroxybenzoic acid Fruit & Vegetables 
 
3,5-Dihydroxybenzoic acid Fruit & Vegetables 
 
3,5-Dihydroxybenzoic acid-3-sulfate Fruit & Vegetables 
 








Caffeic acid Fruit & Vegetables 
 




D, L-Sulforaphane-glutathione Cruciferous Vegetables 
 




Dihydrocaffeic acid Cocoa  
 
Epicatechin Apple, cocoa, coffee, green/black tea, fruit, vegetables  
 
Ferulic acid Coffee, polyphenol-rich foods 
 
Ferulic acid-4-O-sulfate Coffee, polyphenol-rich foods 
  




Hippuric acid Fruit and Vegetables 
 
Isoferulic acid Coffee, polyphenol-rich foods  
 
m-Coumaric acid Coffee, olives 
 








Quercetin Fruits, vegetables, tea 
 
Quercetin-3-O-beta-D-glucuronide Fruits vegetables, tea 
 
Resveratrol Red wine, grapes 
 
Vanillic acid Coffee, cocoa, wholegrain, herbs, olive 
 
p-Cresol Glucuronide Protein 
 
1-Methyl histidine Poultry 
 
2,3-Dihydroxyphenylpropionic acid-3-sulfate Wholegrain 
 
3-Methyl histidine Poultry 
 




5-Methoxyindole-3-acetic acid Poultry 
 




Calystegine A3 Potatoes 
 












Gallic acid Fruits & vegetables, Wine/grape, tea  
 





































4.11. Statistical Analysis 
Two computerized statistical packages were used to analyse data (SPSS version 17.0, SPSS 
inc., Chicago, IL; R Core Team (2013; for metabolomics data)). Specific statistics employed 











Chapter Five:  
 
Developing a protocol for accurate monitoring of habitual diet in a free-living 
environment using multiple spot urine samples 
 
5.1. Introduction 
An important feature in effective implementation of public health programmes is the 
requirement for validated, population-level dietary intake screening tools to establish the 
effectiveness of healthy eating interventions to change dietary behaviour (Lloyd et al., 2019). 
Limitations associated with traditional forms of dietary monitoring include; respondent burden 
(Goris, Westerterp-Plantenga and Westerterp, 2000; Prentice et al., 1986), lack of previous 
user experience (Champagne et al., 2002), decreased recording accuracy over time (Gersovitz, 
Madden and Smiciklas-Wright, 1978) over and underestimation of food intake (Poslusna et al., 
2009; Schaefer et al., 2000), reliance on memory (Castell et al., 2015; Wrieden et al., 2003) 
and perceptions of body image and social desirability (Hill and Davies, 2002). Notwithstanding 
such limitations, it is likely these methods will continue to be utilised for dietary monitoring 
within both health care and academic research environments for the foreseeable future, given 
they are relatively cheap and simple to deliver. However, a significant body of research 
demonstrates the use of urine metabolomic profiling as an alternative approach for measuring 
dietary exposure as well as providing the opportunity to validate existing dietary recording 
methods (Favé et al., 2011). Urine dietary biomarkers are developed based on the notion that 
urinary excretion of specific metabolites quantitatively reflects intake of a corresponding food 
or nutrient over a fixed time period. In some instances, multi-metabolite biomarker panels can 
offer a more reliable estimation of dietary exposure than a single-biomarker approach as well 
as other dietary monitoring protocols (Lloyd et al., 2019). Many studies examining urinary 
124 
 
metabolomics for habitual dietary monitoring have thus far involved participants collecting 24-
hour urine samples, which while robust and accurate, places a significant burden on participants 
due to its adverse impact on normal daily life as well as significant processing costs for the 
researcher (John et al., 2016). Given this limitation, it is unlikely the use of such could be 
applied to a ‘real world’ setting. Therefore, it is of interest to determine whether habitual dietary 
behaviour can be monitored within a free-living environment without intrusive or disruptive 
protocols being administered.  
 
Metabolic profiling of a single spot urine sample can provide comprehensive quantitative data 
of dietary exposure for 12 to 24 hours prior to urine collection (Fave et al., 2011). While a spot 
urine sample is not representative of an individuals' habitual dietary exposure, a series of spot 
samples collected over a prolonged period may give a robust overview of an individual’s 
nutritional behaviour and benefit from reduced logistical costs (Wilson et al., 2019). Work by 
Lloyd et al. (2013) demonstrated spot fasting urine samples to adequately discriminate between 
exposure class for several dietary items, similarly to 24-hour urines. The challenge is selecting 
spot samples that can give the most reliable representation over a sustained dietary exposure 
period whilst maintaining a low burden protocol. Therefore, determining the appropriate 
number of spot urine samples required and the time and frequency of collection which provides 
an accurate and reproducible measurement of dietary exposure, will provide essential 
information on improved and acceptable methods for dietary monitoring. Once established, 
such methods can be applied to individuals within free living environments requiring dietary 







 • Determine sample collection compliance over a six-week sampling period 
 • Determine the number urine samples and at what collection times are needed to provide a 
reliable measure of dietary exposure for a six-week period. 
 • Gather acceptability feedback from participants on the ease of urine collection in the home. 
 
5.2. Method 
5.2.1. Participants  
16 Participants; six female and 10 males volunteered to take part. Two male participants 
withdrew from the study before completion. The characteristics of the remaining participants 
were: mean age 34 ± 13 (SD) years; height 172 ± 8 cm, body mass 72 ± 13 kg and BMI 24.1 ± 
3.4 kg/m2.   
 
5.2.2. Experimental Protocol 
Before commencing the sampling phase, participants visited the laboratory to provide informed 
consent, record their height and body mass, receive the urine collection kits and a 
demonstration and written instructions (see appendix; E, F, G) on how to operate the kit 
correctly (see Chapter Four, General Methods, 4.7.). Participants were instructed to collect two 
urine samples a day for a total of six weeks. The urine samples were collected in the morning 
immediately after participants woke (first morning void; FMV) and before bed time (BT) in 
the evening. The collection straws and vacutainer tubes were contained in a 650 ml plastic 
container. A second 650 ml plastic container was provided to keep used vacutainer tubes in 





Figure 5.1. The urine collection kit used by participants including; collection straw (left), 
vacutainer (centre) and collection cup (right) used by participants in the home.    
 
Following the FMV sample, the collection straw was rinsed under tap water and left to dry, 
ready to be used again for the evening sample. Participants used one transfer straw per day. 
The sample was labelled with the sample number (e.g. one for sample one / 84 for sample 84) 
and stored in a refrigerator at 4ºC for a maximum of 10 days before the sample was returned to 
the laboratory in person for freezing at –80ºC to await analysis. Participants recorded the 
collection details of their urine samples onto a sample collection sheet which noted the sample 
number and the date and time of collection. Participants were permitted to eat and drink freely, 
without restriction, for the entire data collection period. Participants completed online diet 
diaries (FatSecret) however due to technical issues this data was not analysed. At the end of 
the collection period, participants were sent a questionnaire designed by the investigator 
detailing the acceptability of the urine sampling and storage protocols (see appendix H).  
 
5.2.3. Sample Preparation and Multinomial Modelling 
24 hours prior to treatment, individual samples were transferred from -80°C to a refrigerator at 
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4°C to thaw. Once defrosted, samples were normalised by refractive index using a handheld 
refractometer, extracted and adjusted as described previously (see Chapter Four, General 
Methods, 4.8.). For the creation of weekly AM and PM pools, raw individual urine samples 
were vortexed and centrifuged for five minutes at 14,000g. On ice, 50 µl of supernatant was 
transferred to a 2 ml Eppendorf, diluted with 450 µl of -20ºC pre chilled methanol and vortexed. 
Individualised volumes (in µl depending on urine concentration) of extracted urine were then 
transferred into 2 ml labelled Eppendorfs representing weekly AM and PM pools, diluted with 
individualised volumes of distilled water and vortexed. For the creation of global AM and PM 
pools representing the entire six-week collection period, individualised volumes of weekly 
pooled urine were transferred to labelled Eppendorfs, diluted with individualised volumes of 
distilled water and vortexed. For both weekly and global pools, 80 µl of supernatant was 
transferred to glass vials containing a 200 µl micro glass insert. Vial caps were crimped and 
stored at 4ºC ready for same day FIE-MS analysis (see Chapter Four, General Methods, 4.9.). 
 
Models were created using multinomial classification. Multinomial classification has the 
advantage of evaluating the explanatory potential of a model across a series of classes, instead 
of focusing on selected binary comparisons. For example, instead of modelling binary 
combinations of each weekday pair, the question ‘Does weekday have an effect?’ can be asked, 
where the day of the week is the response variable. Model performance was evaluated using 
model accuracy and Hand & Tills (2001) extension of multi class AUC. For each model 
combination, dimensionality was reduced using principle component analysis (PCA). The PCA 
components were then reduced to a single representative vector using multi-dimensional 
scaling (MDS). This allowed for the entire urinary metabolome to be represented in a single 
dimension. Dimensionality reduced components were compared between sample combinations 





Total compliance over the six-week sampling period, including both FMV and BT samples, 
demonstrated percentage compliance to range from 90% - 100%. Seven participants (50% of 
the cohort) successfully provided all 84 samples (Table 5.1.). Comparison between collection 
times showed compliance was higher for FMV samples (93% - 100%) than BT samples (86% 
- 100%; Table 5.2.). Weekday compliance ranged between 87% - 100% (Table 5.3.) while 
weekend compliance decreased modestly in comparison (75% - 100%; Table 5.4.).   
 
 
Table 5.1. Total compliance of sample collection across the six-week sampling period  
Participant Number Total Collected % Collected 
1 84 100 
2 84 100 
3 81 96 
4 84 100 
5 83 99 
6 84 100 
7 84 100 
8 79 94 
13 77 92 
16 81 96 
17 84 100 
19 76 90 
20 83 99 
21 84 100 
Median: 84 100 





Table 5.2. Compliance for AM (FMV) and PM (BT) samples across the six-week sampling 
period 
Participant Sample Total Collected % Collected Sample Total Collected % Collected 
1 AM 42 100 PM 42 100 
2 AM 42 100 PM 42 100 
3 AM 41 98 PM 40 95 
4 AM 42 100 PM 42 100 
5 AM 42 100 PM 41 98 
6 AM 42 100 PM 42 100 
7 AM 42 100 PM 42 100 
8 AM 42 100 PM 36 86 
13 AM 39 93 PM 38 90 
16 AM 41 98 PM 40 95 
17 AM 42 100 PM 42 100 
19 AM 40 95 PM 36 86 
20 AM 42 100 PM 41 98 
21 AM 42 100 PM 42 100 
Median  42 100  42 99 





Table 5.3. Compliance for weekday AM (FMV) and PM (BT) samples across the six-week 
sampling period 
 
Participant Sample Type Total Collected % Collected 
1 AM 30 100 
 
PM 30 100 
2 AM 30 100  
PM 30 100 
3 AM 29 97  
PM 30 100 
4 AM 30 100  
PM 30 100 
5 AM 30 100  
PM 30 100 
6 AM 30 100  
PM 30 100 
7 AM 30 100  
PM 30 100 
8 AM 29 97  
PM 27 90 
13 AM 28 93  
PM 27 90 
16 AM 29 97  
PM 29 97 
17 AM 30 100  
PM 30 100 
19 AM 29 97  
PM 26 87 
20 AM 30 100  
PM 29 97 
21 AM 30 100  
PM 30 100 
Median  30 100 






Table 5.4. Compliance for weekend AM (FMV) and PM (BT) samples across the six-week 
sampling period 
 









PM 12 100 
2 AM 12 100  
PM 12 100 
3 AM 12 100  
PM 10 83 
4 AM 12 100  
PM 12 100 
5 AM 12 100  
PM 11 92 
6 AM 12 100  
PM 12 100 
7 AM 12 100  
PM 12 100 
8 AM 12 100  
PM 9 75 
13 AM 11 92  
PM 11 92 
16 AM 12 100  
PM 11 92 
17 AM 12 100  
PM 12 100 
19 AM 11 92  
PM 10 83 
20 AM 12 100  
PM 12 100 
21 AM 12 100  
PM 12 100 
Median  12 100 





5.3.2. Sample Collection Times 
For weekday samples (in decimal time), the mean FMV sample was 7.17 ± 0.35 (07.10 hours 
± 21 minutes) and the mean weekday BT sample was collected at 10.28 ± 1.48 (22.16 hours ± 
1 hour 28 minutes; Table 5.5.). The mean weekend FMV sample was collected at 7.70 ± 0.90 
(07.42 hours ± 54 minutes) and the mean weekend BT sample at 10.13 ± 1.95 (22.07 hours ± 
1 hour 57 minutes; Table 5.6.).  
 
Table 5.5. Time of sample collection (in decimal hours) for AM (FMV) and PM (BT) weekday 
samples across the six-week sampling period 
Participant Sample Type Mean SD Sample Type Mean SD 
1 AM 5.17 0.69 PM 10.39 0.40 
2 AM 7.99 0.73 PM 10.27 0.37 
3 AM 7.48 0.99 PM 10.00 3.41 
4 AM 7.34 0.62 PM 10.76 0.65 
5 AM 6.37 0.42 PM 10.07 0.53 
6 AM 7.77 0.84 PM 10.74 3.44 
7 AM 7.74 0.85 PM 10.34 1.89 
8 AM 6.92 1.70 PM 9.71 3.66 
13 AM 7.48 0.83 PM 11.24 0.46 
16 AM 7.82 1.01 PM 9.64 4.09 
17 AM 5.70 0.56 PM 11.55 0.35 
19 AM 7.61 1.41 PM 9.48 3.39 
20 AM 7.83 0.99 PM 10.43 1.45 













Table 5.6. Time of sample collection (in decimal hours) for AM (FMV) and PM (BT) weekend 
samples across the six-week sampling period 
 
Participant Sample Type Mean SD Sample Type Mean SD 
1 AM 5.13 0.68 PM 10.30 0.53 
2 AM 8.32 1.01 PM 10.30 0.54 
3 AM 8.54 1.01 PM 8.63 6.83 
4 AM 7.63 0.62 PM 10.67 0.64 
5 AM 6.84 0.47 PM 10.15 0.53 
6 AM 8.56 1.02 PM 11.58 0.71 
7 AM 7.64 0.79 PM 10.72 0.69 
8 AM 7.83 2.09 PM 9.94 1.00 
13 AM 8.54 0.53 PM 11.33 0.48 
16 AM 8.67 1.01 PM 9.01 6.55 
17 AM 5.97 0.83 PM 11.65 0.45 
19 AM 8.18 1.14 PM 8.37 6.22 
20 AM 8.35 0.76 PM 9.87 1.52 








5.3.3. Variability of FMV and BT samples 
Accuracy, RF margins and AUC values were calculated for FMV and BT samples to assess the 
variability of participant’s diet across the six-week sampling period by conducting multiclass 
comparisons between week and day combinations. While RF margins are useful for classifying 
significant discriminations between two classes, their utility is not as effective for multiclass 
analysis and therefore any significant discrimination between weeks and/or days was identified 
using AUC and accuracy values. Previous work by Enot et al. (2008), and more recently in two 
studies by Lloyd and colleagues (2019), have used AUC thresholds of >0.8 to identify 
significant discriminations between metabolic patterns. Tables 5.7. to 5.10. represent week and 
day variability for FMV and BT, and show that overall, diet did not vary considerably between 
weeks or by day, except for participant five where an AUC >0.8 and an accuracy of 0.54 was 
demonstrated. All remaining AUC values were <0.8 and not considered discriminatory in either 
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FMV or BT samples which suggest dietary intake remained similar across the six-week 
sampling period in most participants.    
 
Table 5.7. Accuracy, RF Margin and AUC values for FMV samples by week across the six-
week sampling period  
 
Participant Accuracy RF Margin AUC 
1 0.27 -0.06 0.69 
2 0.17 -0.09 0.64 
3 0.24 -0.03 0.71 
4 0.26 -0.05 0.67 
5 0.57 0.01 0.85 
6 0.12 -0.12 0.63 
7 0.31 -0.06 0.64 
8 0.16 -0.07 0.64 
13 0.13 -0.12 0.64 
16 0.25 -0.06 0.68 
17 0.28 -0.06 0.67 
19 0.25 -0.07 0.68 
20 0.33 -0.03 0.76 





Table 5.8. Accuracy, RF Margin and AUC values for FMV samples by day across the six-
week sampling period.  
 
Participant Accuracy RF Margin AUC 
1 0 -0.11 0.76 
2 0.07 -0.10 0.69 
3 0.09 -0.13 0.66 
4 0.14 -0.11 0.71 
5 0.02 -0.09 0.71 
6 0.14 -0.12 0.69 
7 0.02 -0.14 0.67 
8 0.19 -0.08 0.73 
13 0.08 -0.11 0.72 
16 0.02 -0.12 0.74 
17 0.21 -0.07 0.76 
19 0.03 -0.13 0.73 
20 0.02 -0.09 0.66 
21 0.09 -0.09 0.68 
 
Table 5.9. Accuracy, RF Margin and AUC values for BT samples by week across the six-
week sampling period.  
 
Participant Accuracy RF Margin AUC 
1 0.33 -0.06 0.65 
2 0.31 -0.03 0.74 
3 0.3 -0.04 0.72 
4 0.24 -0.06 0.71 
5 0.41 -0.01 0.78 
6 0.19 -0.09 0.68 
7 0.19 -0.11 0.67 
8 0.12 -0.10 0.74 
13 0.05 -0.09 0.75 
16 0.05 -0.09 0.65 
17 0.07 -0.09 0.66 
20 0.29 -0.07 0.69 





Table 5.10. Accuracy, RF Margin and AUC values for BT samples by day across the six-week 
sampling period. 
 
Participant Accuracy RF Margin AUC 
1 0.07 -0.09 0.67 
2 0.17 -0.08 0.72 
3 0.12 -0.11 0.65 
4 0.05 -0.11 0.78 
5 0.12 -0.09 0.68 
6 0.12 -0.13 0.70 
7 0 -0.13 0.73 
8 0.06 -0.12 0.70 
13 0.19 -0.09 0.69 
16 0.05 -0.11 0.76 
17 0.10 -0.08 0.68 
19 0.03 -0.12 0.74 
20 0.05 -0.1 0.69 
21 0.07 -0.09 0.68 
 
 
5.3.4. Comparisons between spot, weekly and global pool samples 
To establish the degree of correlation and pairwise differences between multinomial spot and 
pooled samples, the data was scaled to two dimensions through multidimensional scaling to 
allow for direct comparison between sample types. For weeks one-six, three randomly selected 
days (FMV samples only) were selected and compared to the weekly pool by means of a 
Spearman’s correlation and paired sample t-tests (Table 5.11.).  Further analysis was conducted 
to compare specific times and phases of the week to the global urine pool to establish how 
frequently samples need to be collected and at what points during the week which most 
resemble the entire 6-week urine metabolome (Table 5.12.) Data presented in Table 5.11. 
demonstrate relatively strong correlations between spot and weekly pool samples in five out of 
six weeks (r > 0.45 < 0.81). Paired t-tests conducted on scaled data demonstrated no statistically 
significant difference between spot and weekly pooled samples in any week (P > 0.05).    
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Table 5.11. Correlation and paired t-test P values for three randomly selected spot samples 
compared to the corresponding weekly pool. Statistical significance* is accepted at P < 0.05. 
 
Week R P 
1 0.81 0.76 
2 0.40 0.64 
3 0.52 0.75 
4 0.63 0.99 
5 0.45 0.85 
6 0.04 0.57 
 
To determine which specific sampling time points best represented habitual dietary behaviour 
whilst maintaining a low burden sampling protocol, a series of sampling combinations were 
created and compared to the global urine pool which comprised of all urine samples collected 
across the entire sampling period. These combinations included; all Saturdays, all Saturdays & 
Sundays, all Weekdays, x3 Weekdays (randomly selected), x3 Weekdays (randomly selected), 
x2 Weekdays + Weekend Day (randomly selected; 6 weeks), x2 Weekdays + Weekend Day 
(randomly selected; 3 weeks) and x2 Weekdays + Weekend Day (randomly selected; 3 weeks; 
Table 5.12.). 
 
Data presented in Table 5.12. demonstrates Spearman correlation values to range from 0.42 to 
0.68, suggesting the correlations between spot sample combinations and the overall global 
urine pool to be moderately strong. The strongest correlation was found when correlating three 
randomly selected weekdays to the global pool (r = 0.68). The weakest correlation was seen in 
samples from Saturdays and Sundays (r = 0.42). No significant differences were found between 
the selected combinations of spot samples and the global pool (P > 0.05).   
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Table 5.12. Correlation and paired t-test P values for different combinations of spot urine 
samples compared to the overall global urine pool. Statistical significance* is accepted at P < 
0.05.  
 
Combination Weeks Used Total Days R P 
All Saturdays 6 6 0.44 0.97 
Saturday & Sunday 6 12 0.42 0.99 
All Weekdays 6 30 0.58 0.86 
x3 Weekdays 6 18 0.68 0.84 
x3 Weekdays 6 18 0.53 0.69 
x2 Weekdays + Weekend Day 6 18 0.65 0.75 
x2 Weekdays + Weekend Day 3 9 0.66 0.81 
x2 Weekdays + Weekend Day 3 9 0.65 0.83 
 
 
Table 5.13. P values from paired t-tests for specific dietary biomarkers from different 
combinations of spot urine samples compared to the overall global urine pool. 1. All Saturdays, 
2. Saturday & Sunday, 3. All Weekdays,4. x3 Weekdays, 5. x3 Weekdays, 6. x2 Weekdays + 
Weekend Day, 7. x2 Weekdays + Weekend Day, 8. x2 Weekdays + Weekend Day. Statistical 
significance* is accepted at P < 0.05. 
 
Biomarker 1 2 3 4 5 6 7 8 
N-Methylhistidine 0.08 0.11 0.01 0.01 0.01 0.01 0.01 0.01 
Hippuric acid 0.12 0.06 0.02 0.01 0.02 0.02 0.02 0.03 
Proline Betaine 0.23 0.28 0.96 0.87 0.93 0.98 0.84 0.76 
P-Cresol Glucoronide 0.71 0.85 0.84 0.78 0.81 0.87 0.90 0.75 
3-Methylglutarylcarnitine 0.01 0.00 0.40 0.87 0.51 0.41 0.01 0.74 
Sucrose 0.11 0.11 0.76 0.87 0.59 0.87 0.48 0.54 
TrimethylamineÂ N-
oxide 
0.05 0.04 0.00 0.00 0.00 0.00 0.00 0.00 
beta-Alanine 0.59 0.68 0.31 0.28 0.32 0.35 0.31 0.32 
Creatinine 0.39 0.25 0.03 0.03 0.03 0.03 0.04 0.03 
Acesulfame 0.53 0.21 0.58 0.61 0.58 0.54 0.50 0.53 
N-Methylxanthine 0.19 0.08 0.55 0.75 0.55 0.18 0.16 0.22 
Tartaric acid 0.04 0.02 0.25 0.22 0.16 0.23 0.85 0.27 




A series of dietary biomarkers associated with the intake of specific foods were analysed using 
the same combinations of days presented in Table 5.12. The biomarkers displayed in Table 
5.13 were selected for analysis based on their links to foods of health importance and to 
establish how different combinations of spot samples affects specific dietary related 
metabolites in comparison to the global urine pool. Significant differences in the concentrations 
of diet specific metabolites were found in all combinations of days when compared to the global 
pool. Combination one (all Saturdays) demonstrated the fewest significant differences (3-
Methylglutarylcarnitine, P = 0.01; Tartaric acid, P = 0.04) while combination seven (x2 
Weekdays + Weekend Day; randomly selected; 3 weeks; N-Methylhistidine, P = 0.01; 
Hippuric acid, P = 0.02; 3-Methylglutarylcarnitine, P = 0.01; TrimethylamineÂ N-oxide, P < 
0.00; Creatinine, P = 0.04) and combination eight (x2 Weekdays + Weekend Day; randomly 
selected; 3 weeks; N-Methylhistidine, P = 0.01; Hippuric acid, P = 0.03; TrimethylamineÂ N-
oxide, P < 0.00; Creatinine, P = 0.03; Citric acid, P = 0.03) demonstrated the largest number 
of metabolites showing a significant difference between spot combinations and the global urine 
pool.  
 
5.3.5 Protocol Feedback 
Feedback from participants regarding the urine sampling procedure was largely positive (Table 
5.14.). One hundred percent of participants suggested the urine collection kit was easy to use 
with 86% stating they successfully used the kit every time they were required to provide a urine 
sample. Seventy nine percent of respondents felt the urine sampling procedure did not cause 
excessive disruption to their usual daily routine whilst the same percentage of participants felt 
procedures for storing their samples was easy. Of interest, 93% of participants suggested they 
would be happy to use a similar urine collection kit for future research purposes. This 
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demonstrates the urine sampling procedure to be wholly acceptable to study participants and 
can feasibly be implemented in future work. 
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Yes No Comments 
Did the time of day you 
were required to provide a 
urine sample cause 
disruption to your usual 
daily routine? 
21% 79% Participant 19: "Yes but only due to the fact that I often work nights" 
Participant 21: "A minor hindrance as it took a few minutes"   
Was the urine sampling kit 
easy to use? 
100% 0% No additional comments 
 
Did you use the urine 
sampling kit successfully 
every time? 
86% 14% Participant 5: "only one malfunction"  
Participant 12: "Sometimes I forgot to put the end of the tube/end of the needle all the way into the 
urine and the tube wasn’t filled up all the way" 
Was it easy to store your 
urine samples once they 
had been collected? 
 
79% 21% Participant 2: "Most of the time this wasn’t a problem. It was more tricky if we were away 
especially when camping but even staying with family was more difficult” 
Participant 9: "Inconvenient when going away on holidays/weekends away/staying at girlfriends 
house" 
Participant 19: "There were some occasions when I was unable to store the samples in the fridge 




Participant 20: "Would have been yes - but when away I didn’t always have access to a fridge”  
Having completed this 
process and knowing what 
it involves, would you be 
prepared to use the urine 
sampling kit for research 
purposes in the future? 
 
93% 7% No additional comments  
Further comments   Participant 3: "As a woman, collecting urine wasn’t much of an issue as I thought it would be 
which is a positive. Fell easily into the routine. I believe it was an effective method  
Participant 4: "The process of using the sampling kit was relatively straight forward" 
Participant 5: "No problems with the urine kit or exchange/resupply arrangements" 
Participant 9: "Every day sampling is inconvenient, but if it was only a couple each week, it would 








Given the limitations associated with traditional forms of dietary monitoring, the use of urinary 
metabolomics as an alternative dietary recording method is a growing area of research which 
can provide useful insights into the effectiveness of dietary change initiatives. Most studies 
examining urinary metabolomics as a dietary monitoring method have thus far involved 
participants collecting 24-hour urine samples, which while being able to represent an entire 
dietary intake phase, places a significant burden on participants due to the method’s adverse 
impact on normal daily life (John et al., 2016) as well as resulting in significant processing 
costs for the researcher (Wilson et al., 2019). Provision of a single spot urine sample can give 
a comprehensive snapshot of dietary exposure for 12 to 24 hours prior to urine collection (Favé 
et al., 2011) although is not representative of an individuals' habitual dietary intake. However, 
a series of spot samples collected over a prolonged period may provide a robust overview of 
an individual’s nutritional behaviour. For example, spot urine samples have been shown to 
adequately discriminate between exposure class for several dietary items, similarly to 24-hour 
urines (Lloyd et al., 2013). Therefore, the challenge of this work was to identify spot urine 
samples which can give the most reliable representation of dietary behaviour over a sustained 
exposure period. This was in addition to maintaining a low burden protocol that could be 
completed within a ‘free living’ environment, required fewer processing resources and 
therefore making it cheaper and subsequently more viable for future application to large scale 
epidemiological research.    
 
To have utility in monitoring habitual free-living dietary behaviour, a urine sampling protocol 
must be easily administered and acceptable for participants. The first aim of this work was to 
establish participant’s adherence to the urine sampling protocol. This included calculating total 
compliance, collection time compliance and weekday and weekend compliance. Participants 
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were instructed to collect an FMV and BT sample every day for a six-week period. Results 
demonstrated total collection compliance to range between 90% to 100%. When separated by 
collection time, compliance for FMV samples was greater than BT samples, ranging between 
93% - 100% and 86% - 100%, respectively. When analysed by day, compliance was higher for 
weekday samples (87% - 100%) compared to weekend samples (75% - 100%). A reduced 
adherence to sample collection on weekend days is significant given dietary behaviour of the 
participants likely changed when compared to week days. Previous work by An (2016) has 
shown significant alterations in dietary intake on weekends including increased intakes of 
sugar-sweetened beverages, alcohol, total fat, saturated fat, sugar and sodium whilst decreasing 
intakes of fruit, vegetables and fibre.  Similarly, a study by Jahns et al. (2017) found intake of 
alcohol increased and intakes of fruit, vegetables, poultry, nuts, seeds and whole grains 
decreased on weekends compared to weekdays. Weekend sample collection compliance was 
reduced in the present work, compared to week day compliance and therefore future research 
should not only include a weekend sample to capture dietary behaviour but also emphasise the 
importance of adhering to weekend sampling to future participants and patients. With the data 
demonstrating FMV samples to be collected more compliantly compared to BT samples, it may 
be beneficial for future research to focus solely on FMV samples to ensure increased 
compliance while further reducing participant burden by removing the BT sample. The shorter 
time frame in which FMV samples were collected by participants also provides a more 
controlled window of sample collection compared to BT samples where the range of collection 
times was wider. Furthermore, findings in work by Wilson et al. (2019) suggests biomarkers 
derived from colonic fermentation may not be highly represented in BT urine samples and so 
therefore recommends the use of FMV urine sampling to ensure full dietary metabolite 
coverage is achieved. An example of such in Wilson and colleagues’ work was the skewed 
distribution towards lower concentrations measured in post dinner spot urines for D-L-
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sulforaphane (a biomarker of exposure to cruciferous vegetables).  
 
The values presented in Tables 5.7.-5.10. demonstrate the composition of both FMV and BT 
samples remained similar across the six-week sampling period and suggests that participants 
dietary behaviour was habitual, with data for only one participant being suggestive of a change 
in dietary intake. The large variation between weeks, and the days within, is unsurprising given 
participants were free to consume any food and drink of their choosing and were not required 
to follow a structured diet plan or intervention during the sample collection period. This 
suggests participants maintained consumption of a habitual diet throughout the sampling phase 
with the primary driver of variation in urinary metabolome models being inter-individual as 
opposed to intra-individual. Given a short temporal phase was used (i.e. six weeks) for sample 
collection, lack of intra-individual differences was not unexpected.  Seasonal changes in dietary 
behaviour are a primary factor that can influence a persons’ habitual diet in the absence of an 
intervention (Ma et al., 2006) with consumption of several fruits and vegetables, for example, 
demonstrating significant variation depending on the season (Capita and Alonso-Calleja, 
2005). Therefore, future work should ensure a dietary monitoring protocol using urinary 
metabolomics, as well as other dietary recording protocols, covers the entire investigative 
period following lifestyle intervention to ensure any seasonal variation in dietary behaviour is 
captured. 
 
Given collection compliance was greater for FMV samples in comparison to BT samples, as 
well as evidence suggesting FMV samples will capture a greater depth of dietary metabolites 
(Wilson et al., 2019), comparisons between spot sample combinations and weekly and global 
urine pools were conducted using FMV samples only. The data presented in Table 5.11. shows 
three randomly selected spot samples compared favourably to their corresponding weekly pool 
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in five weeks out of the six-week sampling period, with moderate to strong correlations 
demonstrated (> 0.4). This provides a reasonable argument to suggest that three urine samples 
a week can adequately describe a person’s dietary intake, in comparison to the weekly pool, 
without imposing a daily and burdensome urine sampling protocol on the participant. In 
support, the data presented in table 5.12. show moderate to strong correlations between 
combinations of spot samples and the global urine pool. Of interest, three randomly selected 
weekday samples showed the highest correlation between spot sampling and the global pool (r 
= 0.68) while a paired samples t-test suggested no significant difference between the metabolite 
content of the spot samples and the pool (P = 0.84). While three weekday samples were shown 
to correlate the strongest, evidence discussed above also highlights the importance of capturing 
dietary behaviour on weekend days. Therefore, combinations to include two randomly selected 
weekdays and a weekend day were included to understand their performance compared to the 
globally pooled urine. When analysed across the entire six-week period, two weekday and a 
weekend day sample correlated well to the global pool (r = 0.65) while no significant difference 
was found in metabolite profiles (P = 0.75). However, given a key aim of this work was to 
establish a low burden urine sampling protocol, an identical combination of samples, 
encompassing two weekdays and a weekend sample, was examined against the global pool, 
only across a three-week period as opposed six weeks. Interestingly, a similar correlation was 
discovered despite reducing the number of samples in the correlation from eighteen to nine (r 
= 0.66) and again finding no significant difference between the spot combinations and the 
global pool (P = 0.81). This shows that three urine samples collected per week for three weeks, 
including two-week day samples and a weekend sample, can provide similar dietary 
information compared to the global pool, which includes FMV samples collected once a day 
for a six-week period. This finding means a significantly reduced sampling protocol can be 
implemented in future work which can both capture useful dietary intake data without 
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excessively burdening the participant, therefore making it more likely sampling adherence will 
be maintained.  
 
While this work has shown promise in developing a low burden protocol for accurate 
monitoring of habitual diet in a free-living environment, this method does have some 
limitations. The data presented in Table 5.11. shows that in week six, three randomly selected 
days did not correlate well with the week six pool, suggesting the spot sampling protocol was 
ineffective in successfully identifying dietary intake when compared to daily sampling. In 
addition, the urine concentration of several metabolites which are associated to specific dietary 
items were shown to be significantly different to the global urine pool across all spot sample 
combinations. This was most apparent for spot sample combinations seven and eight which 
both showed five metabolite concentrations to be significantly different between two weekday 
and a weekend day sample in comparison to the global pool. This is important given it is this 
specific spot sampling protocol (2 x weekday/ 1 x weekend day) that has been suggested as the 
most appropriate in capturing dietary intake information whilst maintaining a low burden 
sampling protocol. However, it must be argued that while the two weekday/one weekend day 
protocol does contain limitations, a balance must be found between capturing highly accurate 
dietary information and the burden imposed by a lengthy and demanding sampling procedure.  
 
This work has successfully demonstrated a sampling protocol encompassing two weekdays and 
a weekend day to correlate well to the overall urine pool, which includes all FMV samples over 
the six-week urine collection period and means an overall quantitative snapshot of dietary 
intake can be accessed through this methodology. The growing use of urine metabolomic 
technology for the purposes of dietary monitoring was and is not designed to fully replace more 
established forms of dietary monitoring, such as dietary recalls and FFQs, but to supplement 
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and validate such methods. While a three per week/three-week sampling procedure may not 
capture every individual metabolite change as demonstrated in Table 5.13., it has been shown 
to provide reasonable agreement with spot samples collected every morning for six weeks 
(Table 5.12.) which can give an acceptable overall impression of dietary pattern. In addition, 
feedback collected from participants demonstrates the urine sampling protocol completed 
within the home setting is highly acceptable, with only a small number of negative comments 
made (Table 5.14.). Such comments mostly related to the inconvenience of every day sampling 
and the difficulty storing samples when away from home. This feedback therefore supports the 
proposal of limiting sampling to three days per week for three weeks given daily sampling 
increased the difficulty of storing samples when away from home and resulted in an increased 
burden generally.  
 
In conclusion, this work has shown that three FMV urine samples collected over three weeks, 
encompassing two-week days and a weekend day, correlates well to daily urine sampling over 
a six-week period for measuring metabolite dietary patterns. This finding, alongside data for 
sampling adherence and acceptability, suggests this protocol can successfully be implemented 











The effects of acute moderate exercise on the urinary metabolome   
 
6.1. Introduction 
Metabolomic profiling of human urine is a developing method for monitoring habitual diet. 
Given the increase in diagnoses of chronic diseases associated with poor dietary habits, 
methods for improved dietary monitoring are becoming more important. The work detailed in 
chapter five has demonstrated a feasible community-based method for collecting urine samples 
in the home across a six-week period using a simple urine collection kit. This method of urine 
collection provided a robust overview of dietary behaviour, was methodologically acceptable 
to the participants and did not cause excessive disruption to participant’s daily life. This method 
will continue to be developed to provide a more accurate way of monitoring diet in the 
community by validating traditional methods of dietary recording, including people at risk of 
chronic disease, such as T2D.  
 
While community-based urine sampling demonstrates a successful and non-disruptive method 
for monitoring diet, several studies have also examined the effects of different modes of 
exercise on the biological metabolome. Exercise has been shown to cause significant metabolic 
disruptions which alter the metabolites present in human bio fluids. This has been demonstrated 
in plasma (Lewis et al., 2010; Chorrel et al., 2012) and in serum (Pohjanen et al., 2007; Yan et 
al., 2009) using a metabolomic approach. More recently, some studies have focussed attention 
on how exercise affects the urinary metabolic fingerprint including; high intensity exercise 
(Enea et al., 2010; Pechlivanis et al., 2010; Pechlivanis et al., 2015; Siopi et al., 2017), 
submaximal exercise (Enea et al., 2010; Ali et al., 2016) and resistance exercise (Siopi et al., 
150 
 
2017). Most of these studies demonstrate significant changes in the urinary metabolome 
following different forms of exercise which vary in duration and intensity. For example, work 
by Pechlivanis et al. (2010) analysed urine samples following two repeated sprint protocols, 
differing in the rest duration between exercise efforts. Analysis revealed clear distinction 
between pre and post exercise samples caused mainly by the presence of lactate in the latter. 
Multivariate analysis found a further 22 metabolites changed significantly from pre to post in 
both groups. When the effect of the rest period was examined, 12 metabolites were found to 
respond differently depending on the amount of rest provided. Sprint exercise resulted in large 
increases in the products of anaerobic carbohydrate degradation, namely lactate and pyruvate, 
both of which were clearly separated by rest duration. The results of this work demonstrate 
repeated high intensity sprints to result in significant changes in the urine metabolome with 
post exercise urines demonstrating different profiles to pre-exercise samples.  
 
In another study, Enea et al. (2010) explored the extent of metabolic changes following both 
short, intense exercise and prolonged exercise. Urine samples were collected before and 30 
minutes after both exercise regimens. Marked differences in signals between pre and post 
samples were demonstrated within the short intensive exercise group. The major identifiable 
signals were attributed to lactate and creatinine. Other metabolites responsible for differences 
between pre and post samples were alanine, acetate, acetoacetate, pyruvate, succinate, 
hippurate and hypoxanthine. Prolonged exercise caused no significant distinctions between pre 
and post exercise urine samples, suggesting prolonged exercise does not significantly alter 
urinary metabolite profiles. In later work examining high intensity exercise, Pechlivanis et al. 
(2015) examined changes in the urinary metabolome in a two-hour period following two 
identical sprint sessions. Sample analysis revealed significant changes in several metabolites 
within post exercise urines, demonstrating short, high intensity sprint exercise to result in 
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significant metabolic disturbance which persists for at least one hour following exercise 
cessation before most metabolites return to baseline values.  
 
The effects of one-hour aerobic activity on the urine metabolome was investigated in a pilot 
study by Daskalaki, Blackburn, Kalna, Zhang, Anthony and Watson (2015). Three physically 
active males underwent a 37-hour protocol with urine samples collected at regular time points 
both before and after one hour of prolonged exercise in which the exercise intensity was 
controlled by the participants. Data analysis revealed changes in the purines; hypoxanthine, 
xanthosine, inosine and guanine which reflected the acute impact of exercise, with peak 
concentrations observed within the first post exercise samples. Metabolites associated to 
tryptophan metabolism were also significantly affected by exercise and included 3-hydroxy 
tryptophan, hydroxyindole pyruvate, hydroxytryptophol, pyridone carboxamide and to a lesser 
extent, kynurenate. Pantothenic acid also increased in the first post exercise sample which the 
authors suggest may be indicative of decreased demand for Acetyl coenzyme A (Acetyl-CoA) 
and a subsequent shift to glycolysis in the place of fat metabolism. Increases in pyruvate 
support this. Given fat oxidation decreases with increasing exercise intensity, this may well be 
a plausible explanation. However, participants were free to control the exercise workload 
themselves and therefore it is difficult to determine the predominant energy system usage 
without specific values for exercise intensity being provided.  
 
In a follow up study, Ali, Burleigh, Daskalaki, Zhang, Easton and Watson, (2016) recruited 10 
participants to complete a standardised light-moderate intensity exercise protocol. Analysis 
revealed clear separation between pre and post exercise samples on the day of exercise. The 
metabolites responsible for separation were hypoxanthine, guanine, deoxyinosine, inosine and 
xanthosine all of which are metabolites within the purine pathway. Changes in these 
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metabolites were not present within samples collected the previous day and suggest the ‘purine 
response’ requires physical activity to result in observable changes. Additionally, an increase 
in nonanoyl carnitine, decanoyl carnitine and ketodecanoyl carnitine, increases which were not 
observed during the rest day, was attributed to a decreased reliance on fatty acid metabolism 
during exercise which represents a shift towards glycolysis to maintain ATP synthesis. The 
results of this work demonstrate the impact of light-moderate exercise on metabolites such as 
hypoxanthine and inosine, both of which are markers of exercise as demonstrated from other 
studies.   
 
In a recent investigation comparing the acute effects of different modes of exercise on the 
urinary metabolic fingerprint was conducted by Siopi et al. (2017). Three forms of exercise 
were investigated including high intensity interval exercise, continuous moderate intensity 
exercise and resistance exercise. In a randomised crossover design, 23 male participants 
completed four trials including high intensity interval exercise, moderate intensity continuous 
exercise, resistance exercise and rest. When comparing the three modes of exercises employed, 
resistance exercise resulted in the greatest and most sustained effect on the metabolome, 
followed by high intensity interval exercise and lastly continuous moderate exercise which had 
little effect. The modes of exercise employed in this study were designed to encompass the full 
energy system with the expectation that different exercise intensities will result in distinct 
variations in the metabolic fingerprint. Previous work has demonstrated such differences in 
plasma (Lewis et al., 2010; Chorrel et al., 2012) and results from this study examining urine 
support those previous findings. The impact of exercise on the urinary metabolome continued 
for several hours following exercise completion with metabolites gradually returning to 
baseline levels after 24 hours. The changing metabolome was indicative of both increased lipid 
oxidation and glycogen synthesis which is synonymous with exercise. The changes occurring 
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in the metabolome over this time were attributed to degradation of purines, carbohydrates, 
proteins and amino acids (Siopi et al., 2017).  
 
Many changes in metabolite concentrations brought about through short duration, high 
intensity exercise and resistance exercise are the result of changes in the compounds related to 
the ATP-PCr system and the glycolytic system. These are the predominant energy pathways 
associated with this high intensity exercise. A clear metabolic theme is present in the above 
studies with several metabolites regularly appearing in urine samples following high intensity 
exercise which provides a clear distinction in the urinary metabolome. Metabolites of the 
purine pathway are a common presence in post exercise samples and represent increased ATP 
utilisation and breakdown with the presence of purines most common following intense 
physical activity. Similarly, the frequent presence of lactate and pyruvate after an intense 
exercise protocol represents a shift in energy metabolism to anaerobic mechanisms. In addition, 
changes in amino acids are attributed to muscle protein breakdown followed by metabolism of 
the released amino acids. However, studies focussed on moderate intensity exercise and its 
effects on urine metabolites have produced mixed findings. Enea et al. (2010) found 
submaximal exercise resulted in no distinctions between the pre and post urine metabolic 
profiles. This study however only used female subjects and therefore may not be representative 
of a general population’s metabolic response to exercise as previous research has demonstrated 
metabolic signatures in urine can be distinguished based on gender (Slupsky et al., 2007). 
Similarly, work by Siopi et al. (2017) also found moderate intensity activity to have little 
metabolic effect. Conversely, Ali et al. (2016) demonstrated several metabolic changes in urine 
following 45 minutes of continuous light and moderate exercise on a cycle ergometer using 
both male and female participants. This study revealed a significant impact of moderate 
intensity exercise on established markers for exercise including purine metabolites 
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hypoxanthine and inosine. Given the disagreement between these studies regarding the effects 
of moderate/submaximal exercise on urine metabolites, it appears prudent to further investigate 
the changes in urine profiles following this mode of exercise and develop a firm understanding 
on the effects of moderate intensity exercise on the urinary metabolome.  
The present study is concerned primarily with moderate intensity exercise as this level of 
physical activity is recommended by national health guidelines and therefore most likely 
undertaken by individuals attempting improved lifestyle behaviours following clinical advice. 
Moderate exercise, such as continuous jogging, swimming or cycling, is defined by the NHS 
as aerobic exercise hard enough to increase heart rate and sweat rate above resting values. 
Thirty minutes of moderate intensity exercise, five times a week, is recommended by Public 
Health England & Wales and the National Health Service (in line with recommendations by 
the four UK chief medical officers; UK Chief Medical Officers' Physical Activity Guidelines, 
2019) to maintain and/or improve general health and is easily accessible in community settings. 
It is suggested by these organisations that these modes of exercise at a moderate intensity are 
most applicable to individuals requiring lifestyle modification. It is therefore of interest to 
determine whether clear distinction between urine samples before and after moderate intensity 
exercise is present and to what extent does the urinary metabolome change. Determining the 
effects of moderate exercise on the urinary metabolome will prove useful for a later chapter 
within this thesis where urine samples (for dietary monitoring purposes) will be collected from 
individuals at risk of T2D who are undergoing lifestyle modification. If moderate exercise does 
result in urinary metabolome change, knowing which metabolites are likely to be present in 
samples will be advantageous.  
 
Aim:  
• Determine change in the urinary metabolome following a 30-minute moderate intensity 
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exercise protocol.  
 
6.2. Method  
6.2.1. Participants  
Participants completed a health questionnaire before commencing the study to identify any 
reason that would prevent the completion of 30 minutes moderate exercise. 17 participants, 10 
female and seven males, volunteered and were recruited to the study. The physical 
characteristics of the participants were: mean age, 41 ± 14 (SD) years; height, 171 ± 9 cm; 
body mass, 75 ± 10 kg; BMI 25.8 ± 3.9 kg/m2 and peak oxygen uptake (V̇O2peak) 2.9 ± 0.9 
L·min-1. 
 
6.2.2. Experimental protocol 
Participants attended the laboratory on three separate occasions, separated by at least seven 
days, having refrained from the consumption of alcohol and any strenuous or unaccustomed 
physical activity for 24 hours prior to each visit. Visit one commenced between the hours of 
0700 to 1700 while visits two and three commenced between the hours of 0700 to 0900. 
Participants recorded their diet for 24 hours prior to visits two and three using a simple diet 
diary designed specifically for the study (see appendix K) and were asked to ensure dietary 
intake was similar for visits two and three. Dietary adherence was confirmed by the researcher 
inspecting each food diary prior to testing. Participants visited the laboratory after an overnight 
fast of > eight hours (not including the V̇O2peak test, see below) but were instructed to consume 
at least 500 ml of plain water, before arriving at the lab for each visit. The first visit required 
participants to complete a ramp incremental exercise test on a cycle ergometer (Lode Corival, 
Groningen, Netherlands) to establish V̇O2peak, using an online breath by breath system (Quark 
PFT, Cosmed, Rome, Italy). Participants completed the remaining two visits in a randomised, 
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crossover design. The order of visits was randomised using an open source software package 
(PEPI for Windows, Brixton Health). During one of the visits, participants exercised on a cycle 
ergometer for 30 minutes at a fixed exercise intensity. The other visit required participants to 
sit quietly for 30 minutes in the laboratory. Participants provided a first morning void (FMV) 
sample prior to arriving in the lab for both experimental visits. Further urine samples were 
collected before and after the exercise and rest trials.   
 
6.2.3. Maximal exercise test  
A 30 W·min-1 ramp test to volitional exhaustion on a cycle ergometer was used to establish 
V̇O2peak. Prior to each test, the breath-by-breath analyser was calibrated using a standard three 
L volume cylinder (Hans Rudolf, Kansas, USA) and gases of known concentration, assuming 
accuracy of the concentration certificates provided by the supplier (BOC, Guildford, UK). 
Participant’s height and body mass were recorded before being fitted with a radio telemetry 
heart rate monitor (Polar, FS2C, Kempele, Finland). Once seated on the cycle ergometer, seat 
height and handle bar position were adjusted into the appropriate position for each participant. 
Participants were fitted with a sterilised silicon face mask (Hans Rudolf, Kansas, USA), which 
was held in place via a head cap (Hans Rudolf, Kansas, USA), and sat quietly on the ergometer 
for one minute to regulate their breathing. The first three minutes of exercise were unloaded (0 
W) and then the power output increased by one W every two seconds until participants reached 
volitional exhaustion. Information regarding revolutions per minute (RPM) and power output 
(PO) was visible to the participant and strong verbal encouragement was provided throughout 
the test.  
 
On completion of the V̇O2peak test, the data were averaged over six second periods and 
exported to Microsoft Excel (Microsoft Excel 2010, Computer Software, USA). Each 
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participant’s gas exchange threshold (defined as an increase in the rate at which V̇CO2 rises 
versus V̇O2, accompanied by an increase in V̇E/V̇O2 while V̇E/V̇CO2 continued to decrease or 
levelled off) was determined using the modified version of the v-slope method (Beaver et al., 
1985). Data for V̇O2 and V̇CO2 were plotted against time for the gas exchange threshold to be 
visually identified and were confirmed by a graph of ventilatory equivalents versus time. 
Identification of the gas exchange threshold for each subject was confirmed by an additional 
investigator. The power output equivalent to 10% below the lactate threshold was calculated 
individually for each subject from the gas exchange data and adopted for the constant-load, 
submaximal exercise visit.  
 
6.2.4. Experimental trials 
On arrival at the laboratory, participants returned their 24-hour diet diary alongside their first 
morning void (FMV) urine sample which was frozen immediately at -80ºC for later analysis. 
Participants provided a mid-stream urine sample (PRE) into a 600 ml Pyrex beaker (Fisher 
Scientific UK Ltd., Loughborough, UK) in private. Urine was transferred from the beaker into 
a four ml additive free evacuated vacutainer tube before freezing. A radio telemetry heart rate 
monitor was fitted on to the chest and baseline heart rate recorded. Participants either exercised 
for 30 minutes on a cycle ergometer at 10% below the lactate threshold (78 ± 22 W) or sat 
quietly in an upright position for the equivalent amount of time. The cycle ergometer was set 
in hyperbolic mode which allowed the required PO to be maintained irrespective of the 
subject’s RPM. Heart rate and ratings of perceived exertion using a 15-point scale (RPE; Borg, 
1982) was recorded every five minutes of exercise. Information regarding RPM and PO was 
visible, but participants were given no feedback on time elapsed. During the rest trial, 
participants sat quietly in a phlebotomy chair within the laboratory. Heart rate was recorded 
every five minutes. Upon completion of the 30 minutes exercise or rest, participants 
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immediately provided a second urine sample in private (POST; Sample treated the same as 
FMV & PRE). Participants were then free to use the shower and changing facilities before 
leaving the laboratory.  
 
6.2.5. Urine preparation and data analysis 
Random forest classification margins were generated to identify discriminations between 
exercise and rest samples, where the greater the margin demonstrates increased confidence in 
the sample classification. RF margins > 0.3 were used to indicate adequate sample 
classification. Feature selection of discriminatory signals was conducted where acceptable 
margins were reached (Enot et al., 2008). For metabolite signal annotation, accurate m/z values 
were extracted from the mass spectra to allow direct identification of metabolites. Signals were 
identified using MZedDB, an interactive accurate mass annotation tool which can directly 
annotate signals (Draper et al., 2009; Lloyd et al., 2017).  
 
Heart rate and RPE data were tested for normality using skewness and kurtosis tests. Heart rate 
data were analysed by two-way repeated measures ANOVA and RPE data analysed by one-
way repeated measures ANOVA. Data are presented as mean ± standard deviation. Statistical 









6.3.1. Heart rate and RPE 
Mean heart rate during exercise was 121 ± 17 beats per minute, this equated to 68% of 
maximum heart rate values during exercise, which agrees with other work examining moderate 
exercise (Siopi et al., 2017). Heart rate was significantly different between the exercise and 
rest trials (P < 0.00), increasing significantly between five and 30- minutes during the exercise 
trial (114 ± 15 to 126 ± 16 bpm; P < 0.00). Heart rate remained similar between five and 30-
minutes during rest (65 ± 12 to 65 ± 11 bpm; P = 0.71). Mean RPE for the exercise trial was 
11 ± 1 arbitrary units. RPE increased significantly between five and 30- minutes of exercise (9 
± 2 arbitrary units to 11 ± 2 arbitrary units; P < 0.00). Values reported by participants ranged 
between six and 15 arbitrary units which represent perceived workloads of “No exertion at all” 
to “Hard” exertion, suggesting most participants were between values in which moderate 
exertion falls. No participants reported values which represent workloads of “very hard” and 
“maximum exertion” (Williams, 2017).  
 
Table 6.1. Mean heart rate (HR; in bpm) and RPE (arbitrary values) in the exercise trial and 
mean heart values in the rest trial between five and 30 minutes.  
Exercise 
HR5 HR10 HR15 HR20 HR25 HR30 
114 ± 15 
 
120 ± 14 
 
121 ± 15 124 ± 14 123 ± 16 126 ± 16 
RPE5 RPE10 RPE15 RPE20 RPE25 RPE30 
9 ± 2 10 ± 2 
 
11 ± 2 11 ± 2 11 ± 2 11 ± 2 
Rest 
HR5 HR10 HR15 HR20 HR25 HR30 
65 ± 12 63 ± 12 
 




Table 6.2. RF classification margins for FMV, Pre and Post urine samples in exercise and rest 
trials. 
Pairwise RF Margin Accuracy AUC 
FMV Rest- Post Rest 0.4 0.83 0.93 
FMV Exercise – Post Exercise 0.32 0.84 0.93 
FMV Rest – Pre-Rest 0.11 0.64 0.73 
Pre-Exercise- Post Exercise 0.07 0.63 0.64 
FMV Exercise – Pre-Exercise 0.03 0.56 0.6 
Pre-Rest – Post Rest 0.03 0.53 0.57 
 
Table 6.3. Annotated metabolites differing significantly between FMV and post urine samples 
in rest and exercise trials.  
Polarity m/z Metabolite P value  





















Polyethylene glycol 500 
 













6.3.2. Urine Metabolomics 
Examination of RF classification margins demonstrated 30 minutes of moderate exercise on a 
cycle ergometer resulted in no urinary metabolome changes. An RF margin of 0.07 strongly 
suggests an untargeted metabolomic approach was unable to detect significant metabolic 
changes which distinguish pre and post exercise urines. Similarly (and expected) no distinct 
classification of samples was detected in resting urine samples (RF margin; 0.03). Lack of 
sample classification is evidenced further by PCA plots (Figures 6.1A and 6.1B) which 
demonstrate no clear visual separation between sample time points. Given no separation was 
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found between metabolites in pre and post samples in both exercise and rest, no feature 
selection of discriminatory signals was required. RF margins between FMV and post urine 
samples in both exercise and rest trials exceeded the 0.3 classification threshold. Feature 
selection was conducted to determine discriminatory signals between time points which 
successfully identified a small group of metabolites contributing towards sample classification. 
In rest, changes between FMV and post rest samples were found in (1R,2R,3S,1'R)-nepetalinic 
acid (P = 0.00), 2-hydroxypropanoic acid (P = 0.00) and polyethylene glycol 500 and (P = 
0.03). In the equivalent exercise samples, 1,8-Epoxy-p-menthan-4-ol glucoside (P = 0.01), 
2',3'-Dihydroxyacetophenone (P = 0.03) and 2-hydroxypropanoic acid (P = 0.03) changed 











Figure 6.1A and 6.1B. Principle Component analysis (PC1; 34.15% of variation, PC2; 23.13% 
of variation, PC3; 15.8% of variation) of participant’s FMV (TO), PRE (PR) and Post (PT) 






6.4. Discussion  
The aim of this study was to examine urinary metabolome change following 30-minutes of 
moderate intensity exercise on a cycle ergometer. Previous work has demonstrated the effects 
of both high intensity exercise and resistance exercise on urinary metabolite changes (Enea et 
al., 2010; Pechlivanis et al., 2010; Pechlivanis et al., 2015; Siopi et al., 2017). However, the 
effects of moderate and submaximal exercise are less established with disagreements in the 
literature regarding the extent of metabolic disturbance following this form of physical activity 
(Enea et al., 2010; Ali et al., 2016). This exercise mode is of interest as UK national activity 
guidelines state all adults should undertake 30 minutes of moderate intensity exercise, five days 
per week. Such guidance is especially encouraged in patients requiring lifestyle modification 
for the prevention of non-communicable diseases, such as those who participated in the pre-
diabetes intervention, detailed in chapter two as well as being applicable to participants in a 
future study, outlined later in this thesis. In chapter five, work was undertaken to develop a 
simple and non-disruptive method for urine collection in the home to monitor habitual diet. As 
discussed previously, metabolites within urine can reflect both individual food intake as well 
differentiate between dietary patterns. Prior to testing the above urine collection procedure in 
a population at risk of T2D, this work aimed to determine metabolic change in urine following 
both 30 minutes of standardised moderate exercise on a cycle ergometer, an intensity based on 
national exercise guidelines, compared to rest. Determining such change provides useful 
information to researchers regarding what metabolites may be present in the urine of 
individuals who are providing samples for dietary monitoring and those who engage in 
moderate physical activity as per advice from lifestyle intervention.   
 
This work demonstrated 30 minutes of standardised moderate intensity exercise to have no 
significant impact on the urinary metabolome. This is evidenced by an RF margin of 0.07 and 
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is further supported by PCA plots which demonstrate no separation between pre and post 
exercise urine samples. The findings from this study agree with Enea et al. (2010) who 
examined both short term intense exercise and prolonged exercise. Despite a significant 
metabolic shift in urines post short-term intense exercise, no changes were found following 30 
minutes of continuous exercise on a cycle ergometer. Following the intense exercise protocol, 
the major identifiable signals responsible for class separation were attributed to lactate and 
creatinine. Other metabolites responsible for separation between pre and post samples were 
alanine, acetate, acetoacetate, pyruvate, succinate, hippurate and hypoxanthine, all of which 
were excreted significantly more following completion of the short intensive exercise test. The 
changes in the urinary metabolite profile following short intense exercise were attributed to 
changes in muscle bioenergetics and specifically compounds related to the ATP-PCr and 
glycolytic systems The authors suggested that given the prolonged exercise test was performed 
at a moderate intensity, predominant energy usage was derived from aerobic metabolism, 
including lipid and carbohydrate oxidation, which has consistently shown to be elevated during 
moderate intensity activity and is well established (Horowitz and Klein, 2000; Achten, Gleeson 
and Jeukendrup, 2001). The authors concluded a lack of urinary metabolome change following 
prolonged moderate exercise was not unexpected as metabolites associated to lipid and 
carbohydrate oxidation are not routinely discovered in urine if the kidneys work effectively 
(Enea et al., 2010).  
 
While the findings from the present work and that of Enea et al. (2010) are similar, the 
conclusions by Ali et al. (2016) are in significant contrast. This study examined metabolome 
changes following 45 minutes of moderate intensity exercise on a cycle ergometer. During the 
submaximal exercise protocol, participants cycled at 50 watts (W) for 5 minutes, 15 minutes at 
40% work rate max (WRMax), 15 minutes at 50% WRMax and 10 minutes at 60% WRMax. 
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Analysis revealed clear separation between pre and post exercise samples on the day of 
exercise. The metabolites responsible for separation between the exercise day FMV and the 
first post exercise sample were hypoxanthine, guanine, deoxyinosine, inosine and xanthosine 
all of which are metabolites within the purine pathway. Changes in these metabolites were not 
present within samples collected the previous non-exercise day and suggest the ‘purine 
response’ requires physical activity to result in observable changes. Additionally, an increase 
in nonanoyl carnitine, decanoyl carnitine and ketodecanoyl carnitine, increases which were not 
observed during the rest day, was attributed to a decreased reliance on fatty acid metabolism 
during exercise, which represented a shift towards glycolysis to maintain ATP synthesis. 
Furthermore, panthothenic acid increased following exercise with this change suggested to 
indicate an inhibition of CoA biosynthesis, which is tightly controlled by pantothenate kinase. 
Acetyl CoA inhibits pantothenate kinase by allosteric binding so an increase in urine 
panthothenic acid indicates a decrease in CoA synthesis (Ali, Burleigh, Daskalaki, Zhang, 
Easton and Watson, 2016). Fatty acid oxidation relies on CoA and therefore a decrease in CoA 
concentration would suggest a shift to glycolysis in the Krebs cycle. An increase in lactate after 
exercise compared to no change during rest is evidence of this. An increase in microbial 
products was also observed with an elevation in testosterone sulphate recorded in the first 
sample following exercise. Similarly, tetrahydroaldosterone increased after exercise with the 
suggestion that increases in both these metabolites are the result of increased energy 
metabolism. Neither metabolite changed during rest. The results of this work demonstrated the 
impact of submaximal exercise on metabolites such as hypoxanthine and inosine, both of which 
are markers of exercise as demonstrated from other studies. This is in addition to many other 
metabolites which changed significantly following submaximal exercise. Whilst samples from 
the rest day demonstrated clear separation at the same time points, many metabolites were 
affected only by the exercise protocol. However, the significant increases in lactate post 
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exercise suggests participants may have been working in an exercise intensity greater than 
considered ‘moderate’ which may explain why the work by Ali et al. (2016) was able to 
demonstrate significant metabolomic changes in urine following exercise considered to be 
submaximal. Furthermore, the authors state it was likely there was a decreased demand for 
fatty acids during exercise, resulting in a switch towards glycolysis to maintain ATP levels 
under conditions of increased oxygen demand. Rather than cycling at a fixed intensity for the 
duration of the test, participants were required to work at increasing power outputs (five min 
warm up at 50 W, 15 min at 40% of maximal cycling work rate (WRMax), 15 min at 50% 
WRMax, and 10 min at 60% WRMax. It is possible the increasing workload resulted in a shift 
in substrate metabolism and therefore caused alterations in the urine metabolome which have 
been demonstrated in other studies examining exercise above moderate intensities. Mean heart 
rates at each respective WRMax of 115 bpm, 156 bpm and 169 bpm suggest participants were 
exercising at greater intensities compared to those in the present work and in Enea et al. (2010), 
although heart rate data for the latter was not published.  
 
Although distinct sample classification was not achieved between pre and post exercise 
samples, RF margins between FMV and post samples for both exercise and rest trials reached 
accepted values (> 0.3; Enot et al., 2008; Table 6.2). From the signals demonstrating a 
significant change between FMV and post sampling time points, a small number were 
identified using MZedDB, an interactive accurate mass annotation tool which can directly 
annotate signals (Draper et al., 2009). In the rest trial, the metabolites; (1R,2R,3S,1'R)-
nepetalinic acid, 2-hydroxypropanoic acid, polyethylene glycol changed significantly. The 
Human Metabolome Database (HMDB) suggests both (1R,2R,3S,1'R)-nepetalinic acid and 
polyethylene glycol are associated with lipid transport and metabolism while 2-
hydroxypropanoic acid is more commonly referred to as lactic acid. Presence of 2-
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hydroxypropanoic acid was also identified as a distinguishable feature between FMV and post 
samples in the exercise trial, alongside 1,8-Epoxy-p-menthan-4-ol glucoside and 2',3'-
Dihydroxyacetophenone. The HMDB states 1,8-Epoxy-p-menthan-4-ol glucoside is found in 
citrus while 2',3'-Dihydroxyacetophenone is listed as a flavouring ingredient. It is unclear as to 
the reasons why such metabolites were distinguishable between FMV and post-exercise 
samples. It is possible that changes between FMV and post-trial urine samples following 
exercise were the result of ‘washout’ from the previous evening meal. While subjects were 
asked to repeat identical eating habits prior to both experimental trials, this was not tightly 
controlled, nor was a specific control meal provided the evening prior to each trial. Another 
explanation, encompassing both trials, is simply the cyclical nature in the concentration of 
urinary metabolites throughout the day (Slupsky et al., 2007). Given there was no acceptable 
classification between pre and post urine samples, suggesting exercise specifically resulted in 
no metabolome shifts, this is a possibility.      
 
Moderate intensity exercise was studied as it is likely to be adopted by participants undergoing 
healthcare led lifestyle intervention, based on UK national exercise guidelines, and is 
applicable to participants involved in a later study in this thesis. These findings therefore 
suggest that metabolome changes and metabolite presence in urines provided by lifestyle 
intervention participants are unlikely to be caused by 30 minutes of moderate intensity physical 
activity. However, it would be unreasonable to suggest that some individuals undergoing 
lifestyle intervention would solely undertake moderate intensity exercise as recommended to 
them by a health care professional with some assuming higher intensity exercises as part of 
lifestyle modification. As discussed above, evidence suggests high intensity exercise results in 
significant metabolome changes which are associated to the purine pathway, anaerobic 
metabolism and amino acid degradation. With this evidence for high intensity exercise, coupled 
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with evidence for moderate intensity exercise (from this work and others) and resistance 
exercise, there is a reasonably strong collection of data sources for linking urinary metabolome 
changes and metabolite presence to physical exercise. In a future study within this thesis, 
examining lifestyle modification in pre-diabetes, participants will provide regular urine 
samples for the purposes of dietary monitoring. Participants in this study will also receive 
advice to undertake 30 minutes of moderate intensity activity, five days a week, as per the UK 
national guidelines for physical activity. While this study has demonstrated that this exercise 
intensity does not cause any significant urinary metabolome change, should metabolites present 
themselves in urines which may be suggestive of higher intensity exercise, previous data from 
other work is available to inform such findings. Cross referencing potential urinary metabolites 
with activity tracker data and physical activity questionnaire data can further inform such 
findings in urine samples if necessary. Furthermore, previous work by Pechlivanis et al. (2015) 
found many metabolites affected by exercise returned to baseline values within two hours of 
exercise cessation. This therefore suggests FMV urine samples are best placed to limit any 
urinary metabolic disturbance caused by exercise while at the same time containing rich dietary 
information, as demonstrated in chapter four.  Dietary monitoring using urine sampling and 
activity tracking in individuals at risk of T2D will be explored in greater detail in chapter seven.       
 
In conclusion, this study demonstrated 30 minutes of standardised moderate intensity exercise 
to have no effect on the urinary metabolome. This finding helps provide a better understanding 
of the effects of this form of exercise in a field or previously mixed results. With reference to 
a future study within this thesis examining lifestyle modifications with urinary dietary 
monitoring, there is little evidence to suggest exercise, based on UK national guidelines, will 






Comparison of the Alere Afinion AS100 Point of Care Analyser and HPLC in the 
Determination of HbA1c  
 
7.1. Introduction 
In chapter two, patients at risk of T2D attended a 30-minute one-to-one consultation with a 
healthcare professional. During this consultation information on the risks of T2D was provided 
as well as discussions on the benefits of increasing physical activity and improving dietary 
behaviours for improving blood glucose control. Eligibility for the study included an HbA1c 
test result from the preceding four weeks of between 42 and 47 mmol/mol. Analyses of 
patient’s HbA1c was conducted at Bronglais Hospital Pathology Laboratory, Aberystwyth, 
using high-performance liquid chromatography (HPLC). HPLC is considered the gold standard 
for analysing HbA1c and is a reference method to standardize other analytical techniques 
(Maesa et al., 2014). However, hospital based HPLC is costly, time consuming and requires 
trained personnel to operate the machinery (Karami and Baradaran, 2014). As a result, the use 
of automated point of care (POC) analysers for immediate HbA1c analysis in primary care and 
research is becoming more common. Use of such systems means those at risk of T2D can be 
tested and receive their HbA1c value within minutes, have a discussion with a health 
professional about the implication of their result and, if necessary, be signposted to relevant 
support services, all within the same appointment and without the lengthy waiting times and 
financial costs associated with HPLC analysis. One such POC device is the Alere Afinion 
AS100, which uses the boronate affinity method which detects attachment of glucose at both 




As the use of POC analysers becomes more widespread it is of interest to determine how closely 
the results agree with those from HPLC. Wood et al. (2012) reported a mean relative difference 
of + 0.5% to + 3.9% when using an Afinion POC analyser compared to an HPLC method across 
a range of values from < 7% (53 mmol/mol) to > 10% (86 mmol/mol), however all samples 
were taken from those with a clinical diagnosis of diabetes. It is not clear from the literature 
what the agreement is between the Alere Afinion AS100 POC analyser and HPLC in values 
between 30 and 60 mmol/mol, which includes individuals from across the healthy, pre-diabetic 
and diabetic ranges. It is also not clear from the literature what, if any, impact on the result 
different methods of blood sampling (e.g. venous and capillary blood sampling) will have on 
HbA1c values. While Mailankot, Thomas, Pravenna, Jacob, Benjamin and Vasudevan (2012) 
and Sharma, Sarmah and Sonker (2013) both report stability in HbA1c values irrespective of 
anticoagulant both studies used HPLC in the determination of HbA1c. As such this study will 
examine agreement between Alere Afinion AS100 POC analyser and HPLC across a range of 
values spanning healthy, pre-diabetic and diabetic individuals. The study will also examine 
different blood sampling methods and any impact of the anticoagulant used on HbA1c result. 
 
Primary Aim: 
• Compare, and establish the limits of agreement, in HbA1c (mmol/mol) values between HPLC 
and Alere Afinion AS100 POC analyser in venous blood samples collected via 








• Compare, and establish the limits of agreement, in HbA1c (mmol/mol) values between venous 
blood samples collected via EDTA and LH vacutainers when analysed by Alere Afinion AS100 
POC analyser (Aim 2). 
• Compare, and establish the limits of agreement, in HbA1c (mmol/mol) values between venous 
blood, collected via EDTA and LH vacutainers, and capillary blood when analysed by Alere 




Twenty-five participants volunteered and were recruited to the study; two participants were 
later diagnosed as anaemic following HPLC sample analysis and were withdrawn from the 
study. Data for 23 participants (16 male and seven female) with a mixture of healthy (n = 18, 
35 ± 2 mmol/mol), pre-diabetic (n = 2, 45 ± 4 mmol/mol) and diabetic (n = 3, 54 ± 5 mmol/mol) 
HbA1c values were used for statistical analysis.   
 
7.2.2. Experimental Protocol 
Participants attended the laboratory on a single occasion. On arrival the procedures and purpose 
of the study were explained before participants gave their informed consent to continue (see 
Appendix; L, M). Participants were seated in a phlebotomy chair prior to a blood sample being 
obtained from the antecubital vein and collected into vacutainer tubes (2 x 4 ml EDTA tube 
and 1 x 6 ml into a LH tube). 1.5 µl of whole blood was transferred directly from one of the 
EDTA vacutainers into the HbA1c test cartridge and assayed immediately on the Alere Afinion 
AS100 POC analyser. The same process was then repeated using the LH vacutainer, the EDTA 
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and LH vacutainers were then disposed of via standard clinical practice. A capillary blood 
sample was then collected from the middle or index finger using a lancet. 1.5 µl of whole blood 
was collected directly into the HbA1c test cartridge from the puncture site and assayed 
immediately. The remaining EDTA vacutainer was sent to Bronglais Hospital pathology 
laboratory for HPLC analysis (Tosoh G8, Tessenderlo, Belgium). All samples were delivered 
to the hospital and analysed by HPLC within eight hours of sample collection. 
 
7.2.3. Statistical Analysis 
Comparison between methods was achieved by calculating the mean difference (MD) between 
HbA1c values with normally distributed mean differences analysed using a one sample t-test 
and non-normally distributed mean differences analysed using a one-sample Kolmogorov-
Smirnov test. One sample analysis was used to determine if the difference between values 
attained from each method varied significantly from zero. Relationships between methods were 
analysed using Spearman’s correlation and Bland Altman plots (Bland and Altman, 1986) were 
used to determine limits of agreement. Statistical significance was accepted at P < 0.05. A 
summary of all comparisons made can be seen in Table 7.1. 
 
Table 7.1: Comparisons to be made in HbA1c values as determined by HPLC and Alere Afinion 
AS100 POC Analyser 
 
  Alere Afinion AS100 POC 
HPLC EDTA LH Capillary 




EDTA   Aim 2 Aim 3 
LH    Aim 3 





Values for HbA1c attained from HPLC and the Alere Afinion AS100 POC analyser can be seen 
in Table 7.2. Statistical analysis indicated HbA1c values attained from HPLC differed 
significantly from POC analysis when samples were collected in both EDTA (MD -2.0 
mmol/mol) and LH (MD -1.7 mmol/mol) vacutainers (P = 0.01) with HPLC on average giving 
higher values. Spearman’s test found significant positive correlations between POC analysis 
(EDTA) and HPLC (r = 0.92, P = 0.00, Figure 7.1A) and POC analysis (LH) and HPLC (r = 
0.93, P = 0.00, Figure 7.2A).  The 95% limits of agreement between HPLC and POC analysis 
with sample collected in EDTA were 2.21 to -6.61 mmol/mol (Figure 7.1B), while the 95% 
limits between HPLC and POC with sample collected in LH were 2.82 to -6.21 mmol/mol 
(Figure 7.2B). 
 
Table 7.2: HbA1c values from point of care and HPLC analysis. Data are represented as median 
(range) 
 
 Alere Afinion AS100 POC analyser HPLC 
 EDTA  LH  Capillary  
HbA1c 
(mmol/mol) 








Figure 7.1A/7.1B: Spearman’s correlation (1A) and Bland Altman limits of agreement plot 
(1B) for POC analysis (EDTA) vs HPLC  
 















































Figure 7.2A/7.2B: Spearman’s correlation (2A) and Bland Altman limits of agreement plot 
(2B) for POC analysis (LH) vs HPLC  
 













































A significant difference in HbA1c was found between EDTA and LH vacutainers (MD = -0.3, 
P = 0.00) with LH vacutainers giving higher values. Results obtained from the two vacutainer 
types were correlated (r = 0.95, P = 0.00, Figure 7.3A) and the 95% limits of agreement 
between the two types of vacutainer were 2.37 to -2.98 mmol/mol (Figure 7.3B).  
 
When capillary samples were compared to venous samples there was a significant difference 
between LH vacutainers and capillary samples (MD = -0.5, P = 0.00) with LH vacutainers 
giving higher values. No significant difference between EDTA vacutainers and capillary 
samples (0.2 MD, P = 0.38) although EDTA vacutainers gave higher values. Spearman’s test 
found significant positive correlations between LH vacutainers and capillary samples (r = 0.93, 
P = 0.00, Figure 7.4A) and EDTA vacutainers and capillary samples (r = 0.93, P = 0.00, Figure 
7.5A). The 95% limits of agreement between LH vacutainer and capillary samples were 2.18 
to -3.2 mmol/mol (Figure 7.4B), while the 95% limits between EDTA vacutainer and capillary 











Figure 7.3A/7.3B: Spearman’s correlation (3A) and Bland Altman limits of agreement plot 
(3B) for EDTA vs LH vacutainers using the POC analysis.  

















































Figure 7.4A/7.4B: Spearman’s correlation (4A) and Bland Altman limits of agreement plot 
(4B) for LH vacutainers vs capillary sampling using POC analysis.  

















































Figure 7.5A/7.5B: Spearman’s correlation (5A) and Bland Altman limits of agreement plot 
(5B) for EDTA vacutainers vs capillary sampling using POC analysis. 










































The primary aim of this study was to compare the Alere Afinion AS100 Point of Care Analyser 
and HPLC in the determination of HbA1c prior to using the former as part of an RCT targeting 
patients at increased risk of T2D. The main finding was that HbA1c values from the two 
methods varied significantly; compared to HPLC the POC analyser underestimated HbA1c by 
two mmol/mol when using an EDTA collection vacutainer and by 1.7 mmol/mol when using 
a LH vacutainer. The 95% limits of agreement indicate that when using EDTA the POC 
analyser gives values in a range of between +2.21 to -6.61 mmol/mol of that obtained from 
HPLC (Figure 7.1B) while POC samples obtained via LH vacutainer give values of between 
+2.82 and -6.21 mmol/mol of those obtained via HPLC (Figure 7.2B). In three cases, the POC 
analyser misclassified participants, placing them into the pre-diabetes range while HPLC 
analysis categorised the participant as T2D. Such misclassification of categories suggests the 
POC analyser is not suitable for accurate monitoring of HbA1c values at a clinical level and 
demonstrates the importance HPLC in confirming pre-diabetes and T2D diagnoses.  The 
findings from this study are however similar to work by Grant, Dunseath, Churm and Luzio 
(2017) who found a median two mmol/mol difference in HbA1c values between HPLC and 
POC analysis using boronate fluorescence quenching technology. Notwithstanding the 
difference, Grant et al. (2017) concluded that the POC analyser could be used for HbA1c 
monitoring, however they recommended that HPLC analysis was undertaken for diagnoses.  
 
Despite significant mean differences, the positive correlation between methods suggests that 
while the POC analyser underestimated HbA1c values compared to HPLC, the results from both 
POC analysis (EDTA (Figure 7.1A) and LH (Figure 7.2A)) and HPLC increased in a similar 
manner to one another. As such, the POC analyser may be used, albeit cautiously, to help track 
trends in HbA1c over time and provide useful information for the patient and/or researcher 
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regarding the effectiveness of lifestyle interventions in combatting T2D. Should an HbA1c 
value approaching 47 mmol/mol be obtained from a POC analyser a strong recommendation 
should be made to get a confirmatory analysis via HPLC.  
 
The significant difference and lack of agreement between LH vacutainers and EDTA 
vacutainers (Figure 7.3B) and capillary sampling (Figure 7.4B) was somewhat surprising. 
Previous work has reported no difference in HbA1c values when collected into vacutainers 
containing different anticoagulants, including EDTA and LH (Mailankot, Thomas, Pravenna, 
Jacob, Benjamin and Vasudevan, 2012), as well as the POC analyser manufacturer’s own 
recommendation that numerous anticoagulants can be used for sample collection. The reasons 
for the significant disagreement among vacutainer types are unknown. In contract to this 
finding venous sampling using EDTA vacutainers and capillary sampling demonstrated no 
significant difference when analysed by the POC analyser and the 95% limits of agreement 
indicated that the two methods differed by +2.5 to -2.07 mmol/mol (Figure 7.5B). Similarities 
in results from venous, collected via EDTA vacutainer, and capillary sampling methods will 
allow flexibility in HbA1c measurement in participants where venous sampling is challenging. 
 
A limitation of this study lies in the relatively low number of participants recruited. General 
recommendations made by Simundic (2016), and as demonstrated by Grant et al. (2017), 
suggest method comparison studies should recruit a minimum of 40 but up to 100 participants 
to cover the whole clinically meaningful measurement range to reduce random error. While the 
present study ensured participants were recruited from healthy (18), pre-diabetes (2) and T2D 
(3) categories, the pre-diabetes and T2D categories are underrepresented.  
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In conclusion, the results from this study demonstrate a laboratory POC analyser for the 
determination of HbA1c underestimates results by a median of two mmol/mol and in some cases 
misclassifies diabetic state. Based on these results, the POC analyser it is not suitable for 
clinically diagnosing T2D. However, the significant positive correlations between the POC 
analyser and HPLC analyses suggest that the former can be used, with caution, to assess 
intervention effectiveness by monitoring longitudinal changes without the waiting time, 



















Chapter Eight:  
 
The feasibility of conducting a randomised control trial to evaluate the effectiveness of a 




In Chapter two, a GP-led 30-minute one-to-one consultation targeting lifestyle modification in 
patients at risk of T2D was associated with significant decreases in HbA1c and other health 
outcomes associated with the condition including body mass, BMI and waist circumference. 
Despite this success, the design of the intervention did not include a control group, and as such, 
direct comparisons with usual care cannot be made. Patients in Chapter two received both 
written information regarding their T2D risk and ways to improve lifestyle as well as the 
opportunity to attend a 30-minute one-to-one consultation with a healthcare professional. It is 
possible that the written information given to this cohort provided the appropriate stimulus to 
initiate behaviour change and that the one-to-one consultation did not provide any additional 
benefit.  
 
In order to establish the benefit of an intervention, a control group with appropriate comparison 
and randomisation is needed. Given the complexity and logistical challenges of conducting an 
appropriately powered Randomised Control Trial (RCT) in primary care, it is prudent to first 
assess the feasibility of initiating such a design with a smaller cohort of patients. Dawes et al. 
(2015) examined the feasibility of conducting a cluster randomised control trial in pre-diabetes 
in a Canadian population which compared a primary care led lifestyle intervention to usual 
care, with 95% of participants remaining engaged in the research after six months. Those 
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receiving lifestyle intervention within primary care reduced body mass, BMI and waist 
circumference significantly compared to control participants, with the authors concluding it 
would be feasible to implement a larger trial with greater follow up duration to assess 
intervention effectiveness in diabetes prevention. The current study was undertaken to establish 
the feasibility of conducting an RCT in mid-Wales to evaluate the effectiveness of a one-to-
one consultation to improve blood glucose control in pre-diabetes. The design of the RCT 
meant the consultation did not involve the collection of baseline data, which was the case in 
Study one (Chapter two), and subsequently the time required to deliver the intervention was 
reduced from 30 minutes to 15 minutes. The findings from studies two and three (Chapters 5 
and 6) informed the development of a urine collection kit and collection procedures for 
monitoring dietary intake in a free-living population and represents the first time such processes 
have been trialled within a clinical population in Wales.  
 
Aims:  
The study’s primary aims were to determine:  
• The percentage of patients eligible to participate who gave consent to be part of the study. 
• The percentage of patients who completed baseline; three-month; and six-month testing. 
 
Secondary aims are to determine:  
• The impact of the consultation on participant biochemistry, anthropometry, physical activity 




8.2. Method  
8.2.1. Participants and Recruitment  
Patients registered with Church Surgery, Aberystwyth, who were at increased risk of 
developing T2D, based on a body mass index (BMI) > 25 kg/m2 or an existing glycated 
haemoglobin (HbA1c; recorded within the last 12 months) of between 42 and 47 mmol/mol, 
were identified on the surgery’s patient record system. Database searches were completed by 
trained surgery employees. Patients who received the 30-minute one-to-one consultation 
detailed in Chapter two were not eligible for inclusion. Patients identified as at risk of T2D 
based on BMI (without a <12-month HbA1c) were invited by letter (see appendix N) to the 
surgery for a blood test to determine their HbA1c. Patients with HbA1c between 42 mmol/mol 
and 47 mmol/mol or patients approaching the HbA1c risk threshold and considered at increased 
risk of T2D, based on clinical judgement by a GP, were informed of the study by their surgery 
via an information pack (see appendix; B, O, P). The pack contained; a letter outlining the 
patient’s increased risk of T2D, a T2D information leaflet and the participant information sheet 
detailing the study. The T2D information leaflet was the same document sent to patients 
participating in Study one and included key information relating to T2D and steps that can be 
taken to avoid developing T2D. The participant information sheet included material on the 
purpose and procedures of the research study and contact details for the research team. For 
patients confirming their involvement, verbal and written informed consent was sought in 
person at the start of their first visit to the Well-being Assessment Research Unit (WARU) 
before being inducted into the study (> 24 hours between receipt of the study invite letter & 
participant information sheet and signing informed consent; see appendix Q). Individuals who 




8.2.2. Experimental Protocol  
Participants visited the WARU on three separate occasions for baseline, three-month and six-
month testing. At the start of each visit; measures for height, body mass, waist and hip girth 
(Seca 201, Seca Gmbh & Co, Hamburg, Germany) were recorded. Body composition was 
analysed with participants in a supine position using bioelectrical impedance (Bodystat 1500, 
Bodystat Ltd, Douglas, British Isles) and a blood sample was collected for the determination 
of HbA1c and lipid profile (See Chapter Four, General Methods, 4.5 & 4.6). WARU informed 
Church Surgery if a participant’s HbA1c was above 47 mmol/mol. Finally, participants sat 
quietly in an upright position for 10 minutes in the laboratory before BP was recorded from the 
upper non-dominant arm (Omron M3, Omron Healthcare Ltd, Milton Keynes, UK). Blood 
pressure was measured in duplicate (recordings separated by five minutes) and the lowest value 
was recorded.  
 
Next, participants completed several validated questionnaires, these included; components of 
the Personal Diabetes Questionnaire (baseline), IPAQ-SF (see Chapter Two, 2.2.2.), and SF-
36 (baseline, three- and six- months) and FFQ (baseline and six-months; see appendix; R, S, 
T). The Personal Diabetes Questionnaire is a validated 19-point questionnaire taken from the 
original Personal Diabetes Questionnaire (Stetson, Shlundt, Rothschild, Floyd, Rogers and 
Mokshagundam, 2011) and addressed the following behaviours relating to diabetes; body mass 
change readiness, dietary change readiness, dietary barriers and exercise barriers. Answers 
provided to questions relating to body mass and dietary change readiness categorised 
respondents into the; pre-contemplation, contemplation, preparation or action group. Answers 
provided to questions relating to dietary and exercise barriers provided respondents with a 
numerical score with higher scores representing greater barriers to change. The SF-36 is a 36-
point validated health questionnaire designed to assess perceptions of physical functioning, 
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bodily pain, role limitations due to physical health problems, role limitations due to personal 
or emotional problems, general mental health, social functioning, energy & fatigue, and general 
health (Hays, Sherborne and Mazel, 1993). Questions were scored on a scale from zero to 100, 
with 100 representing the highest level of functioning. Scores from questions that addressed 
each specific area of functional health status were averaged together to calculate a final score 
within each of the eight categories measured.  
 
The FFQ used was derived from the EPIC-Norfolk version (Bingham et al., 2001) and consists 
of a list of foods (grouped by type) and beverages with response categories to indicate usual 
consumption frequency over the previous six months. Using a consumption frequency score 
between one and nine, respondents can be categorised into high, medium and low consumption 
classes of different foods and nutrients based upon the Alternative Healthy Eating Index 
(AHEI; Varraso et al., 2015). The AHEI is based on foods and nutrients predictive of chronic 
disease risk. Higher scores on the AHEI are strongly associated with lower risk of major 
chronic disease as well as risk of CVD, diabetes, heart failure, colorectal and breast cancer, and 
total and cardiovascular mortality (Chiuve et al., 2012). Food frequency questionnaire 
responses were scored based on a protocol by Chiuve et al. (2012). 1-Vegetables: five servings 
per day was considered ideal, which reflects the upper range of current dietary guidelines. 2-
Fruit: four servings per day was considered ideal, which is consistent with the upper range of 
current dietary guidelines. 3-Wholegrains: 75 g per day was considered optimal (five servings 
per day) for women and 90 g per day (six servings per day) considered optimal for men based 
on current guidelines for total grains. 4-Sugar-sweetened beverages: One serving per day was 
considered least optimal based on the associations in the literature. 5-Nuts, legumes, and 
vegetable protein: One serving per day considered ideal based on the AHEI recommendations 
and the current literature. 6-Red meat and processed meat: Less than one serving per month 
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was ideal. 7-Trans-fats: Cut-offs are consistent with original AHEI cut-offs for trans-fat. 8-
Fish: Two to four servings of fish per week is considered optimal, which is consistent with 
current guidelines. 9-Polyunsaturated Fats: Highest score given to individuals with 10% of total 
energy intake from PUFA based on current guidelines from the USDA and the AHA. 10-
Sodium: Cut-offs were based on deciles of distribution in the population, due to lack of brand 
specificity in the FFQ to accurately estimate absolute intake. Values in lowest decile were 1112 
mg per day in women and 1612 mg per day in men and in highest decile were 3337 mg per day 
in women and 5271 mg per day in men. 11-Alcohol: The highest score was assigned to 
moderate, and the worst score to heavy, alcohol consumers. Non-drinkers received a score of 
2.5. All components of the AHEI were scored from zero (representing a bad diet) to 10 
(representing a perfect diet) based upon consumption frequency. The total AHEI score ranged 
from zero (nonadherence to dietary recommendations) to 110 (perfect adherence to dietary 
recommendations). 
 
The purpose of, and completion process for, each questionnaire was explained to participants 
and the opportunity to ask questions was provided before questionnaires were completed. 
Questionnaires were completed unassisted although the chief investigator was available to 
answer any further questions the participant had. Lastly, participants received instructions on 
the use of the urine collection kit for dietary monitoring and the ActiGraph for physical activity 
monitoring. Participants were then free to leave the laboratory.  
 
An additional acceptability questionnaire designed by the chief investigator was given to 
participants at the end of the six-month visit and included questions relating to the recruitment 
procedures, WARU visits, 15-minute consultation (if received), urine collection and ActiGraph 
use (see appendix X). Visits lasted between 75 minutes and 120 minutes depending on 
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participant mobility and the time taken for participants to complete the questionnaires.     
 
Following completion of the baseline visit, participants were randomised into either the 
intervention group (INT) or the control group (CON). Church surgery were informed of the 
participants who were randomised to receive the intervention with referral arrangements made 
between the chief investigator and surgery staff.  Participants in INT received a 15-minute one-
to-one consultation with a healthcare professional at Church Surgery. The consultation derived 
from the original 30-minute protocol employed during the study outlined in Chapter two. The 
first half of the 30-minute consultation in Chapter two collected data including; height, body 
mass, waist circumference and blood pressure and the second half provided patients with 
lifestyle advice on preventing diabetes. The consultation used in the present study did not 
require general practice to collect baseline data and therefore the consultation time was reduced 
to 15 minutes.  
 
The consultation provided the participant with one-to-one information regarding the benefits 
of physical activity and healthy eating, based upon NICE guidelines. Physical activity advice 
included the recommended completion of at least 150 minutes of moderate intensity activity 
each week, such as 30 minutes per day on five days of the week, or alternatively, 75 minutes 
of vigorous intensity activity spread across the week or combinations of moderate and vigorous 
intensity activity. Participants were also advised to undertake resistance exercise to improve 
muscle strength on at least two days a week and minimise the amount of time spent being 
sedentary for extended periods. Summarised advice regarding healthy dietary behaviours 
included eating at least five portions of a variety of fruit and vegetables every day, basing meals 
on wholegrain carbohydrates, choosing lower fat and lower sugar diary options, consuming 
beans, pulses, fish, eggs, lean meat and other proteins, choosing unsaturated oils and spreads, 
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drinking six-eight cups/glasses of fluid a day and limiting the consumption of alcohol to no 
more than 14 units per week. Furthermore, participants had the opportunity to discuss pre-
diabetes with the health professional and ask questions. Participants randomised to CON 
received written T2D information and attended visits to the WARU only.  
 
8.2.3. Randomisation 
Randomisation was achieved using a minimisation software package (Minim; Evans, Royston 
and Day, 2017). Minimization is a dynamic approach and assigns treatment based on previous 
allocations and ensures balance in important factors (Pandis, 2011). Participant details recorded 
after the first visit were inputted into the randomisation package. Following randomisation of 
the first participant, remaining participants were randomly allocated into either the intervention 
or control based upon age (ages 60 + in both groups) and gender. Randomisation was conducted 
by the primary academic supervisor and a laboratory technician. Information on participant 
allocation was then provided to the chief investigator who informed Church surgery which 
participants required a consultation. Appointment bookings for participants randomised to the 
intervention were co-ordinated by the chief investigator. Participants randomised to control 
were not contacted regarding allocation and were only contacted to book follow up visits to the 
research facility.   
 
8.2.4. Dietary Monitoring by Urine Sampling  
After each WARU visit, participants were asked to collect three First Morning Void (FMV) 
samples each week on non-consecutive days for a three-week period, encompassing two-week 
day samples and one weekend sample. Duplicate samples were collected at each time point. 
Once the sample was successfully collected, the vacutainer tubes were returned to the absorbent 
pouch, placed within a sealed leak-proof plastic bag and kept in the participants’ refrigerator 
192 
 
for storage at 4°C. Vacutainer pouches were labelled anonymously with information including 
participant number, phase, week and sample number. Participants recorded the collection 
details of their urine samples onto a sample collection sheet which noted the sample number 
and the date and time of collection (see appendix U). Samples were stored for a maximum of 
10 days before being placed into an addressed box and returned to the laboratory either in 
person or by free post, see Figure 4.1. Samples were refrigerated temporarily upon arrival at 
the laboratory before processing and freezing at -80ºC. In total, participants collected 27 urine 
samples during their participation in the study.  
 
8.2.5. Physical Activity Monitoring by ActiGraph 
Physical activity was recorded using ActiGraph (ActiGraph LLC, Pensacola, FL, USA) 
following baseline, three and six-month WARU visits. Participants received written and verbal 
instructions (see appendix V) to wear the belt around their waist with the monitoring device 
positioned on the right-hand side of the body. Participants chose one week within the three-
week urine collection period to wear the ActiGraph and were free to choose any day within the 
week to begin wearing the device. The ActiGraph was worn for seven consecutive days from 
waking until going to bed, unless unfeasible to do so (e.g. swimming, bathing or showering). 
Participants recorded the times in which the ActiGraph was worn (see appendix W). If 
participants did not wear the device for a period within the same day; the un-worn times were 
recorded.  If participants missed a whole day; an additional recording day was added directly 
after the seventh day. The ActiGraph was not worn during sleeping hours. Participants returned 
the ActiGraph at the end of the recording period either in person or by post.  
 
8.2.6. Blood Treatment 
Separate 1.5 μl samples of whole blood were transferred by pipette from the heparinised 
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vacutainer into separate HbA1c and lipid test cartridges and analysed respectively by an 
automated point of care blood analyser (see Chapter Four, General Methods, 4.6). The 
remaining whole blood was centrifuged at 1500 g for 10 minutes at 4˚C. Five 250 µl aliquots 
of supernatant were pipetted into five individual Eppendorfs and frozen at -80˚C.  
 
8.2.7. Plasma Extraction  
Plasma samples were defrosted over night at 4°C. A one micro-spoon of glass beads was added 
into new pre-labelled 2 ml Eppendorf tube. Raw plasma samples were vortexed for five seconds 
before 200 µl of the raw plasma sample and 1520 µl pre-chilled solvent mix 
(methanol/chloroform (4/1, v/v) was pipetted into the new Eppendorf tube containing the glass 
beads. Sample were then vortexed for five seconds, shaken for 15 minutes at 4°C and then kept 
at -20 °C for 20 minutes. Samples were then centrifuged at 14 000 rpm at 4°C for 5 minutes 
and kept at -80 °C until further analysis.  
 
8.2.8. Plasma Analysis 
See Chapter Four, General Methods, 4.9.  
 
8.2.9. Urine Treatment  
Vacutainer tubes were labelled with participant ID, phase, week and sample number. The first 
vacutainer tube from each participant was frozen for biobanking at -80°C. The duplicate 
vacutainer tube was centrifuged at 4000 g for 5 minutes at 4˚C. Three, 1 ml aliquots of 
supernatant were pipetted evenly into three separate Eppendorfs which represent each 
collection day (three Eppendorfs were filled to provide adequate sample quantities). From the 
remaining raw urine, a 200 µL aliquot was used to determine refractive index, measured using 
a handheld refractometer (see Chapter Four, General Methods, 4.8.).  
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Following sample preparation, extraction and adjustment (see Chapter Four, General Methods, 
4.8.), weekly and phase pools were created on ice. For weekly pools, 200 µL of sample from 
each of the three extracted spot urines collected per week was pipetted into a new 2 ml 
Eppendorf and vortexed to create a pooled sample representing weeks one, two and three of 
each phase. For phase pools (baseline, three- and six-months), 200 µl of sample from each of 
the three weekly pools was aliquoted into a new 2 ml Eppendorf and vortexed. Next, 20 µl of 
the sample was pipetted into the micro-insert of a HPLC glass vial and 80 µL 70:30 solution 
(methanol/water) added before the vial was crimped and vortexed. Pooled samples were stored 
at -20°C prior to analysis by FIE-HRMS and the remaining volume of weekly pools stored at 
-80°C. Modelling, classification and feature selection (see Chapter Four, General Methods, 
4.9.) was conducted on phase pools to determine differences in the urinary metabolome 
between baseline, three and six months.         
 
8.2.10. Physical Activity Analysis  
Data from ActiGraph were downloaded and analysed using ActiLife software (ActiLife, LLC, 
Pensacola, FL, USA). Data were filtered according to wear time diaries completed by the 
participant. Data recorded on the ActiGraph which did not correspond to reported wear time 
were not included in analysis. Ten second epoch3 length was selected for valid data. Variables 
including; kCal expenditure, time spent in light, moderate and vigorous exercise intensities and 
step counts were downloaded and saved in Excel format prior to statistical analysis.  
 
                                                          
3 Accelerometers function by integrating a filtered digitized acceleration signal over a user-specified time 
interval, referred to as an epoch. The usual accelerometer stored magnitude of accelerations at fixed recording 
intervals (1, 4, 15, or 60 seconds or longer) is called an “epoch”. At the end of each epoch, the some index of 




8.2.11. Statistical Analysis 
For all physiological, biochemical and questionnaire data a three by two mixed model ANOVA 
was conducted. Post hoc analysis used Welch’s t-test for group differences and Student’s t-test 
(parametric) and Wilcoxon’s test (non-parametric) were employed for post hoc time 
differences, with the Bonferroni correction. Additional analyses, using the same statistical tests 
as above, were conducted in participants categorised into the ‘pre-contemplation’ group. 
Significant findings for this group are reported and discussed where relevant.  For correlation 
analyses, parametric data were analysed using Pearson’s correlation and non-parametric data 
analysed by Spearman’s correlation. Parametric data are presented as mean ± standard 
deviation and non-parametric data presented as median (range). Statistical significance was 
accepted at P < 0.05. All data are presented in tables, where statistically significant findings 

















Eighty-eight patients were invited to take part in the study by letter from Church Surgery, 23 
of whom (26%) volunteered to take part and completed a baseline visit to the WARU. Twelve 
participants were randomised into the intervention group. Nineteen participants (83%), 13 
females and six males (age 65 ± 9 years) completed all visits and were included in analysis, 
Figure 8.1. There were no significant differences between groups at baseline except for fat 
percentage (INT 37.1 ± 33.6%, CON 45.4 ± 45.7%, P = 0.02) and hip circumference (INT 106 
± 104 cm, CON 118 ± 122 cm, P = 0.04).  
 
 
Figure 8.1. Participant recruitment, randomisation, retention and analysis.  
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8.3.2. Personal Diabetes Questionnaire  
Following initial contact regarding T2D risk (and prior to randomisation), 12 participants (six 
INT / six CON) indicated they had started to act to achieve weight loss, three (two INT / one 
CON) indicated they were preparing to act, while four (three INT / one CON) were in the pre-
contemplation phase and not considering weight loss. Eight (four INT / four CON) participants 
indicated they had begun to act to change their dietary behaviours, four (two INT / two CON) 
were preparing to make changes to their dietary behaviours, one (INT) was in the 
contemplation phase while six (four INT / two CON) were categorised in the pre-contemplation 
phase. Participants in INT scored lower for barriers to dietary change (12 ± 7 arbitrary units) 
compared to CON (14 ± 4 arbitrary units) although the difference was not statistically 
significant (P = 0.47). Similarly, INT participants scored lower for barriers to exercise (12 ± 4 
arbitrary units) compared to CON participants (13 ± 4 arbitrary units) although the difference 
was not significant (P = 0.88).  
 
8.3.3. HbA1c 
HbA1c decreased significantly between baseline and six months (P = 0.01) and three months 
and six months (P = 0.01) irrespective of treatment group (P = 0.89) despite no initial change 
between baseline and three months (P = 0.84), Figure 8.2. HbA1c did not change in pre-





Figure 8.2. HbA1c at baseline, three and six months following a 15-minute one-to-one 
consultation with a health care professional in a primary care setting (INT) or standard care 
(CON). * Significantly different (P < 0.05) from baseline. # Significant difference between 



























Table 8.1. HbA1c, Total, LDL and HDL Cholesterol and Triglycerides at baseline, three and six months following a 15-minute one-to-one 
consultation with a health care professional in a primary care setting (INT) or standard care (CON). Parametric data represented as mean ± 













Treatment Group INT CON INT CON INT CON INT CON INT CON 
Baseline 40 ± 1.9 41± 2 5.3 ± 0.9 5.1 ± 1.1 2.7 ± 0.9 2.7 ± 0.7 1.5 (1.4) 1.4 (0.8) 1.8 ± 0.8 1.7 ± 0.6 
3 Months 40 ± 2.3 41 ± 2 5.1 ± 1.1 5.4 ± 0.8 2.8 ± 1.0 2.9 ± 0.4 1.5 (1.4) 1.7 (1.0) 1.5 ± 0.8 2.0 ± 0.8 
6 Months 38 ± 3.0 40 ± 2.3 5.2 ± 1.2 5.4 ± 1.0 2.9 ± 0.9 3.0 ± 0.7 1.4 (1.3) 1.6 (0.9) 1.5 ± 0.7 1.8 ± 0.4 
Treatment Effect 
(P value) 
0.89 0.03* 0.53 0.19 0.11 
Time Effect  
(P value) 
0.02* 0.19 0.03* 0.87 0.68 
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Table 8.2. Body Mass, BMI, Hip and Waist Circumference, Fat and Muscle%, Systolic and Diastolic BP at baseline, three and six months 
following a 15-minute one-to-one consultation with a health care professional in a primary care setting (INT) or standard care (CON). 
Parametric data represented as mean ± standard deviation. Non-parametric data represented as median (range). Statistical significance * is 
accepted at P < 0.05. 


















Treatment Group INT CON INT CON INT CON INT CON INT CON INT CON INT CON INT CON 
































































6 Months 77.6 ±  
14.3 
85.2 ± 































0.71 0.51 0.81 0.82 0.32 0.38 0.09 0.48 
Time Effect  
(P value) 
0.06 0.06 > 0.00* 0.03* 0.55 0.09 0.10 0.99 
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8.3.4. Biochemical and Anthropometric Outcomes  
Total cholesterol increased significantly more in CON compared to INT (P = 0.03). In CON, 
total cholesterol increased from baseline to three months (P = 0.04), baseline to six months (P 
= 0.02) and remained similar between three and six months (P = 0.77). Total cholesterol 
remained similar in INT throughout (P > 0.05) and in pre-contemplation participants (P = 0.89). 
LDL cholesterol increased significantly between baseline and six months (P = 0.02) with no 
difference in treatment group (P = 0.53) although remained unchanged in the pre-
contemplation group (P = 0.76). HDL cholesterol and triglycerides remained similar over time 
across both groups (P > 0.05; Table 8.1 and Figures 8.4 and 8.5) and in the pre-contemplation 
group (P = 0.20).    
Hip circumference decreased similarly in both groups (P < 0.05) irrespective of treatment, 
decreasing from baseline to three months (P = 0.00), baseline to six months (P = 0.00) and 
remaining similar between three and six months (P = 0.40). A significant decrease was also 
observed in the pre-contemplation group (P = 0.01). Waist circumference changed significantly 
over time but was unaffected by treatment. Values decreased from baseline to three months (P 
= 0.02), baseline to six months (P = 0.02) and unchanged between three and six months (P = 
0.33). Decreases in waist circumference in the pre-contemplation group did not reach statistical 
significance (P = 0.07) Body mass, BMI, systolic and diastolic BP and fat remained similar 
across treatment and time (P > 0.05; Table 8.2 and Figures 8.6 and 8.7). Muscle percentage 
remained similar across treatment and time when all participants were analysed together (P < 






Figure 8.3. Total cholesterol at baseline, three and six months following a 15-minute one-to-
one consultation with a health care professional in a primary care setting (INT) or standard care 
(CON). *Significantly different (P < 0.05) from baseline. # Significant difference between 
treatments. Data are represented as mean ± standard deviation. 
 
Figure 8.4. LDL cholesterol at baseline, three and six months following a 15-minute one-to-
one consultation with a health care professional in a primary care setting (INT) or standard care 
(CON). * Significantly different (P < 0.05) from baseline. # Significant difference between 
treatments. Data are represented as mean ± standard deviation. 
 
 


















































Figure 8.5. Waist circumference at baseline, three and six months following a 15-minute one-
to-one consultation with a health care professional in a primary care setting (INT) or standard 
care (CON). * Significantly different (P < 0.05) from baseline. # Significant difference between 
treatments. Data are represented as median (range). 
 
Figure 8.6. Hip circumference at baseline, three and six months following a 15-minute one-to-
one consultation with a health care professional in a primary care setting (INT) or standard care 
(CON). * Significantly different (P < 0.05) from baseline. # Significant difference between 




























































Table 8.3. Correlation coefficients for change in HbA1c and changes in Body Mass, BMI and 
Waist Circumference between baseline and six months following a 15-minute one-to-one 
consultation with a health care professional in a primary care setting (INT) or standard care 
(CON). 1 Pearson’s Correlation Test; 2 Spearman’s Correlation Test. Statistical significance* 
is accepted at P < 0.05. 
 
Change in Body Mass / Change in HbA1c 
 
 




Change in BMI / Change in HbA1c 
 
 




Change in Waist Circumference / Change in HbA1c  
 





8.3.5. Baseline to Six Months Correlation Analysis 
Significant correlations were found for changes in HbA1c and changes in body mass (r = 0.60, 
P = 0.00) and changes in BMI (r = 0.67, P = 0.00) between baseline and six months. No 
significant correlation was identified between change in waist circumference and change in 










Figure 8.7. Correlation of weight change and HbA1c change between baseline and six months 
following a 15-minute one-to-one consultation with a health care professional in a primary care 





Figure 8.8. Correlation of BMI change and HbA1c change between baseline and six months 
following a 15-minute one-to-one consultation with a health care professional in a primary care 






















































Table 8.4. Effects of treatment and time on urinary biomarkers of dietary intake following a 
15-minute one-to-one consultation with a health care professional in a primary care setting 
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Dihydrocaffeic acid Cocoa  
 
0.13 0.14 

















Ferulic acid-4-O-sulfate Coffee, 
polyphenol-















Isoferulic acid Coffee, 
polyphenol-
rich foods  
 
0.43 0.94 








































































p-Cresol Glucuronide Protein 
 
0.76 0.35 
1-Methyl histidine Poultry 
 
0.58 0.58 
2,3-Dihydroxyphenylpropionic acid-3-sulfate Wholegrain 
 
0.35 0.54 
3-Methyl histidine Poultry 
 
0.61 0.72 



















Calystegine A3 Potatoes 
 
0.39 0.47 




























































































Table 8.5. Dietary biomarker concentrations (mmol/L) of metabolites which exhibited 
significant differences between groups, changes over time or both (see Table 8.4.) Parametric 


























































INT CON INT CON 
Baseline 
 
3.85798 ±  
1.86808 








3.80716 ±  
1.50185 








2.48414 ±  
0.88638 











Table 8.6A. Mean fold change in the concentration of 4-Hydroxyhippuric acid, Ferulic acid-
4-O-sulfate and Hippuric acid (where treatment had no effect) between baseline, three and six 
months following a 15-minute one-to-one consultation with a health care professional in a 
primary care setting (INT) or standard care (CON).  
4-Hydroxyhippuric Acid  Mean Fold Change 
Baseline to 3 Months -1.16 
Baseline to 6 Months 
3 Months to 6 Months  
-1.61 
-1.32 
Ferulic acid-4-O-sulfate  
Baseline to 3 Months 
Baseline to 6 Months 




Hippuric Acid   
Baseline to 3 Months 
Baseline to 6 Months 






Table 8.6B. Mean fold change in the concentration of Caffeic acid and Taurine (where 
treatment had an effect) between baseline, three and six months following a 15-minute one-to-
one consultation with a health care professional in a primary care setting (INT) or standard care 
(CON). 
Caffeic Acid  Mean Fold Change 
Intervention  
Baseline to 3 Months 
Baseline to 6 Months 





Baseline to 3 Months 
Baseline to 6 Months 







Baseline to 3 Months 
Baseline to 6 Months 





Baseline to 3 Months 
Baseline to 6 Months 








Table 8.7. Dietary biomarker concentrations (mmol/L) of metabolites which exhibited 







































































Table 8.8. Mean fold change in the concentration of 4-Hydroxyhippuric acid, 
Dehydroxybenzoic Acid, Ferulic acid, Hippuric acid and Trans-3-Hydroxycotinine in pre-
contemplation participants between baseline, three and six months. 
4-Hydroxyhippuric Acid  Mean Fold Change 
Baseline to 3 Months 
Baseline to 6 Months 




Dehydroxybenzoic Acid-35  
Baseline to 3 Months 
Baseline to 6 Months 




Ferulic Acid    
Baseline to 3 Months 
Baseline to 6 Months 




Hippuric Acid   
Baseline to 3 Months 
Baseline to 6 Months 





Baseline to 3 Months 
Baseline to 6 Months 















Table 8.9. Correlation coefficients for change in HbA1c and changes in the concentration of 4-
Hydroxyhippuric acid, Caffeic acid, Ferulic acid-4-O-sulfate, Hippuric acid and Taurine 
between baseline and six months following a 15-minute one-to-one consultation with a health 
care professional in a primary care setting (INT) or standard care (CON). 1 Pearson’s 
Correlation Test; 2 Spearman’s Correlation Test. Statistical significance* is accepted at P < 
0.05. 
Change in 4-Hydroxyhippuric Acid / Change in HbA1c   
Correlation Coefficient -0.151 
Significance  0.55 
Change in Caffeic Acid / Change in HbA1c   
Correlation Coefficient -0.411 
Significance  -0.10 
Change in Ferulic acid-4-O-sulfate / Change in HbA1c   
Correlation Coefficient  0.172 
Significance  0.49 
Change in Hippuric Acid / Change in HbA1c   
Correlation Coefficient  -0.431 
Significance  0.07 
Change in Taurine / Change in HbA1c   
Correlation Coefficient  -0.012 
Significance  0.94 
 
8.3.6. Urine Dietary Biomarkers  
Quantified values were available for 73 urinary metabolites at baseline, three months and six 
months (Tables 8.4 and 8.5) and fold changes displayed in Tables 8.6A/B. Complete urine 
profiles from all phases were completed by 15 participants and included in analysis (nine INT, 
six CON). Of the 73 biomarkers identified, five metabolites exhibited significant differences 
either by treatment, time or both. 4-Hydroxyhippuric acid concentration, a biomarker of fruit 
and vegetable intake, decreased from baseline to six months (P = 0.02) and three months and 
six months (P = 0.01) irrespective of treatment (P = 0.51). Concentration of caffeic acid, 
another biomarker of fruit and vegetable intake, was significantly different between treatments 
after three months (P = 0.02) with both treatments demonstrating decreases in concentration 
between baseline and six months (P = 0.01) with the values similar at six months between both 
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treatments (P = 0.92). Excretion of ferulic acid-4-O-sulfate, a biomarker representative of 
polyphenol-rich foods, such as coffee, wine, tomatoes, beer, breakfast cereals, apple 
wholegrain, cocoa, dried fruit, berries, remained similar between treatments (P = 0.49) but 
changed significantly over time (P = 0.03) with concentration decreasing overall between 
baseline and six months (P = 0.01) and three months and six months (P = 0.03). Similarly, 
hippuric acid, another biomarker of fruit and vegetable consumption, remained similar between 
treatments (P = 0.35) but decreased significantly overall between baseline and six months (P 
= 0.00) and three months and six months (P = 0.02). Lastly, but in similar fashion, 
concentration of taurine, a biomarker for striated muscle meat was significantly different 
between treatment (P = 0.03) and decreased significantly over time (P = 0.03). Post hoc testing 
for taurine did not provide conclusive results for pairwise differences. No correlations were 
found between the change in concentration of 4-Hydroxyhippuric acid, Caffeic acid, Ferulic 
acid-4-O-sulfate, Hippuric acid and Taurine and change in HbA1c between baseline and six 
months (Table 8.9). Concentrations of 4-hydroxyhippuric acid and hippuric acid also decreased 
in pre-contemplation participants (P < 0.05). In addition, decreases were also observed 
dehydroxybenzoic acid (P = 0.01; fruit and vegetable intake), ferulic acid (P = 0.00; polyphenol 




Table 8.10. RF classification margins for participant’s urine in intervention and control groups 
between baseline and three months, baseline and six months and three months and six months.  
Participant M0-M3 M0-M6 M3-M6 
Intervention 
 03 0.195 0.207 0.298 
 06 0.039 0.169 0.125 
 07 0.233 0.333 0.094 
 08 0.201 0.281 0.092 
11 0.018 0.094 0.108 
12 0.13 0.187 0.273 
18 0.24 0.246 0.094 
19 0.233 0.234 0.16 
 22 0.245 0.298 0.137 
Control 
01 0.311 0.23 0.292 
02 0.02 0.208 0.157 
 05 0.1 0.305 0.224 
09 0.104 0.113 0.135 
 16 0.257 0.219 0.457 
23 0.223 0.18 0.179 
 
8.3.7. FIE-MS Urine  
Metabolome fingerprints were created by non-targeted FIE-HRMS to determine the chemical 
composition of urines between phases using random forest classification (Table 8.10). Fifteen 
participants provided urine samples across all phases which were included in analysis. Of the 
45 RF margins displayed in Table 8.10, four met the 0.3 RF margin threshold used previously 
in this thesis and in other previous work (Enot et al., 2008), demonstrating acceptable class 
discrimination in the urinary metabolome which may be suggestive of a change in dietary 
behaviour between phases. Analysis of RF margins by Kruskal-Wallis test revealed no 
significant treatment effect between intervention and control at any phase (P > 0.05). From the 
four participants where RF margins suggest a possible change in dietary behaviour, three were 
part of the control group and one was part of the intervention group, demonstrating the 
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intervention to have no effect on dietary behaviour in the context of the urinary metabolome, 
compared to control. To determine if the degree of urine metabolome change by RF margin at 
each phase was associated with change in HbA1c, correlations were conducted. Pearson’s 
correlation revealed no significant relationship between urine metabolome change and HbA1c 
change between either baseline and 3 months (r = -0.12, P = 0.65) or baseline and six months 
(r = 0.10, P = 0.71). Similarly, Spearman’s correlation found no relationship between urine 
metabolome change and HbA1c change between three and six months (r = 0.12, P = 0.65). 
Given no changes were found in HbA1c values in pre-contemplation participants, no correlation 
analysis was conducted.  
 
Table 8.11. RF classification margins for plasma in intervention and control groups between 
baseline and three months, baseline and six months and three months and six months.  
 









 Control  





8.3.8. FIE-HRMS Plasma 
Following non-targeted FIE-MS, random forest classification margins clearly demonstrate no 
distinct class separation in plasma metabolome profiles between any phase (Table 8.11). 
Kruskal-Wallis analysis revealed no difference in RF margins between treatments at any phase 
(P > 0.05) suggesting the intervention had no effect on dietary behaviour in the context of the 
plasma metabolome, compared to control. Given RF classification margins for plasma between 
phases were significantly below the 0.3 threshold margin considered satisfactory in 
discriminating between biological samples, no feature selection of discriminatory signals was 








Table 8.12.  AHEI scores from FFQ responses at baseline and six months following a 15-minute one-to-one consultation with a health care 
professional in a primary care setting (INT) or standard care (CON). 1-vegetables, 2-fruit, 3-wholegrains, 4-sugar-sweetened beverages, 5-nuts, 
legumes, and vegetable protein, 6-red meat and processed meat, 7-trans-fats, 8-fish: 9-polyunsaturated fats, 10-sodium, 11-alcohol. Data are 









5.7 3.4 6.5 2.6 4.5 5.3 3.5 5.5 10.0 9.1 63.8 8.3 6.4 2.1 5.5 4.5 6.3 4.5 3.3 6.2 10.0 8.8 66.0 
SD 2.1 
 
2.4 2.4 3.4 3.3 2.6 2.7 1.2 3.2 0.0 1.0 9.4 1.9 2.8 2.1 4.5 3.5 3.3 1.2 2.4 3.2 0.0 1.0 7.5 
 Intervention 
Mean  8.3 
 
6.3 2.5 5.0 5.2 4.0 5.4 5.2 3.5 10.0 9.3 64.6 8.2 5.9 1.9 4.9 4.7 4.8 5.7 4.7 5.1 10.0 9.3 65.1 
SD 1.7 
 
3.2 1.9 4.2 3.8 2.7 2.5 1.9 2.6 0.0 1.1 11.7 2.2 3.4 1.1 4.8 3.0 2.8 2.7 2.4 2.9 0.0 0.9 12.3 
220 
 
8.3.9. Food Frequency Questionnaire 
At baseline, a Kruskal-Wallis test demonstrated intakes of trans-fats to be significantly 
different between INT and CON (P = 0.03). In CON, participants mean score was 3.4 arbitrary 
units whereas in INT, the mean score was 5.2 arbitrary units, demonstrating participants in INT 
reported more favourable intakes of trans-fat. After six months, there was no significant 
difference for trans-fat intake scores between groups. Analysis of the remaining components 
of the FFQ using the AHEI scoring method demonstrated no differences between groups at 
baseline or six months (P > 0.05). When changes between baseline and six months were 
examined as a collective group, paired t-tests revealed significant difference in scores for both 
intake of wholegrains (P = 0.00) and red and processed meat (P = 0.03). For wholegrain intake, 
the mean score decreased from 2.8 ± 2.0 to 2.0 ± 1.5 arbitrary units while scores for red and 
processed meat increased from 4.1 ± 2.5 to 5.3 ± 3.0 arbitrary units. The remaining dietary 
component scores remained similar between baseline and six months (P > 0.05), Table 8.12. 







Table 8.13. kCal expenditure, time spent in light, moderate and vigorous exercise intensities and step counts recorded by ActiGraph at baseline, 
three and six months following a 15-minute one-to-one consultation with a health care professional in a primary care setting (INT) or standard 
care (CON). Parametric data represented as mean ± standard deviation. Non-parametric data represented as median (range). Statistical 





 kCal Light (mins) Moderate (mins) Vigorous (mins) Step Count 
Treatment Group INT CON INT CON INT CON INT CON INT CON 
Baseline 460 ± 150 
 
323 ± 117 
 




40 ± 19 
 






5862 (9693) 4568 (3971) 
3 Months 426 ± 128 
 
289 ± 88 201 ± 57  
 
151 ± 49 
 
38 ± 16 
 




(0) 5527 (8391) 3524 (2771) 
6 Months 491 ± 282 
 
305 ± 122 
 
237 ± 68 
 
165 ± 49 
 
43 ± 27 
 






5911 (7262) 3913 (3133) 
Treatment Effect (P =) 0.76 0.48 0.78 0.60 0.79 
Time Effect (P =) 0.60 0.29 0.79 0.04* 0.71 
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8.3.10. Physical Activity Outcomes from ActiGraph   
A seven-day average for daily; calorie expenditure, time spent in light, moderate and vigorous 
physical activity domains and step counts (Table 8.13) were calculated for each participant 
after baseline, three- month and six-month ActiGraph use. There were no significant 
differences between kCal expenditure or time spent in light and moderate exercise intensities 
between INT and CON or between baseline, three and six months (P > 0.05). Analysis 
demonstrated time spent undertaking vigorous exercise increased significantly over time 
between baseline and six months (P = 0.04) although the was no difference between treatments 
(P > 0.05). A significant difference was found in step counts between treatments after three 
months (P = 0.04) although no time differences were found between baseline, three and six 
months (P > 0.05). Correlation analysis between changes in HbA1c and changes in recorded 
physical activity including kCal expenditure, light, moderate, vigorous and steps counts 
between time points revealed no significant associations (P > 0.05).  No significant differences 




Figure 8.9. Average step counts at baseline, three and six months following a 15-minute one-
to-one consultation with a health care professional in a primary care setting (INT) or standard 
care (CON). * Significantly different (P < 0.05) from baseline. # Significant difference between 
treatments. Data are represented as median (range). 
5862 5527





















Table 8.14. Weekly walking, moderate, vigorous and total physical activity in met minutes reported in the IPAQ at baseline, three and six months 
following a 15-minute one-to-one consultation with a health care professional in a primary care setting (INT) or standard care (CON). Data are 





 Walking (met mins) Moderate (met mins) Vigorous (met mins) Total (met mins) 
Treatment Group INT CON INT CON INT CON INT CON 
















































Treatment Effect (P =) 0.23 0.25 0.35 0.31 
Time Effect (P =) 
 
0.03* 0.85 0.40 0.28 
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8.3.11. IPAQ-SF Questionnaire  
Moderate and vigorous physical activity and total physical activity (Table 8.14) were similar 
in INT and CON between baseline, three and six months and did not change significantly over 
time (P > 0.05).  Reported weekly met minutes for walking decreased significantly over time 
in both groups (P = 0.03), Figure 8.10. Values reported by pre-contemplation participants 




Figure 8.10. Walking met minutes at baseline, three and six months following a 15-minute 
one-to-one consultation with a health care professional in a primary care setting (INT) or 
standard care (CON). * Significantly different (P < 0.05) from baseline. # Significant 





























Table 8.15A. Physical functioning, role limitations due to physical health, role limitations due to emotional problems and energy/fatigue (a score 
of 100 represents the highest level of functioning) at baseline, three and six months following a 15-minute one to one consultation with a health 
care professional in a primary care setting (INT) or standard care (CON).  Data are represented as median (range). Statistical significance* is 







 Physical functioning Role limitations due to physical 
health 
Role limitations due to 
emotional problems  
Energy/Fatigue 
Treatment Group INT CON INT CON INT CON INT CON 











































Treatment Effect (P =) 0.20 0.19 0.20 0.20 
Time Effect (P =) 
 
0.20 0.19 0.20 0.20 
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Table 8.15B. Emotional wellbeing, social functioning, pain and general health (a score of 100 represents the highest level of functioning) at 
baseline, three and six months following a 15 minute one-to one consultation with a health care professional in a primary care setting (INT) or 
standard care (CON).  Data are represented as median (range). Statistical significance* is accepted at P < 0.05. 
 Emotional wellbeing  Social functioning Pain General health 
Treatment Group INT CON INT CON INT CON INT CON 















































Treatment Effect (P =) 0.20 0.20 0.20 0.20 
Time Effect (P =) 
 
 
0.20 0.20 0.20 0.20 
 
8.3.12. SF36 Questionnaire 
Scores for physical functioning, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional 
wellbeing, social functioning, pain and general health (Table 8.15A and 8.15B) were similar in INT, CON and pre-contemplation participants 
between baseline, three and six months and did not change between time points (P > 0.05)
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Table 8.16A. Study feedback responses (%) for recruitment and data collection from 19 participants.   
Recruitment Strongly  
Disagree 
Disagree Neither agree 
or disagree 
Agree Strongly  
Agree 
 













The information I received in the post about pre-diabetes was useful and informative 
 
0% 0% 5% 74% 21% 
The information I received in the post about the study was clear, useful and understandable 0% 0% 0% 63% 37% 
Contacting the research team and becoming a participant was simple and straight forward 
      
0% 0% 0% 47% 53% 
The research team explained the study clearly and I understood my role as a participant 
from the outset   
     
0% 0% 0% 21% 79% 
Data Collection      
 












I was happy for the research team to record my physical data 
 
0% 0% 0% 26% 74% 
I was happy to provide a blood sample as part of the data collection process 
 
0% 0% 0% 32% 68% 
I was happy to complete the questionnaires at the end of each visit     0% 0% 0% 32% 68% 




Table 8.16B. Study feedback responses (%) for urine collection from 19 participants.   
Urine Collection Strongly  
Disagree 
Disagree Neither agree 
or disagree 
Agree Strongly  
Agree 
 












It was easy to collect urine in the pot       
 
0% 5% 0% 58% 37% 
I was confident collecting urine in the pot       
 
0% 5% 0% 53% 42% 
It was easy to transfer urine from the pot into the sample tube using the transfer straw   
 
0% 5% 5% 48% 42% 
I felt confident transferring urine from the pot into the sample tube using the transfer 
straw  
     
0% 0% 5% 53% 42% 
I was happy to write the collection date and time on the sample tube     
 
0% 5% 5% 37% 53% 
In general, I think collecting a urine sample is difficult       
 
32% 53% 5% 5% 0% 
I think collecting a urine sample in a home environment is embarrassing     
 
53% 42% 5% 0% 0% 
I was happy to store several urine samples collected over a week in a small box in my 
fridge 
 
0% 5% 5% 53% 37% 
Returning my urine samples to the research team was easy and arranged at a time 
convenient for me  
      




Table 8.16C. Study feedback responses (%) for the 15-minute consultation from 11 participants and physical activity recording from 16 
participants.   
15 Minute Consultation Strongly  
Disagree 
Disagree Neither agree 
or disagree 
Agree Strongly  
Agree 
 
I was pleased to be told I would be receiving a 15-minute consultation from my GP  











Booking a 15-minute consultation with my surgery was simple and straightforward  
     
0% 0% 0% 64% 36% 
The consultation provided me with useful information about my diabetes risk and ways I 
can improve my lifestyle  
      
0% 0% 9% 36% 55% 
Since attending the 15-minute consultation I have improved my health through increased 
exercise and better dietary habits  
      
0% 9% 45% 9% 36% 
Physical Activity Recording      
 
I was happy to be asked to record my levels of physical activity using the ActiGraph 











Recording my levels of physical activity using the ActiGraph was easy     0% 6% 6% 69% 19% 
Wearing the ActiGraph did not interfere with my daily tasks and routines    0% 6% 6% 56% 31% 
Recording the times I wore the ActiGraph was easy    0% 0% 19% 50% 31% 
I was more physically active in the weeks I wore the ActiGraph compared to the weeks I 
did not     
0% 31% 63% 6% 0% 
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8.3.13 Feedback Questionnaire 
Feedback responses from 19 participants are detailed in Table 8.16A/B/C. Responses for 
recruitment and data collection procedures (Table 8.16A) produced no negative responses. 
Participants either agreed or strongly agreed to each question asked demonstrating acceptability 
from 100% of respondents. For questions relating to urine collection procedures (Table 8.16B), 
only 5% of participants provided negative responses while 5% neither agreed or disagreed with 
the questions asked. From the participants who attended a consultation (Table 8.16C), no 
negative responses were given to three out of four questions, although 9% of participants 
indicated they hadn’t made positive changes to their levels of physical activity or dietary habits 
while a further 45% of participants neither agreed or disagreed in their response. Only 6% of 
participants provided negative responses in relation to ActiGraph use (Table 8.16C) while 
another 6% neither agreed nor disagreed to ActiGraph related questions. 31% of participants 
indicated they were not more physically active while wearing the ActiGraph while 63% neither 
agreed or disagreed, demonstrating the use of wearable technology to monitor exercise did not 











The primary aim of this study was to determine the feasibility of conducting a randomised 
control trial in primary care targeting lifestyle modification in patients at increased risk of T2D. 
Feasibility was based upon participant uptake, retention and acceptability. Secondary aims of 
the work were to determine the impact of the GP-led one-to-one lifestyle consultation on 
participant biochemistry and anthropometry, dietary intake and physical activity, compared to 
current standard care.  
 
In Chapter two, a GP-led 30-minute one-to-one consultation targeting lifestyle modification in 
patients at risk of T2D resulted in statistically significant decreases in HbA1c and other health 
outcomes associated with the condition. However, the design of the intervention did not include 
a control group, and as such, direct comparisons with usual care were not possible. Patients in 
the initial study received written information regarding their T2D risk and ways to improve 
lifestyle behaviours. Additionally, all patients had the opportunity to attend a 30-minute one-
to-one consultation with a healthcare professional to discuss T2D risks and preventative 
healthy lifestyle behaviours. It is possible the initial literature given to patients provided the 
appropriate stimulus to initiate behaviour change and subsequently improve HbA1c values, as 
well as other T2D related outcomes and suggests a one to one consultation may not provide 
additional benefit. Therefore, a randomised control trial was implemented to examine the 
effects of the GP-led one-to-one lifestyle consultation in comparison to standard practice in 
Wales, which is currently written advice only.  Due to the complexity and logistical challenges 
associated with conducting an RCT within primary care, the feasibility of initiating such a 
design within a smaller cohort of patients was thought prudent prior to a larger study being 




Eighty-eight patients were invited to take part in the study in a letter sent by Church Surgery. 
The patients invited to take part were newly screened for HbA1c and were not involved in the 
previous study detailed in Chapter two. Of the patients initially invited, 23 volunteered to take 
part and successfully completed a baseline visit, this represented 26% of the initially invited 
cohort. 19 participants, 83% of those who completed an initial visit completed all remaining 
visits and suggests once participants were enrolled in the research, retention was high. Uptake 
and retention figures for this study compare similarly with other published work examining 
T2D prevention. In a similar primary care-based study targeting pre-diabetes, work by Dawes 
et al. (2014) demonstrated a 33% study uptake and 95% retention rate over six months in a 
group of 180 eligible patients, of which 59 made an appointment for a baseline visit. In other 
work, a randomised clinical trial examining the effects of resistance exercise in adults with pre-
diabetes demonstrated an overall retention rate of 76% across a 15-month period (Davy et al., 
2017).  
 
From the four participants lost to follow up in this study, one was randomized into the intervention 
group and three randomized to control. Despite polite attempts made to establish reasons for 
withdrawal for the purposes of acceptability, it was not possible to ascertain reasons why 
participants were lost to follow up. While it is possible participants withdrew due to their 
allocation into the control group, participants randomized to control provided positive feedback 
regarding their involvement in the research. In one case, a participant commented in their feedback 
their initial concern regarding their allocation to control, fearing an adverse effect to their health 
due to perceived loss of treatment benefit from non-allocation into the intervention group. 
However, they felt they had benefited from their participation in the study and suggested the three-
monthly visits to the research facility had a beneficial impact on their overall health and healthy 
lifestyle behaviors. This may suggest, albeit speculatively, that regular health monitoring, either 
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within academic or clinical environments, may prove beneficial for some patients in improving 
healthy behaviors and health outcomes without the need for additional meetings with trained 
health professionals who provide consultations specific to T2D prevention. The data provides 
some support for this notion which demonstrate values for HbA1c (Table 8.1), hip and waist 
circumference decreased significantly over time, regardless of treatment allocation, while 
decreases in body mass in both groups also approached statistical significance (Table 8.2). These 
significant decreases may also be considered clinically relevant given the extent of change within 
the six month data collection period, the acceptability of the intervention, and ease of the 
intervention implementation. In many other cases, there were no significant differences in T2D 
related variables across treatment or time suggesting the effect of the consultation was relatively 
minor when compared to standard written advice. Similarly, results from the SF-36 questionnaire, 
which provides an indication of perceived health, indicated values to be similar between 
treatments and over time for all health categories. Of all biochemical, anthropometric, dietary and 
physical activity variables measured, only total cholesterol and intakes of caffeic acid and taurine 
(urinary biomarkers of fruit and vegetables and striated muscle meat, respectively) varied 
significantly between treatments. Total cholesterol decreased in intervention participants by 0.1 
mmol/L and increased in control participants by 0.3 mmol/L. Caffeic acid and taurine 
concentrations decreased in both treatments however the decreases were more pronounced in 
control subjects. In participants categorized into the ‘pre-contemplation’ category of behavior 
change, fewer changes were identified. Values for hip circumference demonstrated a significant 
decrease similarly to the cohort as a whole. Interestingly, percentage muscle also decreased in this 
group suggesting that for those whose behaviours and lifestyle remain unchanged following initial 
intervention, adverse health consequences may follow. This is in contrast to the cohort as a whole 
where muscle percentage remained similar throughout the study. Specific focus therefore needs 
to be given to those categorized into the pre-contemplation group as this study’s data shows fewer 
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positive health changes are achieved in these individuals.   
 
Feedback from participants at the end of the study demonstrated the RCT to be an acceptable 
method for determining the effectiveness of the consultation in combatting T2D. Questions 
relating to participant recruitment and data collection procedures produced no negative responses, 
suggesting these elements of the RCT were wholly acceptable to those taking part. Responses to 
questions relating to the urine collection procedures were positive overall with only 5% of 
participants reporting they found the procedures for collecting, storing and returning urine samples 
to be difficult and suggests this procedure for dietary monitoring can acceptably be tested in a 
larger sample. Similarly, use of the ActiGraph for physical activity monitoring was reported as 
being both easy to use without causing inconvenience to daily life by an overwhelming majority 
of respondents, with only 6% providing disagreeable responses. Again, this suggests this would 
be an acceptable method of physical activity tracking if a larger sample size was used in a future 
RCT. Significantly, when participants were questioned about the 15-minute consultation, all but 
two participants indicated they were pleased to be receiving the consultation while 100% either 
agreed or strongly agreed that booking their consultation was simple and straightforward. Of 
interest, while 91% of participants agreed the consultation provided them with useful information 
about their diabetes risk and ways they can improve their lifestyle, only 45% of participants 
suggested they had improved their lifestyle as a result of attending the consultation, while 55% 
either disagreed or neither agreed or disagreed. This provides some support for the notion that the 
consultation had no additional benefit in combating T2D and suggests in this group of participants, 
the initial written information may have been enough of a stimulus to instigate lifestyle changes. 
Responses provided in the Personal Diabetes Questionnaire which was completed after receipt of 
the written information but prior to the consultations supports this. Twelve participants indicated 
they had actively started to try and achieve weight loss while three were preparing to act. Similarly, 
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eight participants indicated they had taken steps to change their dietary behaviour while another 
four were preparing. This suggests the initial literature detailing T2D and its associated risks was 
largely effective at initiating a change in behaviour associated to the disease prior to contact with 
a health professional. In participants categorised as ‘pre-contemplation’, fewer health enhancing 
changes in the measured variables were found.       
 
Small but statistically significant decreases in outcomes associated to T2D across both 
intervention and control groups suggests, in this cohort, that written advice outlining T2D risk and 
preventative healthy behaviors, is as effective as a GP-led one-to-one consultation delivered by a 
trained healthcare professional. As highlighted above, it may be possible that written advice 
accompanied by regular health monitoring is beneficial in limiting T2D risk and therefore, the 
need for an additional consultation is possibly unwarranted, however, the sample size was small 
and testing on a larger cohort is warranted for greater statistical power. Based on the data, 
providing patients who are identified as at increased risk of T2D with written information on T2D 
risk and strategies for improving health, coupled with three or six monthly health monitoring 
protocols may prove successful in managing HbA1c and other T2D related outcomes as 
participants may feel motivated to maintain their health by the prospect of being followed up in a 
healthcare environment, either clinical or academic. This suggestion is also proposed in a previous 
study by Vermunt et al. (2012) which found intervention participants who received eleven 20-
minute consultations focussing on behaviour change, five group meetings addressing diet and 
physical activity and an additional one-hour consultation with a dietician, demonstrated no 
significant changes in body weight, blood glucose concentration, physical activity and dietary 
intake in comparison to control participants who received only written T2D advice. The authors 
suggested a possible explanation may be due to control participants becoming motivated to 
change behaviour by the prospect of check-up visits with a health care professional. Currently 
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in Wales, patients identified as at increased risk of T2D are followed up in primary care annually 
to monitor changes in blood glucose status. As opposed to current practice, bi-annual or quarterly 
appointments at primary care level may provide the necessary contact time to initiate and maintain 
decreases in factors relating to T2D risk. While increased patient contact comes with increased 
financial requirements, the costs of preventing manifest T2D is outweighed by the financial 
burden of treating diagnosed T2D and its well-established complications, where current estimates 
suggest annual treatment costs in Wales are currently £500 million (Diabetes UK, State of the 
Nation, 2015). Previous work suggests lifestyle intervention is cost effective in comparison to 
pharmacological-only approaches, such as metformin, and can delay and/or prevent the onset of 
T2D (Herman et al., 2009). Future work therefore may examine the effects of written T2D advice 
with a form of additional health monitoring or follow up compared to written advice only with 
annual primary care HbA1c measurement (current practice).  
 
A limitation identified in Chapter two was the lack of effective physical activity and dietary 
monitoring following lifestyle intervention in patients at risk of T2D. In Chapter two participants, 
many decreases in HbA1c were associated with decreases in body mass, BMI and waist 
circumference in individual surgeries as well as combined surgery data. Similarly, in the present 
study, reduction in HbA1c correlated positively with decreases in both body mass and BMI. This 
has also been demonstrated in recent work by Lean et al. (2017) which found significant weight 
loss was strongly associated with rates of T2D remission.  However, in Chapter two, HbA1c 
decreases also occurred independently of changes in anthropometric measures. A possible 
explanation for this finding was attributed to increased levels of physical activity undertaken by 
the patient. As part of the 30-minute one-to-one consultation, patients were encouraged to increase 
their level of weekly physical activity in line with UK recommendations. In many cases, patients 
were also referred to classes which specialized in supervised exercise provision, such as NERS. 
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Previous work demonstrates significant improvements in insulin sensitivity following exercise, 
independent of significant changes in body mass (Duncan et al., 2003, Nassis et al., 2005) with 
the effects of increased exercise induced GLUT4 translocation through increased skeletal muscle 
contraction supporting this notion (Lund et al., 1995). Additionally, Duncan, Perri, Theriaque, 
Hutson, Eckel and Stacpoole (2003) found insulin sensitivity improved significantly following six 
months of walking training in previously sedentary individuals with the improvement in insulin 
sensitivity occurring in the absence of weight loss. While the GP cluster surgeries aimed to 
significantly reduce anthropometric values, the data attained from that work potentially 
demonstrates the importance of increasing levels of physical activity in patients with pre-diabetes, 
even in the absence of weight loss. The data also suggested patients may have engaged more in 
physical activity compared to improving dietary habits given HbA1c values improved despite lack 
of body weight decreases in some surgeries. While indications of patient’s physical activity and 
habitual dietary intake were sought prior to the initial consultation visit in Chapter two, this 
information was not followed up at 12 and 24 months by surgeries, nor were the initial 
questionnaire responses provided for analysis. Therefore, to gain a better understanding as to the 
reasons why HbA1c values may improve in relation to physical activity and diet, it was suggested 
greater evidence regarding physical activity and dietary behaviours should be sought within a 
similar cohort at risk of T2D.  
 
In the present work, physical activity was recorded by both self-report questionnaire and an 
electronic activity tracker while dietary monitoring was achieved by self-report questionnaire and 
by metabolomic analysis of urine and plasma. Previous work has demonstrated the validity of the 
ActiGraph activity tracker in monitoring physical activity (Powell, Dowd, Carson and Donnelly, 
2017) and has been used in similar work examining physical activity in adults at risk of T2D 
following structured education (Biddle et al., 2015). In addition, work demonstrating the utility of 
239 
 
urine sampling as a method of dietary monitoring was reviewed in depth in Chapter three, while 
work in Chapters five and six demonstrate both a successful, feasible and acceptable protocol for 
urine collection in the community as well as demonstrating the stability of the urinary metabolome 
in the presence of nationally recommended moderate intensity exercise.  
 
Although not significant, ActiGraph data demonstrates participants in the intervention group 
modestly increased kCal expenditure as well as time spent engaging in light and moderate 
intensity activity as well as increasing step counts between baseline and six months. Conversely, 
control group participants demonstrated reduced kCal expenditure as well as reduced time spent 
engaging in light intensity activity and reduced step counts between baseline and six months, 
although similarly to intervention, the differences did not reach statistical significance. Of interest, 
trends in ActiGraph data did not match responses given in the self-reported IPAQ-SF. 
Respondents in the intervention group reported significantly less time walking. Reported time 
spent engaging in moderate activity and total met minutes also decreased after six months, 
although neither reached significance. In control participants, reported walking decreased after six 
months which corresponds with ActiGraph data, while trends between ActiGraph data and self-
reported moderate and vigorous were also similar. Such a disparity of findings represents an 
established limitation in self-reporting questionnaires where misreporting of physical activity has 
been demonstrated (Shephard, 2003; Finger et al., 2015). Participants were instructed to wear the 
ActiGraph during waking hours and wear time diaries indicate good compliance with this 
instruction. Given the reported validity of the ActiGraph as a reliable measure of physical activity 
compared to the limitations of self-reported physical activity, data acquired from the ActiGraph 
were used to assess the effects of physical activity on HbA1c changes, a key measure of T2D risk. 
Given the association between exercise and HbA1c, participants exhibiting higher levels of 
exercise may have had an associated decrease in HbA1c concentration. Conversely, reduced levels 
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of exercise may have correlated with increased HbA1c values. However, analysis revealed changes 
in physical activity including; kCal expenditure, time spent in light, moderate and vigorous 
exercise intensities and step counts between all visits did not correlate with changes in HbA1c. 
Given the data available, it is reasonable to suggest neither the consultation, nor the written 
literature, was effective in increasing rates of physical activity in either group. Accepting the 
documented influence of physical activity in managing blood glucose concentration, future work 
of similar design may need to place greater emphasis on the importance of engaging in regular 
exercise as per national guidelines for physical activity. Furthermore, work by Biddle et al. (2015) 
suggests a single three-hour structured education workshop targeting reduced sedentary time in 
young adults at risk of T2D may not be enough to achieve positive changes in sedentary time. 
Therefore, it is rational to claim either more extensive literature is provided to at risk patients 
regarding physical activity or more one-to-one consultation time is spent emphasizing its 
importance.   
 
Alongside investigating the efficacy of a GP-led one-to-one lifestyle intervention in pre-diabetes, 
a focus of this thesis has been the use of urine sampling as a means of dietary monitoring to support 
more established recording methods, such as the FFQ. Evidence outlined in Chapter three 
demonstrates several urinary biomarkers have been established for foods associated to high health 
importance as well biomarkers linked to smoking and alcohol consumption. Evidence also 
demonstrates different dietary patterns can be distinguished in urine. In addition, work in Chapter 
five demonstrated a feasible and acceptable method of community urine sampling which 
identified the appropriate time and frequency of urine sampling necessary to represent habitual 
diet without causing excessive disruption to daily life. Furthermore, given participants in the 
present study were advised to undertake regular moderate intensity exercise as part of UK national 
guidelines for physical activity, work in Chapter six aimed to determine the effects this exercise 
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intensity on the urinary metabolome to establish metabolite presence in urines would be 
significantly disrupted. Following 30 minutes of moderate intensity exercise, it was found this 
level of exercise had a negligible impact on the urine metabolome and it was therefore concluded 
that urine samples provided by individuals undergoing lifestyle modification would be unaffected 
by exercise at this intensity. In the current study, participants in both the intervention and control 
groups collected three urine samples a week for three weeks following each visit to the research 
facility for analysis of diet.  
 
To the investigator’s knowledge, this is the first study to use urine sampling for dietary monitoring 
purposes in an NHS approved study involving patients at risk of T2D. Analysis of samples took 
both a targeted metabolomic approach to identify quantified metabolites of specific foods and 
food groups in addition to an untargeted approach which has the ability to identify and 
discriminate between varying diets. From 19 participants completing all visits, 15 successfully 
provided adequate samples for all time phases which could successfully be analyzed for dietary 
content, suggesting urine collection in participants at risk of T2D is feasible. 73 metabolites of 
known chemical composition reflective of intake of commonly consumed foods/beverages and 
food types were successfully quantified for each phase demonstrating it possible to monitor 
consumption of such items in a community setting. In all but five cases, there were no significant 
changes in the urinary concentration of these metabolites suggesting dietary behaviours remained 
mostly similar across time points and between treatments. The concentration of five metabolites; 
4-hydroxyhippuric acid, caffeic acid, ferulic acid-4-O-sulfate, hippuric acid and taurine decreased 
significantly over time. 4-hydroxyhippuric acid, caffeic acid, ferulic acid-4-O-sulfate, hippuric 
acid have been identified as markers of fruit and vegetable and polyphenol intake and as such, an 
increase in urinary concentration of these metabolites as a result of increased intake may have 
been expected following dietary advice. Similar decreases in fruit, vegetable (dehydroxybenzoic 
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acid) and polyphenol (hippuric acid) intake were observed in pre-contemplation participants as 
well as a promising decrease in trans-3-hydroxycotinine, a biomarker of nicotine and regularly 
detected in individuals who smoke cigarettes. A possible explanation for reduced presence of these 
food related metabolites in three- and six-months urines may reflect reduced dietary intake in an 
attempt at improved calorie control, although this is speculative. Recent work by Lloyd et al. 
(2019) has shown absolute concentrations of selected urinary dietary biomarkers in FMV samples 
the day after consumption increases with increased portion size of the associated foods and 
beverages.  A lack of change observed in most quantified dietary metabolites over time and 
between treatments is further reflected in FIE-HRMS data which show overall poor class 
discrimination in participant urines and plasma between phases, inferring individual dietary 
patterns remained largely unchanged between baseline, three and six months and between 
treatments. This is supported by FFQ data which show consumption of most of the food and 
beverage categories (9 of 11 categories) remained similar between baseline and six months. One 
possible explanation may be attributed to the timing of the baseline urine collection period. 
Responses to the Personal Diabetes Questionnaire demonstrate eight participants had begun to 
act to change their dietary behaviours while four were preparing to make changes to their 
dietary behaviours. This shows a large proportion of participants had made efforts to change 
their diet before they visited the research facility for a baseline visit and the provision of 
baseline urine samples which acted as a comparator for dietary behaviour at three and six 
months. Therefore, given diets had likely changed before baseline sampling, it is perhaps 
unsurprising that no clear discrimination was achieved in urine samples across phases as dietary 
change had already likely occurred prior to urine sampling procedures being introduced.  
 
Future work needs to give this issue consideration in order to detect observable changes in the 
urine metabolome following dietary advice. Determining how to collect samples at the earliest 
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possible opportunity following a pre-diabetes diagnosis is therefore a potential focus for further 
research. Examination of FFQ data suggests dietary behaviour, overall, remained relatively 
unchanged over six months. However, significant changes were found for intakes of 
wholegrain and red and processed meat consumption. For wholegrain, while no treatment 
difference was evident, a significant change over time was found, with the mean AHEI score 
decreasing from 2.8 to 2.0 arbitrary units. In contrast, the mean AHEI score for red and 
processed meat consumption increased from 4.1 arbitrary units at baseline to 5.3 arbitrary units 
at six months, although again no treatment differences were present. Higher AHEI scores are 
strongly associated with lower risk of major chronic disease suggesting dietary behaviour 
relating to red and processed meat consumption improved while consumption of wholegrains 
was less optimal after six months. A benefit of urine sampling is the ability to validate self-
report dietary questionnaires using metabolomics. As evidenced in Table 8.4, the urinary 
concentration of biomarkers for wholegrain intake; 2,3-dihydroxyphenylpropionic acid, 
benzoxazolinone and 2,3-Dihydroxyphenylpropionic acid-3-sulfate remained unchanged over 
time. This is also similar for the biomarker of red meat consumption, L-carnitine and suggests 
the FFQ is either more sensitive to changes in dietary behaviours or participants were wrongly 
estimating their intake of wholegrain and red meat, a limitation heavily evidenced previously 
in works in chapter three. Based on the general trend from urine metabolome analysis and self-
report FFQ, dietary behaviour remained relatively unchanged over time and suggests using 
both forms of dietary monitoring in conjunction to assess dietary adherence following 
intervention is, at least, moderately successful, despite a small number of different dietary 
changes detected by each method. Future work needs to continue use of such methods to 
provide further evidence for the utility of urine sampling in free-living community settings for 
the purposes of dietary monitoring.  In relation to the effectiveness of the intervention in 
promoting dietary change, it is interesting to note that 12 participants indicated they had or 
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were planning to change their dietary behaviour simply because they had been informed of 
their heightened risk of T2D and had been provided with some brief information on healthy 
dietary behaviours. These responses were provided prior to any participant attending a 
consultation and suggests written advice regarding T2D risk and the importance of a healthy 
diet is an adequate stimulus to instigate a change in dietary behaviour in some patients.  
 
While care was taken to ensure the RCT was conducted within a robust study design, some 
limitations arose which warrant discussion, one of which concerned statistical analysis of 
secondary outcomes. In cases where data was non normally distributed, it was not possible (to 
the investigator’s knowledge) to identify a non-parametric test, equivalent to a three by two 
mixed model ANOVA, which could provide information on treatment and time interactions of 
two independent unequal groups measured at multiple time points. While an examination of 
resources suggested a Kruskal-Wallis test is the equivalent non parametric analysis to an 
ANOVA, it does not provide the group and time interactions the research team required and 
therefore this option was not utilised where interaction analyses was sought. According to 
Blanca, Alarcon, Arnau, Bono and Bendayan (2017) there are also disadvantages to using non-
parametric procedures, such as the Kruskal-Wallis test, which converts quantitative continuous 
data into rank-ordered data, which result in a loss of information. Attempts to log transform 
the data to a normal distribution were also unsuccessful. Following discussions with academics 
with expertise in statistical analysis, it was decided a three by two mixed model ANOVA was 
a robust alternative which would provide the necessary information on treatment and time 
interactions. This decision is supported in work by Blanca, Alarcon, Arnau, Bono and 
Bendayan (2017) who suggest ANOVA is robust to violations of normality and can be utilised 
under a wide variety of conditions when variables including; equal and unequal sample sizes; 
group sample size and total sample size; shape of the distribution and equal or unequal 
245 
 
distributions were examined. While such work has shown ANOVA to be robust to violations 
of normality, the use of such a test on non-normal data divides opinion among academics and 
therefore the results from the present work should be treated with caution.  
 
In conclusion, this NHS approved randomised control trial has successfully shown it feasible 
to implement an RCT targeting pre-diabetes in primary care. Rates of recruitment and retention 
as well as feedback relating to acceptability have shown such a design has the potential to be 
applied ethically and practically to a larger sample at risk of T2D. Given the present work was 
designed to assess feasibility and was statistically underpowered, development of a similar 
design and applied to a larger cohort is a prudent next step to determine the true impact of the 
one-to-one consultation on factors associated to T2D, compared to current practice. 
Furthermore, this work successfully employed the use of a home-based urine collection kit for 
the purposes of dietary monitoring which was informed by previous work detailed within this 
thesis. Use of such urine sampling protocols in a future RCT has the potential to monitor dietary 
behaviours on a larger scale and demonstrate the utility of such a method in monitoring 
community wide, free-living dietary behaviours.       








Chapter Nine:  
 
9.1. General Discussion and Future Directions 
 
The overall aim of this thesis was to evaluate the efficacy of a one to one lifestyle consultation 
delivered through primary care in reducing progression to T2D in a north Ceredigion pre-
diabetic population. Specific objectives included; 1. The completion of a service evaluation of 
the North Ceredigion GP cluster pre-diabetes intervention; 2. The development and validation 
of methods to quantify dietary changes over time; and 3. Establishing the feasibility of 
conducting a randomised control trial to determine the efficacy of a low-cost diabetes 
prevention programme delivered through primary care. The work presented here addresses 
important gaps in the literature. To the investigator’s knowledge, this is the first time a T2D 
prevention programme of this design has been examined both alone and in conjunction with a 
novel method for dietary monitoring and physical activity tracking. In order to achieve the aims 
and objectives of this thesis, several studies were conducted. The discussion below will chart 
the progressive pathway between studies, discuss the limitations of the research and suggest 
the potential future direction of T2D prevention and lifestyle monitoring within Wales.  
 
9.2. Realisation of Aims 
According to a Public Health England report published in 2016, approximately four million 
people in the UK were suffering with diabetes, 90% with T2D, while a statistic report by the 
NHS in 2014 demonstrated one in three UK adults were considered to have pre-diabetes, a 
condition which classifies an individual as being at increased risk of developing T2D. In Wales, 
the incidence of T2D is increasing unsustainably. In 2015 it was estimated that 182,600 people 
had T2D and by 2025 that number will have increased to 300,000, the highest percentages by 
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population in the UK (Diabetes UK, State of the Nation, 2015). The financial implications for 
Wales’ NHS are extremely worrying, with approximately 10% of the annual budget spent on 
treating a preventable condition and its complications, equating to approximately £500 million 
(Diabetes UK, State of the Nation, 2015). Of great concern are the estimated 540,000 
individuals in Wales at risk of developing T2D, as approximately 10% of unaddressed cases 
will progress to manifest T2D (Tabak et al., 2012). In the absence of effective treatments and 
interventions these estimations are projected to increase (Diabetes UK, State of the Nation, 
2015).  Given the increasing rate of T2D cases in Wales and projected future cases, an urgent 
need for an effective intervention programme which can prevent the onset of T2D was 
identified as a key objective.   
 
In 2015, a north Ceredigion GP cluster comprised of seven surgeries initiated a pre-diabetes 
intervention which targeted patient education and lifestyle modification. Lifestyle intervention 
has been shown to be at least as effective as pharmacological approaches (such as metformin) 
in preventing progression to T2D (Gillies et al., 2007) and more cost effective (Herman et al., 
2009). The intervention comprised of a 30-minute one-to-one consultation for patients 
identified as having an HbA1c concentration of between 42 and 47 mmol/mol, the concentration 
range considered to increase the risk of developing T2D. The 30-minute consultation included 
the collection of baseline data (including; HbA1c, weight, BMI, waist circumference and blood 
pressure) and information on diet, exercise and the importance of avoiding manifest T2D. In 
partnership with the cluster, work outlined within chapter two of this thesis undertook an 
evaluation of the intervention. Analysis of data at 12 and 24 months following the 30-minute 
consultation demonstrated a significant overall decrease in HbA1c. In many cases, participation 
in the intervention led to HbA1c decreasing to values below the range considered to increase 
the risk of T2D development. The data for HbA1c recorded post intervention reached values 
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regarded as healthy by NHS Wales, Public Health Wales and Diabetes UK in 37% of cases 
after 12 months (217 of 592 participants) and 41% of cases after 24 months (119 of 292 
participants). Conversely, only 3% (17 of 592 participants) and 6.5% (19 of 292 participants) 
had HbA1c values which fell in the diabetes range after 12 and 24 months, respectively. 
Statistically significant overall decreases were also observed for body mass, BMI and waist 
circumference after 12 months and BMI and waist circumference after 24 months, although 
changes in BMI were small and unlikely to be clinically relevant. These findings are similar to 
those observed in an initial analysis of NHS England’s DPP which observed a significant 
decrease in weight after 12 months (NHS DPP, 2018) and a 1.2 mmol/mol decrease in HbA1c 
(Valabhji et al., 2019). In many cases, decreases in HbA1c were associated with decreases in 
body mass, BMI and waist circumference in individual surgeries and pooled data. In other 
cases, however, decreases in HbA1c occurred independently of changes in anthropometric 
measures. A possible explanation for this finding was attributed to increased levels of physical 
activity undertaken by the patient, independent of weight loss. The benefits of physical activity 
in improving health outcomes were discussed as part of the 30-minute one-to-one consultation. 
Patients were encouraged to increase their level of weekly physical activity to 150 minutes of 
moderate intensity exercise, 75 minutes of vigorous intensity exercise or a combination of both 
intensities plus additional resistance exercise. In many cases, patients were also referred to 
classes which specialised in supervised exercise provision, such as NERS. Patients may have 
engaged more in physical activity compared to improving dietary habits, given HbA1c values 
improved despite lack of body weight decreases in some surgeries. While patients were asked 
to provide an indication as to their physical activity and dietary habits during the initial 
consultation visit, this information was not followed up at 12 and 24 months by surgeries. 
Furthermore, limitations associated with self-report questionnaires, as discussed in chapter 
three, suggest information provided by participants at baseline GP visits regarding diet and 
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physical activity may have been unreliable. To gain a better understanding as to the specific 
reasons why HbA1c values improved following lifestyle intervention, it was suggested future 
work within a similar cohort should generate better evidence regarding physical activity and 
dietary behaviours. Therefore, work was undertaken to determine alternative ways of 
monitoring healthy behaviours associated to T2D risk which don’t rely on self-report. It was 
subsequently suggested that developing a greater understanding of physical activity and dietary 
practices following intervention would identify what elements of the intervention were 
successful and what could be improved upon in future T2D prevention initiatives.  
 
In chapter three, a review of the literature examining traditional dietary monitoring methods 
highlighted several limitations. As an alternative approach, a significant body of research 
demonstrated urine metabolome profiling to be another method for measuring dietary exposure 
as well as providing the opportunity to validate existing dietary recording methods (Favé et al., 
2011). The establishment of biomarkers of foods of high health importance including fruit, 
vegetables, meat, fish, wholegrain, tea, coffee, sugar, as well as the ability to discriminate 
between metabolic profiles derived from different diets means it is possible to both improve 
and validate traditional dietary monitoring methods with urinary metabolomics. Many studies 
examining urinary metabolomics for habitual dietary monitoring have involved participants 
collecting 24-hour urine samples or participating in intensive laboratory-based control studies, 
which while robust and accurate, place a significant burden on participants due to its adverse 
impact on normal daily life (John et al., 2016). This limitation means it unlikely the use of 
urine sampling could be applied to a ‘real world’ setting using current practices. Therefore, 
work in chapter five aimed to determine whether habitual dietary behaviour could be monitored 
within a free-living environment without intrusive or disruptive protocols being administered. 
This was attempted through the collection of a series of spot samples collected over a six-week 
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period with the ultimate aim to establish a less burdensome collection protocol for participants 
in future research. Data regarding sample collection compliance, sample collection time and 
frequency and protocol acceptability were collected to inform the aims of the study. Collection 
compliance for FMV samples was higher (93% - 100%) compared to BT samples (86% - 
100%) while weekday collection compliance (87% - 100%) was greater than weekend 
compliance (75% - 100%). It was argued that while a weekend sample resulted in lower 
compliance, a sample should be included in any future protocol as dietary behaviour will likely 
change on a weekend compared to a week day (An, 2016; Jahns et al., 2016). Therefore, it was 
proposed a weekend urine sample should be collected to capture that dietary information in 
future work utilising urinary metabolomics. As compliance for FMV samples was highest, 
work was undertaken to assess its utility in capturing dietary information compared to BT 
samples. FMV samples were as effective independently compared to FMV and BT samples 
combined in capturing dietary behaviour. Given a key aim of the study was to develop a non-
disruptive protocol for dietary monitoring, analysis was undertaken to determine how many 
samples each week were required to provide an accurate representation of dietary behaviour, 
compared to weekly and global pools, which contained all FMV samples collected throughout 
the week and entire sampling phase respectively. It was demonstrated that three samples 
collected each week, two on weekdays and one on a weekend, was effective in capturing similar 
dietary information compared to the global pool, which comprised of an FMV urine sample 
collected every day for the six-week sampling period. Data regarding the acceptability of the 
protocol, which was gathered from feedback questionnaires, suggested an overwhelming 
majority of participants found the urine collection kit and the collection procedures to be easily 
utilised and was a feasible method for use in future work. This sample collection protocol 




Following the development of the urine collection protocol for dietary monitoring, further work 
was conducted to examine the effects of acute moderate exercise on the urine metabolome. The 
aim of the study detailed in chapter six was to examine the extent of urinary metabolome 
change following 30-minutes of moderate intensity exercise on a cycle ergometer. Previous 
work demonstrated the effects of both high intensity exercise and resistance exercise on urinary 
metabolites. However, the effects of moderate and submaximal exercise were less established. 
This exercise modality was of interest in this thesis as UK national activity guidelines state all 
adults should undertake 30 minutes of moderate intensity exercise, five days per week. These 
recommendations are especially encouraged in patients undergoing lifestyle modification for 
the prevention of non-communicable diseases, such as those who participated in the initial pre-
diabetes intervention, as well as the participants in the later RCT. Prior to testing the urine 
collection protocol in a population at risk of T2D, the work in chapter six aimed to determine 
metabolome change in urine following both 30 minutes of standardised moderate exercise on 
a cycle ergometer, an intensity based on national exercise guidelines, compared to rest. 
Determining such change provided useful data regarding the extent of urine metabolome 
disturbance in individuals who engage in moderate physical activity as per advice from lifestyle 
intervention. The study demonstrated 30 minutes of standardised moderate intensity exercise 
to have no significant impact on the urinary metabolome. With reference to the RCT, it was 
concluded that nationally recommended moderate exercise will not result in significant 
metabolome disturbance in urines which are collected as part of a dietary monitoring protocol.  
 
Prior to conducting the RCT, a short study detailed in chapter seven compared the Alere 
Afinion AS100 Point of Care Analyser (used in the RCT) and HPLC in the determination of 
HbA1c. While HPLC is considered the gold standard for clinical monitoring and diagnosis of 
diabetes status, the Alere Afinion AS100 POC analyser was to be used in the proceeding RCT 
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for monitoring HbA1c. It was therefore of interest to determine how closely the results from 
both analytical methods agreed. The data demonstrated the Alere Afinion AS100 POC analyser 
to underestimate HbA1c concentration by a median of two mmol/mol and in some cases 
misclassify an individual’s glycaemic state. Based on the results, it was concluded the POC 
analyser was not suitable for clinically diagnosing T2D. However, the significant positive 
correlations between the POC analyser and HPLC analyses suggested the former can be used, 
with caution, to assess intervention effectiveness by monitoring longitudinal HbA1c changes 
without the waiting time, additional costs and expertise associated with HPLC analysis. A 
comparable study by Grant, Dunseath, Churm and Luzio (2017) also found a median two 
mmol/mol difference in HbA1c values between HPLC and POC analysis. Similarly, the authors 
concluded that the POC analyser could be used for HbA1c monitoring, although HPLC analysis 
should be undertaken for diagnostic purposes. 
 
In relation to the objectives of this thesis, the work detailed in chapter two successfully 
evaluated the north Ceredigion GP cluster pre-diabetes intervention. Limitations from that 
work included the lack of accurate and reliable dietary monitoring. Therefore, work detailed in 
chapters five and six developed methods to quantify dietary change and confirm moderate 
intensity exercise to have no significant impact on the urine metabolome. Additional work 
outlined in chapter seven compared two different analytical methods for the determination of 
HbA1c. The findings from chapters two, five, six and seven informed the development of an 
RCT, detailed in chapter eight. This study examined the feasibility of conducting a randomised 
control trial to evaluate the effectiveness of a one-to-one consultation to improve blood glucose 
control in pre-diabetes. While results from chapter two demonstrated promise in reducing T2D 
prevalence in at risk groups, the design of the project as a service evaluation was regarded as a 
limitation, as it was difficult to identify the primary reasons for reduction in HbA1c and 
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associated risk factors. Potential drivers of behaviour change included; the initial letter 
confirming T2D risk and accompanying information and/or the information received during 
the one to one consultation. Therefore, a randomised control trial was proposed to assess the 
effectiveness of the consultation in comparison to current practice in pre-diabetes care in Wales 
(written information only).  
 
In both intervention and control participants, the previously tested urine sampling protocol was 
used for the purposes of dietary monitoring while ActiGraph physical activity trackers were 
utilised to monitor physical activity levels more closely than in the initial GP cluster 
intervention. Due to the complexity and logistical challenges of conducting an RCT within 
primary care, it was thought necessary to first assess the feasibility of initiating such a protocol 
within a smaller group of patients prior to a future larger study being conducted. Based upon 
rates of recruitment and retention as well as feedback relating to acceptability, the study 
demonstrated such a design has the potential to be applied both ethically and practically to a 
larger sample of patients at risk of T2D. Furthermore, the work successfully employed the use 
of the urine collection kit for the purposes of dietary monitoring which demonstrated its utility 
in successfully monitoring a range of dietary biomarkers as well as demonstrating changes in 
dietary patterns in free-living individuals. Measures of physical activity were also monitored 
more closely using the ActiGraph activity tracker although few significant changes were found. 
Neither the diet nor exercise monitoring protocols were administered in the initial GP cluster 
intervention. The use of such in the RCT represented an alternative and potentially more 
accurate measure of lifestyle behaviour compared to self-report which have previously been 
shown to be prone to bias. The results demonstrated values for HbA1c, hip and waist 
circumference decreased significantly over time irrespective of treatment group. Most other 
biochemical, anthropometric, dietary and physical activity variables measured remained similar 
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across treatment and time. While this suggests the intervention had little impact on T2D risk, the 
study was limited by its sample size and therefore a suitably powered study with a larger sample 
is the logical next phase.  
 
9.3. Future Directions     
The sample size for the RCT was decided based upon potential numbers of eligible patients 
provided to the research team by the participating general practice. This was based upon the 
number of registered patients with a BMI > 25 kg/m2, an existing HbA1c < 12 months between 
42 and 47 mmol/mol or patients otherwise deemed at clinical risk of T2D by their GP. As this 
was a feasibility study designed to inform a future large-scale randomised control trial, no 
formal sample size calculation was employed. Given this limitation, the development of a 
similar design applied to an appropriately powered sample is a prudent next step to determine 
the true impact of the one-to-one consultation on factors associated to T2D, compared to 
current practice. The initial GP cluster intervention has demonstrated the ability of GP surgeries 
across north Ceredigion to work in collaboration with a university research group to design, 
deliver and analyse a T2D prevention programme. With this pathway in place, a future multi-
centre randomised control trial utilising a similar method to examine the effectiveness of the 
one to one consultation is a realistic and feasible next step. The results also demonstrated the 
minimal impact of the consultation on dietary and physical activity behaviours. Future work 
may aim to place greater emphasis on the importance improving diet and increasing physical 
activity in improving blood glucose control. Work detailed in chapter eight has shown an RCT 
can successfully be conducted alongside primary care in an ethically acceptable and 
scientifically robust manner. Utilising the services of the initial seven general practices of 
Borth, Church, Llanilar, Padarn, Tanyfron, Tregaron and Ystwyth and accessing their pre-
diabetic populations will facilitate this aim. Additionally to this, a formal financial assessment 
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should be undertaken to determine the cost effectiveness of the intervention in reducing 
prevalence of T2D in Wales, as up to now only approximate costs are known.   
 
Given the health complications associated with T2D as well as financial implications involved 
in treating the condition, it is of extreme importance that an effective pathway is implemented 
within NHS Wales’ healthcare structure which has been thoroughly evaluated and proven to 
be effective in reducing population T2D risk. Despite significant support being provided for 
T2D prevention in England, a similar model for Wales has yet to be implemented. This is 
despite the prevalence of the disease being highest in Wales compared to the remaining areas 
of the UK (Diabetes UK, State of the Nation, 2015) and there being a considerable portion of 
the Welsh population considered at increased risk of T2D. In August 2019 it was announced 
that in addition to the NHS England’s Diabetes Prevention Programme, up to 8000 people in 
England at increased risk of T2D will be offered digital wearable technology to help track 
physical activity to manage T2D risk. Given the appropriate resources are made available, 
similar pilot work in Wales should be conducted. One possible line of research may be to offer 
such technologies to patients who attend a one to one consultation to determine if additional 
digital support following the consultation has further health benefits compared to a consultation 
and associated information alone.     
 
9.4. Conclusion  
The work presented in this thesis has successfully evaluated a GP led pre-diabetes intervention 
and informed the development of a future multi-centre randomised control trial which will 
demonstrate the effectiveness of the intervention in preventing the onset of T2D in patients 
considered at increased risk of the condition. Furthermore, an effective and acceptable protocol 
for monitoring habitual diet using urinary metabolomics has been developed and implemented 
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in a group of participants who have been subjected to dietary advice from a health professional.  
It is crucial future work continues to develop evidence regarding the most effective approach 
for T2D prevention in Wales, where prevalence of the disease is increasing unsustainably. This 
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We are writing to you because a blood test you have had in the last year or so, suggests 
you may be at risk of becoming diabetic. Unfortunately, being at risk of diabetes (called pre-
diabetes) also increases your risk of developing heart disease or a stroke.  However, 
recently it has become very clear that improving diet and increasing physical activity can 
massively reduce the risk of getting diabetes (even if your weight stays the same). This is 
good news!   The enclosed leaflet has more information. 
 
GP surgeries in North Ceredigion are offering a 30-minute consultation with a Lifestyle 
Advisor; in our surgery this will be provided by _________.  Please will you fill in the short 
questionnaires on diet and physical activity, enclosed with this letter and bring these along to 
your appointment.  During the consultation there is the option of giving some measurements 
such as blood pressure, weight, and having a blood test if not done recently.  _________ will 
also have useful information to share with you and be able to signpost resources and make 
referrals to exercise classes or food education classes if needed.   
If you would like to take part, then please make your 30-minute appointment by telephoning 
___________.  If you wish to discuss anything before booking your appointment please 
contact ____________ at the surgery. You are encouraged to bring someone with you. 
GP surgeries in North Ceredigion with Hywel Dda Health Board have joined with health 
scientists at Aberystwyth University to evaluate this project; this will not affect your 
confidentiality or the service we provide.  There will be the opportunity to find out more about 
this and future opportunities for research when you attend. 
We are excited to be involved in this project and we hope you take this opportunity to make 
positive lifestyle changes which will benefit you in many ways. 
Best wishes,  






Appendix B: Diabetes Information Leaflet  
 
Will I receive check-ups? 
Yes, at least once a year around the time of your birthday, your GP will invite you for a check-up.  Your 
blood will be tested and any changes to your blood sugar and what it means for your health will be 
discussed. 
In most cases you only need to have your blood tested once a year as it takes time for significant 
changes to happen.  Testing too often can lead to misleading results.   
 
Feeling anxious? 
Being told you have pre-diabetes can be difficult to 
hear, it does need to be taken seriously, but keep in 
mind that at this early stage, simple changes to your 






Some people may go on to develop diabetes.  If you experience any of the symptoms below, please 
visit your GP: - 
 Feeling very thirsty. 
 Urinating frequently, particularly at night. 
 Feeling very tired. 
 Weight loss and loss of muscle. 
For general support and advice about lifestyle changes, call .us at Church Surgery on 01970 624855 and make 
an appointment with Mandy Glennie (Lifestyle advocate) 
https://www.diabetes.org.uk for more information 
Early diagnosis, 
treatment and good 
control of diabetes is 









People who have pre-diabetes have a blood sugar level that is higher than normal but not quite high 
enough to be classed as diabetic. Having pre-diabetes puts people at a high risk of developing Type 2 
diabetes (which is controlled by diet or tablets).  Unfortunately, people with pre-diabetes are also at 
almost double the risk of suffering from a heart attack and/or stroke compared to someone who has 
a normal blood sugar level. 
 
The good news is something can be done to reduce the risk of pre-diabetes progressing to diabetes. 
Find out more inside....... 
 
What causes Pre- Diabetes? 
There are three main things that contribute to Pre-Diabetes and the progression to Type 2 Diabetes: - 
1. What you eat and drink: eating healthy food and drinking water can help you keep well.  
Irregular and unhealthy eating habits cause blood sugars to rise and fall. 
2. Being overweight: this affects the body’s ability to process sugar in your blood. 
3. What you do: long periods of being inactive reduce the ability of your body to deal with sugar 
in your blood. 
For some people, the genes you inherit from your family can also contribute to the development 
of borderline diabetes, your risk is increased if a close relative has Type 2 Diabetes. 
 
Research suggests that up to 60% of Type 2 diabetes cases could be prevented by making healthy 
lifestyle changes.  





What do I need to do? 
If you are overweight the most important thing you can do is to stop high risk diabetes 
progressing is to lose weight.  Any weight loss will make a difference, but if you are able to lose 
5% of your body weight in the next few months you could reduce your chance of developing Type 
2 diabetes by almost 60%. 
 
Your starting weight Amount to lose (5% of 
body weight). 
8st 8 (55kg) 6lb (2.8kg) 
9st 12 (57kg) 7lb (3kg) 
11st (69kg) 8lb (3.5kg) 
12 9 (81kg) 9lb (4kg) 
14st 5 (92kg) 10lb (4.6kg) 
15st 10 (95kg) 11lb (4.8kg) 
17st 5 (111kg) 12lb (5.6kg) 
19st 2(121kg) 13lb (6kg) 
20st 6 (130kg) 14lb (6.5kg) 
22st (139kg) 15.5lb (7kg 
 
Eating a balance of different food groups and portion control will help control your blood sugar 
levels which reduced your risk of getting diabetes and heart disease. 
 
Being more physically active increases how well your body can deal with and manage sugar which 
also helps you to control your blood sugar levels. 
 
A combination of healthy eating and being more physically active will have the greatest impact.  






What support is available? 
When you are diagnosed with Pre-Diabetes you benefit from the free support of a Lifestyle 
Advisor. 
 Lifestyle Advisors are in your GP Surgery 
 They offer a range of times and places to meet 
 They will work with you to assess your current lifestyle and help you to set some goals 




























Appendix D: IPAQ-SF Questionnaire  
 




SHORT LAST 7 DAYS SELF-ADMINISTERED FORMAT  
  
  
FOR USE WITH YOUNG AND MIDDLE-AGED ADULTS (15-69 years)  
  
The International Physical Activity Questionnaires (IPAQ) comprises a set of 4 
questionnaires. Long (5 activity domains asked independently) and short (4 generic items) 
versions for use by either telephone or self-administered methods are available. The 
purpose of the questionnaires is to provide common instruments that can be used to obtain 
internationally comparable data on health–related physical activity.  
  
Background on IPAQ  
The development of an international measure for physical activity commenced in Geneva in 
1998 and was followed by extensive reliability and validity testing undertaken across 12 
countries (14 sites) during 2000.  The final results suggest that these measures have 
acceptable measurement properties for use in many settings and in different languages and 
are suitable for national population-based prevalence studies of participation in physical 
activity.  
  
Using IPAQ   
Use of the IPAQ instruments for monitoring and research purposes is encouraged. It is 
recommended that no changes be made to the order or wording of the questions as this will 
affect the psychometric properties of the instruments.   
  
Translation from English and Cultural Adaptation  
Translation from English is supported to facilitate worldwide use of IPAQ. Information on the 
availability of IPAQ in different languages can be obtained at  www.ipaq.ki.se. If a new 




methods available on the IPAQ website. If possible, please consider making your translated 
version of IPAQ available to others by contributing it to the IPAQ website. Further details on 
translation and cultural adaptation can be downloaded from the website.  
  
Further Developments of IPAQ   
International collaboration on IPAQ is on-going and an International Physical Activity 
Prevalence Study is in progress. For further information see the IPAQ website.   
  
More Information  
More detailed information on the IPAQ process and the research methods used in the 
development of IPAQ instruments is available at www.ipaq.ki.se and Booth, M.L. (2000).  
Assessment of Physical Activity: An International Perspective.  Research Quarterly for 
Exercise and Sport, 71 (2): s114-20.  Other scientific publications and presentations on the 
use of IPAQ are summarized on the website.  
 
INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE  
  
We are interested in finding out about the kinds of physical activities that people do as part 
of their everyday lives.  The questions will ask you about the time you spent being physically 
active in the last 7 days.  Please answer each question even if you do not consider yourself 
to be an active person.  Please think about the activities you do at work, as part of your 
house and yard work, to get from place to place, and in your spare time for recreation, 
exercise or sport.  
  
Think about all the vigorous activities that you did in the last 7 days.  Vigorous physical 
activities refer to activities that take hard physical effort and make you breathe much harder 
than normal.  Think only about those physical activities that you did for at least 10 minutes 
at a time.  
  
6. During the last 7 days, on how many days did you do vigorous physical activities 
like heavy lifting, digging, aerobics, or fast bicycling?   
  
 _____ days per week    
  
 No vigorous physical activities   Skip to question 3     
  
  




2.  How much time did you usually spend doing vigorous physical activities on one of 
those days?  
  
_____ hours per day   _____ minutes per day    
  
     Don’t know/Not sure   
  
  
Think about all the moderate activities that you did in the last 7 days.  Moderate activities 
refer to activities that take moderate physical effort and make you breathe somewhat harder 
than normal.  Think only about those physical activities that you did for at least 10 minutes 
at a time.  
  
  
6. During the last 7 days, on how many days did you do moderate physical activities 
like carrying light loads, bicycling at a regular pace, or doubles tennis?  Do not 
include walking.  
  
_____ days per week  
  
 No moderate physical activities   Skip to question 5     
  
  
6. How much time did you usually spend doing moderate physical activities on one of 
those days?  
  
_____ hours per day _____ minutes per day  
  
     Don’t know/Not sure   
  
  
Think about the time you spent walking in the last 7 days.  This includes at work and at 
home, walking to travel from place to place, and any other walking that you have done 
solely for recreation, sport, exercise, or leisure.  
  




6. During the last 7 days, on how many days did you walk for at least 10 minutes at a 
time?    
  
_____ days per week  
   
 No walking     Skip to question 7     
  
  
6.  How much time did you usually spend walking on one of those days?  
  






























Viability of urine collection and analysis for identifying nutrient content of diet in a 




Analysis of human urine is able to provide us with comprehensive information on the diet you 
consume up to 24 hours before providing a urine sample. While a single urine sample does 
not provide us with the information necessary to inform us on your long term dietary exposure, 
a number of urine samples over a prolonged period of time can give us a robust overview of 
your long term dietary exposure. Our aim is to determine how many urine samples are needed 
to give us a strong overview of an individual’s habitual dietary exposure without causing 
unnecessary disturbances to their everyday lives. This information will help us to better 




What is required of me if I agree to take part in the study? 
 
If you agree to participate you will be provided with all the information necessary to 
successfully complete the study. Before beginning the study, you will be asked to complete a 
simple physical activity questionnaire and a diet questionnaire which will provide us with 
information on your current physical activity and exercise habits. You will then be provided 
with a urine sampling kit. You will be given verbal and written information on how to use the 
kit and at what times of day you must provide a urine sample. 
 
Participation in this study requires you to provide two urine samples a day for a total of six 
weeks. You must provide us these urine samples every day, when you first wake up in the 
morning and before you go to bed in the evening. You will be provided with all of the 
equipment and instruction necessary to successfully collect and store your urine samples. 
You will be required to store your urine samples in a refrigerator for a maximum of 5 days 
before returning the samples to our laboratory in the envelopes provided to you. The kits you 
will use to store your urine samples are fully sealed and safe to store in the refrigerator.  You 
do not need to alter your diet at any point during the 6 week period; you’re free to consume 
any foods or drink you normally would. You will be required to complete an online electronic 
daily diet diary during the 6 weeks which records all of the food and drink you have consumed 
during the day. Upon completion of the 6 weeks, you will be asked to complete a questionnaire 




analysis kit.  
 
All the urine samples you have provided to us will be stored safely and securely for the 
duration of the study. Urine samples may be stored safely and securely until the host institute 
(IBERS) deems that they are no longer required. Urine samples will only be used for analysis 
which directly pertains to this study. 
 
During analysis of urine, only biomarkers which relate to either acute or habitual dietary 
exposure will be measured. Urine samples will never be used to test for anything which is not 
a dietary biomarker.  
 
 
Can I change my mind if I decide I no longer want to take part in the study? 
 





Should you have any further questions regarding participation in the study, we will be pleased 
to answer them, and may be contacted on:  
 
Dr Thomas Wilson 
Email: tpw2@aber.ac.uk 
 
Nick Gregory (PhD Candidate) 
Email: nig5@aber.ac.uk 
 
Prof John Draper 
Email: jhd@aber.ac.uk 
 
Dr Rhys Thatcher 
Email: ryt@aber.ac.uk 
 
If you have any complaints about any aspect of this study you can contact: 
Dr Rhys Thatcher (Academic Supervisor to Nick Gregory) 
Email: ryt@aber.ac.uk  
Telephone: 01970628425  
 
Institute Director of Research: Dr Alison Kingston-Smith  
Email: ahk@aber.ac.uk 














Viability of urine collection and analysis for identifying nutrient content of diet in a 
free-living environment    
 
NAME OF VOLUNTEER: …........................................................................... 
 
PRINCIPAL INVESTIGATOR: Dr Thomas Wilson, Nick Gregory 
 
ADDITIONAL INVESTIGATORS: Dr Rhys Thatcher, Prof John Draper 
 
 
I have read the volunteer information sheet on the above study and have had the opportunity 
to discuss the details and ask questions.  The investigator has explained to me the nature 
and purpose of the study to be undertaken.  I understand fully what is proposed to be done. 
 
I have agreed to take part in the study as it has been outlined to me, but I understand that I 
am completely free to withdraw from the study at any time I wish.  
 
I understand that this study is part of a research project designed to promote scientific 
knowledge, which has been approved by Aberystwyth University Ethics Committee, and may 
be of no benefit to me personally.   
 
 





I understand any data collected will be kept confidential, and only be seen by the principal 
investigators  
 




SIGNATURE OF VOLUNTEER: …..........................................……................... 
 
          
     Date: …............................... 
 
I confirm that I have explained to the volunteer named above, the nature and purpose of the 




SIGNATURE OF INVESTIGATOR: …............................................................... 
           












Appendix G: Urine Collection Instructions 
 
Instructions for Urine Collection 
A part of this study each week you will be given a urine collection kit, which 
will enable you to collect two urine samples a day, for 7 days. 
 
The contents of the urine collection kit are; 
1 x Sealed plastic box; containing 7 urine transfer straws and 14 white ended 
4mL vacutainter tubes 
1 x Empty sealed plastic box 
1 x Small plastic bag 
1 x 125mL urine collection up. 
 
1. To collect a urine sample; take a clean collection straw and empty 
vacutainer tube.  
2. Fill the collection cup with a mid-stream urine sample. 
3. Submerge the tip of the transfer straw into the collection cup. 
4. Insert the vacutainer tube into the transfer straw and keep pressure 
applied until tube is filled to capacity.  
5. Label the tube according to the information on the sample log sheet 
6. Place the labelled vacutainer tube in the empty plastic box, and store in 
your refrigerator. 




sample, simply rinse the straw with cold water and allow to dry at room 
temperature. After using the straw again in the evening, rinse the straw 
with cold water and place in the plastic bag provided. You can return 
the bag of used straws each week when you drop off your urine 
samples, so they can be disposed safely. 
 
8. Empty the remaining contents of the urine collection cup into the toilet 
and rinse the collection cup with cold water and allow to dry. The 


















Appendix H: Urine Collection Feedback Questionnaire  
 
The following questions relate to the use of the urine sampling kit you have been using over the 
past six weeks. Please indicate your answer in each case by circling the appropriate response and 
when further detail is requested please use the space provided. 
 
1. Did the time of day you were required to provide a urine sample cause disruption to your 















































5. Having completed this process and knowing what it involves, would you be prepared to use 










































Monitoring the metabolic response of human urine following a bout of prolonged 




It is now established that analysis of human urine is able to provide us with comprehensive 
information on the diet you consume up to 24 hours before providing a urine sample. Previous 
work in the Institute of Biological, Environmental and Rural Sciences (IBERS) has 
investigated the feasibility of urine collection in a free living environment and the subsequent 
analysis for identifying nutrient content of diet. This work has demonstrated that urine can be 
collected in the home successfully and analysis of the samples provides robust information 
on habitual diet. Some evidence suggests that exercise can cause changes to human urine 
which may also influence the dietary information present in the urine. Given the general 
recommendations that individuals should complete at least 150 minutes of exercise each 
week in order to maintain a healthy lifestyle, it is our aim to investigate the effects of exercise 
on human urine and how that may influence our ability to monitor diet effectively.      
 
What is required of me if I agree to take part in the study? 
 
If you agree to participate, you will be provided with all the information necessary to 
successfully complete the study. You will need to sign a consent form and complete health 
and physical activity questionnaires. The study requires you to visit the laboratory on three 
separate occasions. We will ask you to drink at least a pint (or 500 ml) of ordinary tap water 
before visiting the laboratory to ensure that you are properly hydrated. You must arrive at the 
laboratory for visit 2 and 3 following an overnight fast of at least 8 hours. 
During the first visit (1), we will assess your body composition using a DEXA scanner. We will 
then determine your maximal oxygen uptake value (V̇O2max), which we will use to calculate 
the appropriate exercise intensity for subsequent visits. This is a maximal test where you will 
be asked to cycle at a fixed rev rate until you fatigue, while the workload gets progressively 
harder, and normally lasts between 10 and 15 minutes. You will breathe into a mouthpiece 
which is connected to a computer, while wearing a nose clip throughout the exercise, to allow 
us to measure your oxygen uptake.  
 
At least 48 hours after the first visit; you will begin the main experiment. You are required to 
visit the laboratory in the morning to complete two experimental trials following an overnight 
fast of at least 8 hours. You must record your diet on the evening prior to each visit using a 
simple dietary record provided to you. The two trials will be separated by at least 7 days. You 
must provide a urine sample when you wake up prior to each trial. We will give you all the 
equipment you need to collect the sample at home.  When you arrive at the laboratory, you 




positioned on your chest. You will then be asked to either (1) exercise at a moderate intensity 
for 30 minutes on a cycle ergometer or (2) sit quietly for 30 minutes (you are free to bring 
reading materials or electronic devices for this trial). You are free to drink water throughout 
each trial, if you wish. We will measure your heart rate in both trials every 5 minutes .We will 
ask you how hard you think you’re working (usual a simple visual scale) every 5 minutes in 
the exercise trial. The order in which you complete the trials will be randomised by the study 
investigators. Once complete, you will provide a second urine sample in private. You will then 
be free to use the shower and changing facilities in the building before you leave, if you wish. 
Please allow approximately 90 minutes for these visits.  
 
It is important to maintain similar conditions during each trial.  We will therefore ask you to 
refrain from unaccustomed strenuous activity, and avoid drinking alcohol for 24 hours prior to 
each visit.  You should consume foods of similar quantity and nature in the evening before 
each trial.  
 
 
Can I change my mind if I decide I no longer want to take part in the study? 





Should you have any further questions regarding participation in the study, we will be pleased 
to answer them, and may be contacted on:  
 
Nick Gregory (PhD Candidate) 
Email: nig5@aber.ac.uk 
 
Dr Rhys Thatcher 
Email: ryt@aber.ac.uk 
 
If you have any complaints about any aspect of this study you can contact: 
Dr Rhys Thatcher (Academic Supervisor to Nick Gregory) 
Email: ryt@aber.ac.uk  
Telephone: 01970628425  
 
Institute Director of Research: Dr Alison Kingston-Smith  
Email: ahk@aber.ac.uk 
    















Monitoring the metabolic response of human urine following a bout of prolonged 
exercise 
 
NAME OF VOLUNTEER: .............................................................................. 
 
PRINCIPAL INVESTIGATOR: Nick Gregory (PhD Candidate)  
 
ADDITIONAL INVESTIGATORS: Dr Rhys Thatcher, Dr Thomas Wilson 
 
 
I have read the volunteer information sheet on the above study and have had the opportunity 
to discuss the details and ask questions.  The investigator has explained to me the nature 
and purpose of the study to be undertaken.  I understand fully what is proposed to be done. 
 
I have agreed to take part in the study as it has been outlined to me, but I understand that I 
am completely free to withdraw from the study at any time I wish.  
 
I understand that this study is part of a research project designed to promote scientific 
knowledge, which has been approved by Aberystwyth University Ethics Committee, and may 
be of no benefit to me personally.   
 
I understand this study involves a whole body scan using dual energy x-ray absorptiometry 






I understand that participation in the research study involves a maximal exercise test and two 
further trials involving submaximal exercise, both of which require attendance following an 
overnight fast 
 
I understand any data collected will be kept confidential, and only be seen by the principal 
investigators  
 




SIGNATURE OF VOLUNTEER: .............................................…...................... 
 
          
     Date: .................................. 
 
I confirm that I have explained to the volunteer named above, the nature and purpose of the 




SIGNATURE OF INVESTIGATOR: .................................................................. 
           










Appendix K: 24 Hour Food Diary  
 
For the day BEFORE urine collections please note everything you eat, without specifying 
the amounts. Thank you 
 
Example 24 hr before test : breakfast, 
lunch, snacks dinner 



































































Appendix L: Participant Information Sheet 
 
Participant Information Sheet 
 
A comparison of blood sugar values between a commercial point of care 
analyser and a hospital pathology analyser 
 
You are being invited to take part in a research study. Before you make a decision to take part, it is 
important to explain why the research is being done and what it will involve. Please take your time to 
read the following information carefully. Please do not hesitate to contact the research team if you 
would like any additional information about the study. It is important that you fully understand what 
the study will involve, so take your time when deciding if you would like to take part.  
 
What is the purpose of the study?  
Pre-diabetes is defined as a higher than normal blood sugar level and is associated with an increased 
risk of developing diabetes. A number of research projects currently taking place at Aberystwyth 
University are examining the effects of lifestyle interventions on blood sugar control in participants 
at risk of diabetes and other chronic diseases. Blood sugar is regularly monitored in these studies 
using a commercial point of care analyser located within the Wellbeing and Health Assessment 
Research Unit (WARU) at Aberystwyth University.  
 
The aim of this study is to compare blood sugar results between the point of care analyser used at 
the WARU laboratory and results provided by a local NHS Pathology Laboratory. Comparison of the 
results from both laboratories will help us to understand if there are any differences in blood sugar 
values and if so, to what extent they different.  
 
 
Do you have to participate in the study? 
It is up to you to decide if you would like to participate or not. You will be asked to sign a consent 
form at the start of the study. If you decide to take part but then for any reason wish to withdraw 
your participation, you can do so at any point without giving reason or prior notice, this will not stop 
you from participating in any future research studies.  
 
 
What will happen if you agree to take part in the study?   
You will be asked to visit the Carwyn James Building at Aberystwyth University on one occasion at a 
time of your choice. When you arrive, the researcher will explain the purpose of the study, provide 
you with the opportunity to ask any questions and then ask you to sign the consent form.  A blood 




blood sample will be collected by a trained member of the research team. Another blood sample will 
then be collected from your index finger.  
 
The first tube we collect will be sent to Bronglais Pathology Laboratory, Aberystwyth, for them to 
analyse. The second and third tubes and the blood sample collected from your finger will be analysed 




What will you have to do? 
You are free to eat and drink what you wish prior to your visit to the WARU. However, please refrain 
from alcohol consumption and any vigorous exercise for 24 hours prior to your visit.  
 
 
Will there be any negative side effects if you participate? 
There will be no long term side effects if you participate in the study. Blood tests can cause some mild 
discomfort when being collected however all members of the research team who are responsible for 
blood collection are highly trained and experienced. Attendance to your WARU visit will alter your 
daily routine however the research team will do their best to organise a date and time most 
convenient for you.  
 
 
Will you benefit from taking part in the study?  
By participating in the study, you will know your current blood sugar value which will provide an 
indication as to your current risk of diabetes. 
 
 
What happens if something goes wrong?  
If you feel that you have a reason to complain about any aspect of the study or the way you have 
been treated, you can do so by instigating Aberystwyth University complaints procedures. Contact 
information is at the end of this document.  
 
 
Will my participation in the study be kept confidential?  
All the information about you will be kept strictly confidential throughout the study.  
 
 
What will happen with the results generated by the research?  
The findings from our study may be published in scientific journals and presented at conferences. 
However all the results will be anonymous and will not identify you as a participant in any way. We 
will provide you with your results either in person or by telephone at your request. If your results 






Who is organising and funding the research?  
Aberystwyth University have organised and are funding the research study.  
 
Who has reviewed the study?  
Our research study has been reviewed by academic scientific researchers and approved by 
Aberystwyth University Ethics Procedures.  
 
Contact Information:  
Investigator 
Nicholas Gregory BSc (Hons), MPhil 
PhD Researcher 
Email: nig5@aber.ac.uk 
Telephone: 01970 622075 
 
Academic Supervisor 
Dr Rhys Thatcher BSc (Hons), MSc, SFHEA, FBASES 
Reader in Exercise Physiology 
Email: ryt@aber.ac.uk 
Telephone: 01970 628630 
   
If you have a complaint about the research, you can contact:  
 
Dr Alison Kingston Smith     
IBERS Director of Research 
Email: ahk@aber.ac.uk 
Telephone: 01970 823062 
 
Research Site Address: 
 
Wellbeing Assessment Research Unit 















Appendix M: Informed Consent  
 
ABERYSTWYTH UNIVERSITY 
-Institute of biological, Environmental and Rural Sciences- 





A comparison of blood sugar values between a commercial point 
of care analyser and an NHS hospital pathology analyser 
 
 
NAME OF PARTICIPANT: .............................................................................. 
 
INVESTIGATOR: Mr Nick Gregory 
 
ADDITIONAL INVESTIGATORS: Dr Rhys Thatcher 
 
 
I have read the participant information sheet about the above study and have had the 
opportunity to discuss the details and ask questions.  The investigator has explained to me 
the nature and purpose of the study to be undertaken.  I understand fully what is expected of 
me as a participant. 
 
I have agreed to take part in the study as it has been outlined to me, but I understand that I 
am free to withdraw from the study at any time I wish.  
 
I understand that this study is part of a research project designed to promote scientific 





I understand that my anonymised personal information will be stored confidentially for the 
entire duration of the study and will be retained by the research team after completion of the 
study 
 




SIGNATURE OF PARTICIPANT: .............................................…...................... 
 
       
                                            Date: .................................. 
I confirm that I have explained to the volunteer named above, the nature and purpose of the 
tests to be undertaken. 
 
 


















Appendix N: Blood Test Invitation Letter  
 
Examining the feasibility of conducting a randomised control trial to evaluate the effectiveness 
of a focussed 15-minute one-to-one consultation to improve blood glucose control in pre-
diabetes 
 
Dear (Insert Patient Name),  
 
We are writing to invite you to the surgery to take part in our diabetes screening programme. 
Our patient records suggest that you may be at risk of developing diabetes. A simple blood 
test can help us to identify if you are at risk or not.  
 
Being at risk of diabetes (called pre-diabetes) can increase your risk of developing heart 
disease and/or stroke risk. However, recently it has become very clear that improving your 
lifestyle, such as eating more healthily and exercising more can massively reduce the 
chances of getting diabetes (even if your weight stays the same). This is good news! It is 
important that we test you so we can monitor your diabetes risk in the future.  
 
 
We have an exciting partnership with Aberystwyth University who are interested in preventing 
diabetes in people who live in and around Ceredigion. Based on your results, you may be 
able to take part in their work.  
 
 
If you would like to book an appointment at the surgery to be tested for diabetes, please call 










Appendix O: Study Invitation Letter  
                                                                                                           
Examining the feasibility of conducting a randomised control trial to evaluate the 
effectiveness of a focussed 15-minute one-to-one consultation to improve blood glucose 
control in pre-diabetes 
 
Dear (Insert Patient Name)                                                                 
We are writing to you because a blood test you have had recently suggests you may be at 
risk of becoming diabetic. Being at risk of diabetes (called pre-diabetes) can increase your 
risk of developing heart disease and/or stroke risk. However, recently it has become very 
clear that improving diet and increasing physical activity can massively reduce the risk of 
getting diabetes (even if your weight stays the same). This is good news! The enclosed leaflet 
has more information. 
Scientists at Aberystwyth University are conducting a research study which, in part, is 
examining the effectiveness of a 15 minute one to one consultation which focuses on 
preventing diabetes in people who are at risk. You have been sent this letter because you 
may be eligible to participate in their research. You can read more about the study in the 
accompanying Participant Information Sheet.   
 
You can contact the research team at Aberystwyth University if you would like to participate 
in the research study using the contact information on the participant information sheet. It is 
important to highlight that at this stage, Aberystwyth University have no information relating 
to you and will only be made aware of your diabetes risk if you choose to participate in their 
research. If you wish to discuss anything before participating, you can contact the research 
team who will be happy to answer any questions. Choosing not to take part will not affect you 
rights as a patient in any way and will not stop you from participating in future research studies 
should you wish to.   
Church Surgery and Aberystwyth University are working together to help improve diabetes 
care in Ceredigion. We are excited to be involved in this project and we hope you take this 







Appendix P: Participant Information Sheet  
 
Participant Information Sheet 
 
Examining the feasibility of conducting a randomised control trial to evaluate the effectiveness of 
a 15-minute one-to-one consultation to improve blood glucose control in pre-diabetes  
 
You are being invited to take part in a research study. Before you make a decision to take part, it is 
important to explain why the research is being done and what it will involve. Please take your time to 
read the following information carefully and discuss it with friends and family if you wish. Please do 
not hesitate to contact the research team if you would like any additional information about the 
study. It is important that you fully understand what the study will involve, so take your time when 
deciding if you would like to take part.  
 
 
What is the purpose of the study?  
Pre-diabetes is defined as a higher than normal blood sugar level and is associated with an increased 
risk of developing diabetes. As the complications of diabetes, such as heart problems blindness and 
risk of amputation, develop over time it is beneficial to delay the onset of the condition for as long as 
possible. Researchers at Aberystwyth University aim to assess the feasibility of running a large scale 
scientific trial to evaluate the effectiveness of a 15-minute one-to-one consultation to improve blood 
sugar control in people with pre-diabetes and delay the development of diabetes.  
 
 
Why have you been chosen to participate? 
You have been chosen as a potential participant because your GP surgery has identified you as 




Do you have to participate in the study? 
It is up to you to decide if you would like to participate or not. Deciding not to participate will not 
affect your rights as a patient in any way. It is important to highlight that the research team will only 
be made aware of your diabetes risk if you decide to take part. At this stage, only your GP surgery 
knows of your risk. If you do decide to take part, you will need to contact the research team to book 
your first appointment. You will be asked to sign a consent form at the start of the study. If you decide 
to take part but then for any reason wish to withdraw your participation, you can do so at any point 
without giving reason or prior notice, this will not affect your rights as a patient or stop you from 






What will happen if you agree to take part in the study?   
If you would like to participate, you can arrange your first visit by contacting the research team. You 
can find contact details at the end of this information sheet.  
 
You will attend the Wellbeing Assessment Research Unit (WARU) at the Carwyn James Building, 
Aberystwyth University on 3 separate occasions. After your first visit, you will come back to the WARU 
after 3 months and 6 months. During these visits, we will record some physical data including your 
weight, height, waist circumference, blood pressure and body composition. We will take a blood 
sample from your arm to test your blood sugar level and analyse it further to understand what kinds 
of food you consume. We will ask you to fill out some questionnaires which relate to your diet, level 
of physical activity and general wellbeing. After your first visit to the WARU, the research team may 
inform you that you have been selected to visit your GP surgery to attend a pre-diabetes consultation 
with a practice nurse. Participants who attend a pre-diabetes consultation will be randomly selected 
by an electronic system.   
 
 
What will you have to do? 
You will also be asked to collect some urine samples when you are at home using a simple urine 
collection kit so we can analyse your diet. You will need to store the samples in your fridge before 
returning them by free post or in person. Full instructions will be provided to you on how to use the 
collection kit.  
You might also be asked to record your levels of physical activity for one week after each visit your 
make to the WARU. We will provide you with a simple activity tracker which sits around your waist 
like a belt. You only need to wear this during the hours you are awake. You do not need to wear the 
tracker when it is not feasible to do so (e.g. when you are washing). Participants who are asked to 
track their physical activity levels will be picked randomly.  
 
 
Will there be any negative side effects if you participate? 
There will be no long term side effects if you participate in the study. Blood tests can cause some mild 
discomfort when being collected however all members of the research team who are responsible for 
blood sampling are highly trained and experienced. Attendance to each WARU visit will alter your 
daily routine however the research team will do their best to organise a date and time most 
convenient for you.  
 
 
Will you benefit from taking part in the study?  
By participating in the study, you will gain a better understanding and increase your knowledge of the 
factors that need to be controlled in managing your blood sugar levels.  
 
 
What happens if something goes wrong?  




been treated, you can do so by instigating NHS complaints procedures or Aberystwyth University 
complaints procedures. Contact information is at the end of this document.  
 
 
Will my participation in the study be kept confidential?  
All the information about you will be kept strictly confidential throughout the study. Your GP will be 
made aware of your participation if you are randomly selected to receive a consultation. Similarly, we 
will inform your GP if we suspect you have developed diabetes, with your permission.  
 
What will happen with the results generated by the research?  
The findings from our study may be published in scientific journals and presented at conferences. 
However all the results will be anonymous and will not identify you as a participant in any way. You 
are welcome to request a summary of our findings once the study is complete.  
 
Who is organising and funding the research?  
Aberystwyth University and Church Surgery (Aberystwyth) have organised the research study.  
Aberystwyth University is funding the research.  
 
Who has reviewed the study?  
Our research study has been reviewed by academic scientific researchers and medical professionals. 
A NHS Research Ethics Committee has reviewed and accepted the study’s proposals.  
 
Contact Information:  
 
Chief Investigator 
Nicholas Gregory BSc (Hons), MPhil 
PhD Researcher 
Email: nig5@aber.ac.uk 
Telephone: 01970 622075 
 
Academic Supervisor 
Dr Rhys Thatcher BSc (Hons), MSc, SFHEA, FBASES 
Reader in Exercise Physiology 
Email: ryt@aber.ac.uk 
Telephone: 01970 628630 
   
If you have a complaint about the research, you can contact:  
 
Dr Alison Kingston Smith     
IBERS Director of Research 
Email: ahk@aber.ac.uk 





Research Site Addresses: 
 
Wellbeing Assessment Research Unit 















































Appendix Q: Informed Consent  
 
ABERYSTWYTH UNIVERSITY 
-Institute of biological, Environmental and Rural Sciences- 





Examining the feasibility of conducting a randomised control trial to evaluate the 
effectiveness of a 15-minute one-to-one consultation to improve blood glucose 
control in pre-diabetes 
 
 
NAME OF PARTICIPANT: .............................................................................. 
 
CHIEF INVESTIGATOR: Mr Nick Gregory 
 
ADDITIONAL INVESTIGATORS: Dr Rhys Thatcher, Dr Simon Payne, Dr Thomas Wilson, 
Mr Sam Chapman, Dr Heather Cox   
 
 
I have read the participant information sheet (Version 1, 22/1/18) about the above study and 
have had the opportunity to discuss the details and ask questions.  The investigator has 
explained to me the nature and purpose of the study to be undertaken.  I understand fully 
what is expected of me as a participant. 
 
I have agreed to take part in the study as it has been outlined to me, but I understand that I 
am completely free to withdraw from the study at any time I wish.  
 
I understand that this study is part of a research project designed to promote scientific 
knowledge, which has been approved by an NHS Research Ethics Committee, and may be 





I understand that my anonymised personal information will be stored confidentially for the 
entire duration of the study and may be retained by the research team even if I decide to 
withdraw my participation.  
 
I understand that my GP will be made aware of my participation in the study if I am to receive 
a consultation.  
 
I understand that my GP will be informed if the research team suspect I have become diabetic 
during   my participation in the study. The research team will inform my GP with my 
permission.  
 




SIGNATURE OF PARTICIPANT: .............................................…...................... 
 
       
                                            Date: .................................. 
 
I confirm that I have explained to the volunteer named above, the nature and purpose of the 
tests to be undertaken. 
 
 
SIGNATURE OF INVESTIGATOR: ................................................................. 
 










Appendix R: Readiness to Change Questionnaire (Extracts from)  
 
A. WEIGHT CHANGE READINESS. 
1. Are you currently trying to lose weight?  
 
- Yes, I am trying to lose weight 
- No, but I am trying to keep from gaining weight                     
- No, I am not making any attempts to control my weight now  
 
2. If you are NOT currently trying to lose weight or avoid gaining weight, is this 
something you plan to do in the future? 
  
- Yes, I plan to start within the next month  
- Yes, I plan to start within the next six months  
 - No, I have no plans right now for starting a weight control plan  
 - I am already following a weight control plan  
 
B. DIET CHANGE READINESS.   
Please answer the following questions about the things you may or may not do 
to control your blood glucose using food.  
 
1. Are you currently trying to follow a diet plan in order to better control your 
blood glucose? 
  
- Yes, I have a plan I am trying to follow  
- No, I am not following a plan but I am conscious of how food affects my blood 
sugar  
- No, I really do not pay attention to how food affects my blood sugar  
 
2. If you are following a plan, what kind of plan are you using?  
 
-  I do not use any kind of diet plan  
- Carbohydrate counting  
- The food exchange system  
- Total available glucose (TAG) 
- Healthy foods 
- The food guide pyramid 









3. If you are NOT currently following a diet plan or meal plan to better control your 
blood glucose, is this something you plan to do in the future?  
 
- I am already following a diet or meal plan                                                         
- Yes, I plan to start within the next month 
- Yes, I plan to start within the next six months   




Rate questions C and D with the following scale:
(1) Never,  
(2) 1 time per month or less,  
(3) 2-3 times per month,  
(4) 1-2 times per week,  
(5) 4-6 times per week,  
(6) 1 or more times per day 
 
C. DIET BARRIERS.  
The next set of questions has to do with when and where overeating, 
unplanned snacks and poor food choices occur.  Each question asks about a 
particular kind of situation.  Think about these behaviors and how much of a 
problem each situation is for you in trying to control these behaviors. 
 
During the past 3 months, how often have you had a problem with each of the 
following?  
 
1. Eating problems when feeling stressed, anxious, depressed, angry, or bored                                         
2. Eating problems because of hunger or food cravings 
3. Eating problems because family or friends tempt you or are not very supportive 
of your efforts to eat right 
4. Eating problems when eating away from home (e.g. fast food, restaurants) 
5. Eating problems because you feel deprived due to trying to follow a diet 
6.  Eating problems because you feel discouraged due to lack of results (e.g. no 
weight loss, high blood sugars)  
7. Eating problems because you are too busy with family, work, or other 
responsibilities  
 
D. EXERCISE BARRIERS. The next set of questions has to do with why you find it 
hard to start exercising or hard to stick with an exercise plan. 
 
During the past 3 months, how often have you had trouble exercising because of 
each of the following?  
 
1. Feeling stressed, anxious, depressed, angry, or bored 
2. Exercise and physical activity cause pain and discomfort for me 
3. Family or friends are not very supportive  
4. When away from home (e.g. on vacation, business trips, at relatives) 
5. My daily schedule (waking, go to bed, eat, work, etc) is different from one day to 
the next  
6. Feel discouraged due to lack of results (e.g. no weight loss, high blood sugars)  





Subscale Description and scoring:  
A (Weight Change Readiness): readiness for change for attempting weight loss; “Pre-contemplation” if A2=3 or A1=3; 
“contemplation” if A2=2; “preparation” if A2=1; “action” if A1>1 or A2=4 
B (Diet Change Readiness): Readiness for change for attempting dietary self-management; “Pre-contemplation” if B3=4; 
“contemplation” if B3=3; “preparation” if B3=2; “action” if B1=1 B2≥1 or B3=1 
 
C (Diet Barriers): Environmental, social, and emotional factors interfering with attempts to adhere to regimen; Sum C1-C7 
(Higher score indicates more frequent barriers) 
 
D (Exercise Barriers): Environmental, social and emotional factors interfering with attempts to adhere to regimen; Sum 
D1-D7 (Higher score indicates more frequent barriers) 
 
The PDQ survey and scoring protocol may both be obtained from the authors by request or may be downloaded from the 
internet (PDQ survey: http://healthbehavior.psy.vanderbilt.edu/PDQ.pdf   A PASW syntax file is available upon request. 
 
 
The questions in the above questionnaire have been drawn from the validated Personal Diabetes 
Questionnaire and have not been changed or altered in any way.  
 
Stetson, B., Schlundt, D., Rothschild, C., Floyd, J.E., Rogers, W. and Mokshagundam, S.P. (2011). 
Development and validation of The Personal Diabetes Questionnaire (PDQ): A measure of diabetes 









































































































































ID:       
Phase:       
 
 
Thank you for agreeing to take part in this study.  
This is a simple questionnaire designed to help us understand what foods you normally 
eat. It is not a test, so there are no right or wrong answers. It is your usual diet we 
are interested in. 
 
All information will be treated in the strictest confidence. 
 
Please turn over and read the instructions for answering questions before completing 
the questionnaire. Thank you for your time. 
 
ID M E D E s v V 
 Date d d m m y y 





About the food you eat 
 
The following questions are about the food you usually eat and how often you eat 
certain foods. Please read the following instructions before answering the questions.  
For each food there is an amount shown, either a “medium serving” or a common 
household unit such as a slice or teaspoon.  Please put a tick () in the box to indicate 
how often, on average, you have eaten the specified amount of each food during the 





For white bread the amount is one slice, so if you ate 4 or 5 slices a day, you should 
put a tick in the column headed “4-5 per day”. 
 
FOODS & AMOUNTS AVERAGE USE LAST 6 months 
BREAD & SAVOURY 






























White bread and rolls 
 









For chips, the amount is a “medium serving”, so if you had a helping of chips twice a 
week you should put a tick in the column headed “2-4 per week”. 
FOODS & AMOUNTS AVERAGE USE LAST 6 months 
POTATOES, RICE & 

































It is your turn to answer now! 
 
Please put a tick () in each box to indicate how often, on average, you have eaten 
each food during the past 6 months. 
 
Please estimate your average food use as best you can, and please answer every 
question - do not leave ANY lines blank.  Please put a tick () on every line. 
 
 
FOODS & AMOUNTS AVERAGE USE LAST 6 months 






























Beef: roast, steak, mince, stew 
casserole, curry or bolognese 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            




            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Pork: roast, chops, stew, slice or 
curry 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Lamb: roast, chops, stew or 
curry 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Chicken, turkey or other poultry: 
including fried, casseroles or 
curry 
 
           
  
 
           
  
 
       
      
 
           
  
 
          
   
 
            
 
 
         
    
 
     
       
 
        








            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            




            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Corned beef, Spam, luncheon 
meats 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            




            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Savoury pies, e.g. meat pie, pork 
pie, pasties, steak & kidney pie, 
sausage rolls, scotch egg 
 
           
  
              1                      
 
           
  
       2                     
 
       
      
        3                     
 
           
  
        4                      
 
          
   
       5                      
 
            
 
       6                      
 
         
    
       7                      
 
     
       
       8                      
 
        
     





































PLEASE PUT A TICK () ON EVERY LINE. 
 
FOODS & AMOUNTS AVERAGE USE LAST 6 months 































Liver, liver pate, liver sausage 
 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Fried fish in batter, as in fish 
and chips 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Fish fingers, fish cakes 
 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Other white fish, fresh or 
frozen, e.g. cod, haddock, plaice, 
sole, halibut 
 
           
  
              1                      
 
           
  
       2                     
 
       
      
        3                     
 
           
  
        4                      
 
          
   
       5                      
 
            
 
       6                      
 
         
    
       7                      
 
     
       
       8                      
 
        
     
       9                      
Oily fish, fresh or canned, e.g. 
mackerel, kippers, tuna, salmon, 
sardines, herring 
 
           
  
              1                      
 
           
  
       2                     
 
       
      
        3                     
 
           
  
        4                      
 
          
   
       5                      
 
            
 
       6                      
 
         
    
       7                      
 
     
       
       8                      
 
        
     
       9                      
Shellfish, e.g. crab, prawns, 
mussels 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            




20. BREAD & SAVOURY BISCUITS 
(one slice or biscuit) 
White bread and rolls 
 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Scones, teacakes, crumpets, 
muffins or croissants 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Brown bread and rolls 
 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Wholemeal bread and rolls 
 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Cream crackers, cheese biscuits 
 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Pitta bread, naan bread, chapati  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            




            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            







































PLEASE PUT A TICK () ON EVERY LINE. 
 


































            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Sugar coated cereals e.g. Sugar 
Puffs, Cocoa Pops, Frosties 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Non-sugar coated cereals e.g. 
Cornflakes, Rice Crispies 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
All Bran, Bran Flakes, Muesli  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Wholegrain cereals e.g. Cheerios, 
Weetabix, Shredded Wheat 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
22. POTATOES, RICE & PASTA 
(medium serving) 
Boiled, mashed, instant or jacket 
potatoes 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      




             
              1                      
            
       2                     
            
        3                     
            
        4                      
            
       5                      
            
       6                      
            
       7                      
            
       8                      
            




            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Yorkshire pudding, pancakes, 
dumpling 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            




            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
White rice  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Brown rice  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
White or green pasta, e.g. 
spaghetti, macaroni, noodles 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Tinned pasta, e.g. spaghetti, 
ravioli, macaroni 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            





































PLEASE PUT A TICK () ON EVERY LINE. 
 
FOODS & AMOUNTS AVERAGE USE LAST 6 months 
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              6  
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              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Lasagne, moussaka, cannelloni  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            




            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
23. DAIRY PRODUCTS & FATS 
 
       
Single or sour cream 
(tablespoon) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Double or clotted cream 
(tablespoon) 
 
            
 
            
 
            
 
            
 
            
 
            
 
            
 
            
 




              1                             2                             3                             4                             5                             6                             7                             8                             9                      
Low fat yoghurt, fromage frais 
(125g carton) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Full fat or Greek yoghurt (125g 
carton) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Dairy desserts (125g carton), 
e.g. mousse 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Cheese, e.g. Cheddar, Brie, Edam 
(medium serving) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Cottage cheese, low fat soft 
cheese (medium serving) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Eggs as boiled, fried, scrambled, 
omelette etc. (one) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Quiche (medium serving) 
 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            




































PLEASE PUT A TICK () ON EVERY LINE. 
 
FOODS & AMOUNTS AVERAGE USE LAST 6 months 
23.(b) The following on 


































            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Block margarine, e.g. Stork, 
Krona 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Polyunsaturated margarine, e.g. 
Flora sunflower 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Other soft margarine, dairy 
spreads, e.g. Blue Band, Clover 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Low fat spread, e.g. Gold  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Vegetable oil  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Olive oil  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            




24. SWEETS & SNACKS 
 
        
Sweet biscuits, chocolate, e.g. 
digestive (one) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Sweet biscuits, plain, e.g. Nice, 
ginger (one) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Cakes e.g. fruit, sponge, sponge 
pudding (medium serving) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Sweet buns & pastries e.g. flapjacks, 
doughnuts, Danish pastries, cream 
cakes (medium serving) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Fruit pies, tarts, crumbles 
(medium serving) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Milk puddings, e.g. rice, custard, 
trifle (medium serving) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Ice cream, choc ices (one)   
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Chocolates (small bar or ¼ pound 
of chocolates) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
 





PLEASE PUT A TICK () ON EVERY LINE. 
 
FOODS & AMOUNTS AVERAGE USE LAST 6 months 
































Sweets, toffees, mints (one 
packet) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Sugar added to tea, coffee, 
cereal (teaspoon) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Crisps or other packet snacks 
e.g. Wotsits (one packet) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Peanuts or other nuts (one 
packet) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
25. SOUPS, SAUCES AND SPREADS 
 
      
Vegetable soups (bowl)  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Meat soups (bowl)  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            




Sauces, e.g. white sauce, cheese 
sauce, gravy (medium serving) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Tomato based sauces e.g. pasta 
sauces (medium serving) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Tomato ketchup, brown sauce 
(tablespoon) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Relishes e. g. pickles, chutney, 
mustard (tablespoon) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Low calorie, low fat salad cream 
or mayonnaise (tablespoon) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Salad cream, mayonnaise 
(tablespoon) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
French dressing (tablespoon)  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            



































PLEASE PUT A TICK () ON EVERY LINE. 
 
FOODS & AMOUNTS AVERAGE USE LAST 6 months 
































Other salad dressing 
(tablespoon) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Marmite, Bovril (teaspoon) 
 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Jam, marmalade, honey, syrup 
(teaspoon) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Peanut butter (teaspoon) 
 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Chocolate spread, chocolate nut 
spread (teaspoon) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Dips e.g. houmous, cheese and 
chive (tablespoon) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
26. DRINKS 
 
         




            
              1                      
            
       2                     
            
        3                     
            
        4                      
            
       5                      
            
       6                      
            
       7                      
            
       8                      
            
       9                      
Coffee, instant or ground (cup)  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Coffee whitener, e.g. Coffee-
mate (teaspoon) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Cocoa, hot chocolate (cup)  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Horlicks, Ovaltine (cup)  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Wine (glass)  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Beer, lager or cider (half pint)  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Port, sherry, vermouth, liqueurs 
(glass) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            



































PLEASE PUT A TICK () ON EVERY LINE. 
 
FOODS & AMOUNTS AVERAGE USE LAST 6 months 





























Spirits, e.g. gin, brandy, whisky, 
vodka (single) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Low calorie or diet fizzy soft 
drinks (glass) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Fizzy soft drinks, e.g. Coca cola, 
lemonade (glass) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Pure fruit juice (100%) e.g. 
orange, apple juice (glass) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Fruit squash or cordial (glass)  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
27. FRUIT (1 fruit or medium serving)       
*For very seasonal fruits such as strawberries, please estimate your average use when 




            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      




            
              1                      
            
       2                     
            
        3                     
            
        4                      
            
       5                      
            
       6                      
            
       7                      
            
       8                      
            
       9                      
Oranges, satsumas, mandarins, 
tangerines, clementines 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Grapefruit  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Bananas  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Grapes  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Melon  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
*Peaches, plums, apricots, 
nectarines 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
*Strawberries, raspberries, kiwi 
fruit 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            



































PLEASE PUT A TICK () ON EVERY LINE. 
 
FOODS & AMOUNTS AVERAGE USE LAST 6 months 
27. FRUIT (continued) 































Tinned fruit  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Dried fruit, e.g. raisins, prunes, 
figs 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
28. VEGETABLES Fresh, frozen or tinned 
(medium serving) 




            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Spinach  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Broccoli  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Brussels sprouts  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      




            
              1                      
            
       2                     
            
        3                     
            
        4                      
            
       5                      
            
       6                      
            
       7                      
            
       8                      
            
       9                      
Peas  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Green beans, broad beans, 
runner beans 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Marrow, courgettes  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Cauliflower  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Parsnips, turnips, swedes  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Leeks  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Onions  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Garlic  
            
              1                      
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        3                     
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       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            






































PLEASE PUT A TICK () ON EVERY LINE. 
 
FOODS & AMOUNTS AVERAGE USE LAST 6 months 
28. VEGETABLES 

































            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Sweet peppers  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Beansprouts  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Green salad, lettuce, cucumber, 
celery 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Mixed vegetables (frozen or 
tinned) 
 
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Watercress  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Tomatoes  
            
              1                      
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        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            





            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Beetroot, radishes  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Coleslaw  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Avocado  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Baked Beans  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Dried lentils, beans, peas  
            
              1                      
 
            
       2                     
 
            
        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            
       9                      
Tofu, soya meat, TVP, 
Vegeburger 
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        3                     
 
            
        4                      
 
            
       5                      
 
            
       6                      
 
            
       7                      
 
            
       8                      
 
            




































Appendix U: Urine Sample Collection Log Sheet 
 
Urine Sample Collection Log Sheet 
Participant ID................... 
 
Week Sample ID Date Time 
1 01   
 02   
 03   
2 04   
 05   
 06   
3 07   
 08   




- Please collect 3 urine samples a week for 3 weeks 
 
- 2 urine samples should be collected on non-consecutive days in the 
week (e.g. Tuesday and Thursday) and the 3rd sample should be 





- All urine samples should be collected during the first time you go to 
the toilet after waking up in the morning  
 
- Keep your collected samples in the fridge within the absorbent 
pouches provided 
 
- Post the samples back to us using the addressed box provided or bring 





Appendix V: ActiGraph Instructions  
Instructions for wearing the Actigraph activity monitor 
For a period of 7 days: 
- Wear the device around your waist during the day, with the device on your RIGHT side. 
- Record when you wear the device on the time sheets provided 
 
More details: 
 The device consists of a red small box (the ActiGraph), attached to a strap. The strap 
should go around your waist and fit close to your body. One option would be to wear 
it as a normal belt; that it is the best position to track your movements. Alternatively, 
over your underwear but under clothing is also fine. 
 
o Other clothing such as shirts and coats could be placed over the device, which 
will also help protect it from getting wet, and getting caught. 
o Adjust the belt so that the Actigraph is positioned just above the right hipbone 
(see photo). The Actigraph must fit tightly but comfortably against your body. 
Adjust the strap to make a snug and comfortable fit.  
 
 You should start to wear the Actigraph within 7 days during one week of the 3 week 
urine collection period, for the next 7 days. 
o Your week can start mid-week, but you should wear it for the 7 days that 
follow. 
o Before and after this week, it is recommended to keep the device in one place 
and not move it. 
o You can return the device in person, via the postal bag we can provide, or let 
us know when you’re done and we could be able to pick it up. 
 
 Wear the device for 7 days, every day, throughout the complete time, including 
sleeping.  Write down when you start wearing the device on the sheet. Remember to 
put it on your RIGHT side on your waist when getting out of bed. 
 
 It might not be feasible to wear the device at certain times. In that case, record the 
time you taken it off on the accompanying timesheet. 
o An example of non-wear would be when you go swimming, have a bath or 
shower, or some sporting activities where you’re not allowed to wear 
jewellery. The device is not waterproof. Please remember to put it on again 




stopped being worn, including the type of activities you did, and for how long 
(see the timesheet). 
o If you simply forget to wear the device, please note that also on the timesheet. 
If you miss a whole day; record for an extra day directly after the 7th day 
 
 Every evening, record the time you go to bed, on the log sheet.  
 Every morning, record the time you get up, on the log sheet. 
 At the end of the measurement period, please return the Actigraph and the time 
sheets  
 
 When you receive the Actigraph, a light might be flashing; this is normal and shows 
the device is set up, but not recording yet. Once it starts actually recording, the light 
will disappear. So, don’t wear the device as long as the light is flashing (possibly for 
one or two days at the start).  
 
PLEASE RETURN THE ACTIGRAPH WHEN YOU’RE DONE 
 
Illustration of where to place the ActiGraph during the day, at this height, with the red device on the 
side. It can be placed under your clothing. 
 
 





Any questions, or not sure about anything, or experiencing problems? Contact Nick Gregory 








Day Date Start of day 
wear  
(time of getting 
out of bed) 
End of day 
wear  
(time of 







Reason of non-wear Any Additional 
Comments 
        
        
        
        
        
        
        
        
        
        




Appendix X: Feedback Questionnaire  
 
Study Feedback Questionnaire 
 
The following questions relate to the pre-diabetes study you have been involved in.  
 
Recruitment  
The following questions relate to the recruitment process:  
 



























































5. The research team explained the study clearly and I understood my role as a participant 

















Data collection  
The following questions relate to your baseline, 3 month and 6 month visit to the Carwyn 
James Building:   
 
 





2. I was happy for the research team to record my physical data (e.g. weight/height/waist 













































The following questions relate to the urine collection procedures in the home: 
 
 
1. I was successful in collecting urine using the urine collection kit 
 
2. It was easy to collect urine in the pot  
3. I was confident collecting urine in the pot 
4. It was easy to transfer urine from the pot into the sample tube using the transfer 
straw  
 
5. I felt confident transferring urine from the pot into the sample tube using the transfer 
straw 
 


























































7. In general, I think collecting a urine sample is difficult  
 
8. I think collecting a urine sample in a home environment is embarrassing  






10. Returning my urine samples to the research team was easy and arranged at a 

































11. Further comments (if required) 
 
 
15 Minute Consultation 
The following questions relate to the 15-minute consultation received in your GP surgery. 
These questions only need to be answered if you attended a consultation:  
 
 















3. The consultation provided me with useful information about my diabetes risk and ways I 






4. Since attending the 15-minute consultation I have improved my health through increased 





































5. The 15-minute consultation has had a beneficial impact on my health and I would 






Further comments (if required) 
 
 
Physical Activity recording 
The following questions relate to the methods for recording physical activity. These 
questions only need to be answered if the research team asked you to record your physical 
activity:    
 
 























          






































5. I was more physically active in the weeks I wore the ActiGraph compared to the weeks I 















Disagree Agree Strongly 
agree 
